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ABSTRACT 
Isoflavones are found in the human diet almost exclusively in soybeans and soy 
products. Because of their structural similarities to the main female hormone estrogen, they 
have been extensively studied for improving health and preventing several chronic diseases. 
Isoflavones have been studied for their protecting effects against cancer, osteoporosis, 
cardiovascular disease, hypercholesterolemia and menopause-related symptoms. Little is 
known about health-adverse and toxic effects associated with these compounds. Moreover, 
the need to better understand bioavailability of isoflavones is essential with respect to their 
overall metabolism and modes of actions. Two aspects of isoflavone bioavailability are 
investigated in the present research project: establishment of a human-relevant animal model 
to study bioavailability and subsequent health effects as well as identifying the 
microorganisms influencing the extensive and variable degradation of isoflavone in the 
human large intestine to obtain a better screening tool of individual capability to degrade 
these compounds, which may greatly affect health outcomes measured in clinical trials. 
Golden Syrian hamsters were investigated in three studies to attempt the validation of 
this model as relevant to human for isoflavones bioavailability and their cholesterol lowering 
effect. Apparent absorption of isoflavones, as reflected in urinary excretion, showed great sex 
differences in daidzein, glycitein and genistein; females were 2-3 fold higher excreters than 
males. Fecal excretion did not exceed 0.5% ingested dose and did not correlate with urinary 
excretion. Cecal but not fecal in vitro isoflavone degradation rates were strongly correlated 
with individual urinary excretion levels of daidzein and genistein. However, glycitein urinary 
excretion and the lack of relationship to urinaiy excretion showed an unstable pattern of 
bioavailability compared to daidzein or genistein. Finally, hamsters excreting large amounts 
of isoflavone in their urine had significantly lower levels of total cholesterol compare to 
animals excreting smaller amounts of daidzein, genistein and total isoflavone. Thus, we 
concluded that sex-difference, similar pattern of urinary excretion between females and 
women, differences between sex (females>males) and isoflavone (daidzein>genistein) and 
clustering of animals as high excreters/low degraders and low excreters/high degraders were 
common features shared with humans that may lead to validating hamsters as a good model 
to study bioavailability of isoflavones. Lower levels of excretion in male hamsters compared 
vii 
to human males, instability in glycitein metabolism and concordance between human fecal 
and hamster cecal but not hamster fecal bacterial activity were observed differences that may 
contraindicate the use of this animal model. 
To understand the complexity of human fecal microflora related to isoflavone 
disappearance (apparent degradation), we coupled molecular biology with microbiology 
techniques. The use of polymerase chain reaction coupled with denaturing gradient gel 
electrophoresis allowed the profiling both qualitatively and quantitatively of fecal microbial 
profiles based on each strain's 16S DNA. When comparing gut microbial profiles to in vitro 
fecal degradation of isoflavones, 7 bands of interest were identified when focusing on intra-
individual variability of fecal glycitein degradation over a one month interval. Screening of 
33 subjects (13 females and 20 males) to determine high versus low fecal isoflavone 
degraders (determined by ranking and clustering of individual degradation rates for each 
isoflavone) gave 5 bands of greater intensity in the 4 highest degraders compare to the 4 
lowest glycitein degraders, 5 bands for genistein and no bands for daidzein. 
Sequencing and identification of microorganisms using Basic Local Alignment 
Search Tool (BLAST) gave matches to Bacteroides, Prevotella, Bacteroidales and 
Clostridials species (.Bacteroides fragilis, Bacteroides uniformis, Bacteroides ovatus, 
Bacteroides vulgatus, Bacteroides thetaitaomicron, Bacteroides eggerthii, Porphyromonas 
gingivalis, Prevotella pallens, Prevotella ruminicola, Prevotella oralis, Prevotella veroralis, 
Ruminococcus obeum, Fusobacterium prausnitzii, Bacteroides acidifaciens and Tannerella 
Forsythensis). Eubacterium ramulus and Clostridium orbiscindens were also selected from 
previously published literature. Investigations of these strains were done using a fecal 
suspension matrix in which nutrient availability was either rich (attempting to mimic a rapid 
gut transit time and expected low degradation rates) or poor (to mimic long gut transit time; 
high degradation rates). Nutrient rich media contained several nutrient sources including 
sterilized rumen fluid, peptone, brain heart infusion powder, yeast extract and sucrose 
whereas nutrient poor media was obtained by incubating lg of feces overnight in brain heart 
infusion media. Species increasing significantly isoflavones degradation in both nutrients 
were B. acidifaciens (143.6 ± 16 vs. 180.3 ± 5.0 band intensity arbitrary units in low vs. high 
degraders; p<0.05), T. forsythensis (120.5 ± 18.1 vs. 187.5 ± 22.5 intensity arbitrary units; 
p<0.05), E. ramulus and C. orbiscindens (both selected from previous literature), and to 
some extent P. pallens (123.0 ± 2.8 vs. 170.0 ± 1.4 intensity arbitrary units; p<0.05) and B. 
uniformis (171.3 ± 21.0 vs. 210.0 ± 10.8 intensity arbitrary units; p<0.05) that will deserve 
further analysis. These species were of greatest interest and therefore hypothesized to be 
present in both high and low excreters with greater proportions of these strains in high 
compared to low degraders, as reflected by DGGE analysis. These findings support the idea 
that low and high degradation patterns may share common microorganisms, some being 
more active in one pattern of degradation compared to the other. In addition, other species 
investigated showed significant effect in increasing isoflavones degradation nutrient-poor 
media only (P. pallens, P. oralis, B. eggerthii and to some extent B. vulgatus, B. fragilis, P. 
ruminicola, P. veroralis and F. prausnitzii), suggesting that a wider range of species may be 
capable of increasing isoflavone when nutrients are lacking, also explaining the phenomenon 
of high degradation in humans. 
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GENERAL INTRODUCTION 
Introduction 
Isoflavones are bioactive components found mostly in soybeans and soy products. 
Amounts of isoflavones found in food vary from 1 to 3 mg/g food and are found in two major 
forms. The glucoside forms are daidzin, genistin and glycitin, mostly found in non-processed 
foods while the aglycone forms are daidzein, genistein and glycitein, mostly found in 
processed and fermented soy foods. Small amounts of acetyl and malonyl isoflavones also 
occur in soyfoods. Special focus on isoflavones has been brought over the years because of 
their potential in improving health and preventing chronic diseases. Their chemical structures 
are close to estrogen, the main female hormone, thus classifying isoflavones as 
phytoestrogens. The range of health effects is wide and includes prevention of cancer, 
osteoporosis, hypercholesterolemia and menopausal symptoms as well as potential beneficial 
effects on immune function and menstrual cycle. Toxic and adverse effects are controversial, 
with little substantial evidence of any major concern so far for individuals who ingest large 
amounts of isoflavone on a daily basis. To study these health effects, animal models (from 
rats to monkeys) have been extensively used. 
Isoflavone bioavailability is quite complicated and defined by an intricate scheme of 
absorption, plasma and urinary kinetics and gut microbial metabolism and degradation. We 
now know that isoflavone glucosides undergo cleavage of their sugar moiety by intestinal p-
glucosidases to be absorbed mostly in the stomach and the small intestine, as evidenced by a 
rapid peak appearance in plasma (less than 6 h after ingestion). After absorption, isoflavones 
undergo intestinal and hepatic biotransformation mainly to glucuronide conjugates. 
Clearance of isoflavone occurs within 24-48 h after ingestion, but the amounts excreted in 
urine and feces account for less than half of the amount ingested. Most of the conjugates are 
excreted through bile back into the intestine. Deconjugation, mostly by bacteria in the large 
intestine, is necessary for reabsorption. Bacteria are also responsible for degrading and 
producing by-products and metabolites of isoflavones. Colonic microbial metabolism has 
been established as a critical factor in understanding the concept of isoflavone 
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bioavailability. This extent of microbial degradation is wide and inversely correlated to 
urinary and fecal excretion in humans. Establishment of phenotypes of isoflavone 
bioavailability was introduced less than 10 years ago to categorize individuals as high, 
moderate or low degraders. However, despite a greater understanding of gut microbial 
degradation and metabolism/bioavailability of isoflavones, the actual bacterial species 
responsible for this degradation remain unknown. 
With regard to health-related effects of isoflavones investigated in animals, relevance 
of the data extrapolated to humans underlies the assumption that bioavailability is similar 
between the animal model studied and humans. To our knowledge, there is very limited 
evidence about the validity of a specific model in terms of bioavailability or metabolism that 
could be suitable for data extrapolation to humans. 
With respect to what is or is not known about bioavailability of isoflavones, we 
decided to investigate in greater detail two of the main questions still limiting the overall 
knowledge of isoflavone mode of action and metabolism. First, it is essential to validate an 
animal model with close resemblance to humans with respect to bioavailability so that 
health-related effects investigated in that particular model would be of greater relevance. We 
chose Golden Syrian hamsters, because of a similar cholesterol metabolism compared to 
humans. If hamsters do resemble humans in metabolizing isoflavones, then health-related 
effects studied in this model would be of greater relevance. Second, identifying gut 
microorganisms responsible for isoflavone degradation would fill one of, if not the greatest 
gaps in understanding bioavailability. It would provide a useful tool to screen people for their 
bacterial isoflavone degradation, which would predict the overall pattern of apparent 
absorption and bioavailability. This would be the first step in a long process of limiting these 
species in the gut to improve absorption and possibly promote health effects. Limiting 
isoflavone-degrading microorganisms would also limit inter-individual variation in 
bioavailability so that a dose given orally would be closer to the dose actually exerting a 
physiological effect. 
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Dissertation organization 
This dissertation contains a general introduction, a literature review focusing mainly 
on health-effects, bioavailability and metabolism of isoflavones, and composition and 
metabolism of the human gut microflora. All three papers "Isoflavone excretion phenotypes 
influence plasma cholesterol in Golden Syrian hamsters" and "Bioavailability of soy 
isoflavones in Golden Syrian hamsters" and "Identification of isoflavone-degrading 
microorganisms in humans using polymerase chain reaction and denaturing gradient gel 
electrophoresis" will be submitted to the Journal of Nutrition. 
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LITERATURE REVIEW 
A. Structures, sources and dietary intake of isoflavones 
Isoflavones are found almost exclusively in soybeans and soy products (Wang and 
Murphy. 1994; Wang and Murphy. 1996). Soybean isoflavones are daidzin, genistin and 
glycitin, the glucoside form of daidzein, genistein and glycitein, respectively (Figures land 
2). Other isoflavone forms, such as malonyl- and acetyl-isoflavones also occur in soy foods 
(Wang and Murphy. 1994; Wang and Murphy. 1996). 
HO 
R 
OH 
Compounds R R' 
daidzein H H 
genistein H OH 
glycitein OCH3 H 
Figure 1: Isoflavone chemical structure 
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CH2-R3 
OH 
HO 
OH 
R2 
OH 
Compound R1 R2 R3 
daidzin H H -OH 
6"-0-acetyldaidzin H H -OCOCH3 
6"-0-malonyldaidzin H H -OCOCH2COOH 
genistin OH H -OH 
6"-0-acetylgenistin OH H -OCOCH3 
6"-0-malonylgenistin OH H -OCOCH2COOH 
glycitin H OCH3 -OH 
6"-0-acetylglycitin H OCH3 -OCOCH3 
6"-0-malonylglycitin H OCH3 -OCOCH2COOH 
Figure 2: Chemical structure of the different isoflavone forms found in soy foods 
According to the US Department of Agriculture/Iowa State University Isoflavone 
Database (1999) and analytical studies conducted by Murphy et al. (1999), isoflavones are 
found almost exclusively in soybeans and soy products (Table 1). Exceptions include alfalfa 
and clover sprouts. Isoflavone concentrations in soybean foods are close to 150 mg/100g 
(Table 1). 
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Food item Isoflavone mean SD n 
Miso daidzein 16.13 4.36 7 
genistein 24.56 4.23 9 
glycitein 2.87 0.47 3 
total isoflavone 42.55 9.18 7 
Instant beverage, soy daidzein 40.07 6.19 6 
powder genistein 62.18 2.78 6 
not reconstituted glycitein 10.9 0.14 4 
total isoflavone 109.51 4.11 6 
Soy flour, full fat, daidzein 71.19 6.95 20 
row genistein 96.83 7.38 21 
glycitein 16.18 2.65 7 
total isoflavone 177.89 12.57 21 
Soymilk, fluid daidzein 4.45 0.75 14 
genistein 6.06 0.84 16 
glycitein 0.56 0.09 5 
total isoflavone 9.65 1.76 14 
Soy protein isolate daidzein 33.59 5.99 14 
genistein 59.62 6.68 14 
glycitein 9.47 1.81 11 
total isoflavone 97.43 11.11 14 
Soybeans, mature daidzein 52.04 14.04 7 
seeds, dry roasted genistein 65.88 14.89 8 
glycitein 13.36 5.94 5 
total isoflavone 128.35 33.38 7 
Tempeh daidzein 17.59 3.13 6 
genistein 24.85 5.47 6 
glycitein 2.1 0.67 3 
total isoflavone 43.52 8.34 6 
Tofu, firm, prepared daidzein 9.44 1.68 6 
with calcium sulfate genistein 13.35 2 7 
and nigari glycitein 2.08 0.15 4 
total isoflavone 24.74 3.77 6 
Table 1: Mean individual and total isoflavone levels in selected soy foods (mg/100 g edible 
protion), standard deviation (SD) and total number of individual values (n) (Adapted from 
US Department of Agriculture/Iowa State University database on the isoflavone content of 
foods. 1999). 
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The differences observed in isoflavone content from one soyfood to another are partly 
due to food processing losses of isoflavones. Wang and Murphy (1996) analyzed the 
isoflavone content in the different steps of making tempeh, soymilk and tofii from whole 
soybeans. Using HPLC as an analytical method, they observed a 76% decrease in isoflavone 
content during production of tempeh, mostly due to the soaking and cooking step. They also 
observed that fermentation increased the aglycone content. Significant losses of isoflavones 
also occurred during coagulation (44%) in tofu processing as well as alkaline extraction 
(53%) during soy protein isolate production. On the other hand, the isoflavone content after 
processing of soymilk was not significantly different from raw soymilk. Although soy foods 
are the main contributor of isoflavones in the diet, isoflavone content varied from one variety 
of soybean to another or within the same variety from one year to another (Wang and 
Murphy, 1994). Therefore, accurately analyzing isoflavone intake is a challenge. 
Due to the low consumption of soy products in the Western diet, isoflavone intake 
has been estimated not to exceed 1-2 mg/d per person in the US (Munro et al. 2003). On the 
other hand, a traditional Asian diet, usually associated with consumption of soybeans or soy 
foods, may provide about 50 mg/d of isoflavones (Nagata et al. 1998). Overall, isoflavone 
consumption in a Western diet has been evaluated to be -0.01 mg/kg body weight/d whereas 
in an Asian diet, isoflavone consumption may reach up to 0.5 mg or ~1.8 pimol/kg body 
weight/d (Munro et al. 2003). 
B. Isoflavones and health 
Protection from certain chronic diseases (cancer, osteoporosis) and health-related 
factors (blood lipid profile, consequences of menopause) has been extensively studied with 
respect to isoflavones, either alone or in combination with a food matrix. The discrepancies 
in protocols and methods along with a wide range of isoflavone doses applied across studies 
lead to difficult comparisons of data and conclusions. Whenever possible and available, 
doses applied to either humans or animals will be converted to mole concentrations of 
individual or dose of total isoflavone/kg body weight/d in order to make comparison across 
studies more relevant. Discussion of these intakes with respect to an established "normal" 
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dietary intake of isoflavones from soyfoods in humans will also be included. An Asian diet 
provides up to 0.5 mg total isoflavone/kg body weight/day, which corresponds to ~ 1.8 jumol 
total isoflavone/kg body weight (BW)/day (d). The following is a review of isoflavones with 
respect to cancer, blood lipid profile, immune function, osteoporosis, menstrual cycle, 
menopause, infants and toxicity in humans and/or animals and/or in vitro. 
1. Isoflavones and cancer 
According to the American Cancer Society (2000), cancer is the second leading cause 
of death in the US (25% of all deaths). In women, the most prevalent types of cancer are 
lung, breast, colon, ovary, pancreas, stomach and liver whereas in men, the main cancer sites 
are lung, prostate, colon, pancreas, stomach and liver. Nutrition has been extensively studied 
with respect to cancer because dietary compounds may protect against this chronic disease. 
Soy foods and the numerous bioactive compounds they contain are now widely studied for 
their possible cancer-preventive effect. 
a. Human studies 
In humans, the role of soy in preventing cancer has emerged from epidemiological 
studies. Asians consuming a traditional Asian diet (high in soy products) have lower cancer 
rates compared to Caucasians consuming a typical western diet. 
In a case control study, Zheng et al. (1999) looked at urinary phenol and total 
isoflavonoid as markers of soyfood intake in women with or without breast cancer from 
Shanghai (n=60/group; 25 to 64 years of age with aged-matched control subjects) and found 
a significant difference in breast cancer incidence between the highest (n=35; >18.66 nmol 
isoflavone/mg creatine) and lowest (n=14; <5.58 nmol/mg creatine) fertile of urinary phenol 
and isoflavonoid excretion (p=0.04). 
Dai et al. (2003) studied urinary isoflavones excretion and breast cancer risk with 
respect to hormonal levels, body mass index (BMI) and waist:hip ratio (WHR) (n=117 case-
control pairs of postmenopausal women from Shanghai). Mean age of subjects was -56 years 
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of age. They found a negative relationship between urinary excretion of isoflavone and breast 
cancer risk for subjects with higher BMI (>25; p for trend =0.06), higher WHR (>0.84; p 
=0.02), higher plasma estradiol (>5.73 pg/mL; p=0.01), lower blood estrone sulfate (<0.96 
ng/mL; p=0.01) and lower sex hormone binding globulin concentrations (<81.4 nmol/L; 
p=0.03). Therefore isoflavone intake was considered a key factor in decreasing risks of breast 
cancer, but other parameters must be considered in the analysis (blood hormonal levels, BMI, 
WHR) in order to make the correlation statistically significant. 
With respect to endometrial cancer risks, Horn-Ross et al. (2003) performed a case-
control study of 500 women who developed endometrial cancer and 470 healthy women. 
They found a negative relationship between cancer risk and isoflavone intake estimated from 
a food frequency questionnaire. Isoflavone intake was divided in quartiles and comparison 
between the highest (>2726 ug total isoflavone/d or 0.14 pmol/kg BW/d) and the lowest 
quartile (<1150 ug/d or 0.06 pmol/kg BW/d) showed the strongest correlation between 
cancer protection and isoflavone consumption (adjusted odds ratio=0.59; 95% confidence 
interval=0.37 to 0.93; p value for trend=0.2). BMI was not a significant factor in this study (p 
value for interaction=0.27), which differs from Dai et al. (2003). However, levels of 
isoflavones were assessed as intake and not urinary excretion, thereby bypassing 
bioavailability that could have greatly influenced the measured outcomes. 
Prostate cancer was also studied epidemiological^ with respect to isoflavone intake 
by Lee et al. (2003). Chinese subjects with (n=133) or without (n=265) prostate cancer were 
assessed for their soy food and isoflavone intake using a food frequency questionnaire. A 
significant negative correlation (p value for linear trend=0.032) was observed between 
prostate cancer risk and intake of tofu. 
Correlations between equol, the main daidzein metabolite, and cancer have also been 
investigated in epidemiological studies. Akaza et al. (2004) examined the prevalence of 
prostate cancer and equol production in Japanese (133 patients, 162 controls), Koreans (61 
patients, 61 controls) and Americans (24 patients, 21 controls). The percentage of equol 
producers was significantly higher in controls vs. patients in Japanese (46 vs. 29%; p=0.004) 
and Koreans (59 vs. 30%; p=0.001). In Americans, equol producers were similar between 
patients (17%) and controls (14%), but plasma daidzein and genistein measured in this 
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population was -10 times lower than in Japanese or Korean groups. The authors concluded 
that a diet high in soy products coupled with the ability to produce equol may be more 
significant in protecting against prostate cancer. 
Despite significant data negatively correlating soy food intake and the prevalence of 
cancer, isoflavones by themselves have not been clearly identified in humans as one of the 
factors responsible for preventing cancer. In addition, other bioactive compounds in soy 
foods, such as enzyme inhibitors or saponins, could be important in the process of cancer 
protection (Birt et al. 2001). To understand better if isoflavones by themselves are cancer 
protective, animal studies and in vitro data are of great interest. 
b. Animal studies 
A great number of studies performed in animals have investigated the possible 
beneficial effects that soyfoods and in particular isoflavones may have in protecting against 
cancer. Cancer was induced either by radiation or chemical injection to mimic a model that 
can be extrapolated to humans. For example, mammary cancer can be induced by radiation, 
N-methyl-nitrosourea (MNU) or 7,12 dimethylbenz[a] anthracene (DMBA). Barnes et al. 
(1990) found a dose response between exposure to soy protein isolate (20 to 200 g/kg diet) 
and mammary cancer (up to 50% reduction with 200g soy protein isolate/kg diet) in rats. 
More recently, Cohen et al. (2000) examined the effect of soy protein isolate (20 or 200 g/kg 
diet) with (2.89 mg total isoflavone/g isolate; 50% aglycone/50% glucosides) or without 
isoflavones with respect to mammary cancer development in F-344 rats (n=30/group). 
Twenty or 200 g SPI/kg diet provided -105 and 215 |imol total isoflavone/kg BW/d. Cancer 
was induced by N-methyl-nitrosourea (40 mg/kg body weight; animal age was 50d) one 
week after the feeding period started and continued for 18 weeks after cancer initiation. None 
of the treatment groups prevented cancer compared to the control fed casein (n=10), as 
observed in tumor incidence, multiplicity, volume and latency, thereby questioning the role 
of isoflavones and soy in general as being cancer-protective. 
Without a soy protein matrix, isoflavones by themselves have also been studied, 
especially genistein. Its weak estrogenic or anti-estrogenic activity has been examined along 
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with its ability to inhibit protein tyrosine kinase and DNA topoisomerase, two enzymes 
necessary for proliferation of cancer cells (Messina et al. 1994). Two studies by 
Lamartiniere's team (Lamartiniere et al. 1995; Fritz et al. 1998) focused on breast cancer and 
genistein administered neonatally or perinatally to female Sprague-Dawley rats. When 
administered neonatally (Lamartiniere et al. 1995) at day 2, 4 and 6 with 5 mg genistein in 20 
pL DMSO subcutaneously (or 370 pmol genistein/kg BW/d; control was DMSO alone) and 
cancer induced at d 50 with 80 mg DMBA/kg body weight, genistein-exposed animals had a 
significant delay in the appearance of tumors (124 ± 33 d) compared to the controls (87 ± 37 
d). By d 190, only 88% of the genistein exposed animals developed tumors compared to 
100% of the controls. Moreover, the mean number of tumors per animals was lower with the 
genistein treatment (3.67 ± 0.45) compared to the control group (6.35 ± 0.67). In this study, 
genistein had a role in protecting against cancer. However, the route of administration 
(subcutaneous and not oral) and the dose injected (pharmacologic, not dietary) were not 
suitable for extrapolation to humans (dose given on molar basis was -100 times higher than 
normal dietary dose in humans). Indeed, it would be unethical to inject intravenously or 
subcutaneously such large doses of isoflavone without knowing potential toxic or adverse 
effects that might occur. Moreover, these studies should be conducted so that they would be 
relevant to dietary ingestion of isoflavones by humans. This includes the process of 
metabolism/absorption/microbial degradation, which are essential factors when studying 
these compounds (See section C). 
In a subsequent study (Fritz et al. 1998), animals were fed genistein at 0, 25 or 250 
mg/kg diet (0, 8.8 and 92 p.mol/kg BW/d) from d 0 to d 21. At d 50, mammary cancer was 
initiated with DMBA and animals were fed a genistein free diet from d 21 to d 200. Animals 
fed the highest dose of genistein had a 50% reduction in the mean number of tumors 
compared to animals fed no genistein during the first 21 d of the experiment. (4.4 ± 0.6 vs. 
8.8 ± 0.8 tumors/animal). By d 50 and compare to the control, the group fed 92 pmol/kg 
BW/d had fewer terminal end buds (65 ± 6 vs. 31 ±4 end buds/animal) and type I lobules (45 
± 4 vs. 15 ± 3 lobules/animals). Terminal end buds and type I lobules were chosen in this 
study to reflect mammary gland differentiation, a phenomenon associated with increased 
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risks of breast cancer. The authors concluded that genistein had a long-term protective effect 
against mammary cancer. 
This latter study was more relevant to humans because of oral ingestion of 
isoflavones at doses relevant but still higher than those of a typical Asian diet. On the other 
hand, complete extrapolation between the human and any animal model should take into 
account interspecies metabolic and physiologic differences. This might explain why a higher 
dose is required for animals with the authors' assumption that it is still relevant to humans 
(based on blood isoflavone concentration and previous bioavailability data in both human 
and animal models) (Fritz et al. 1998). Thus a dose of -50 pmol/kg body weight/d in rats 
(-10-15 fold higher than humans) would best mimic an Asian human diet (Fritz et al. 1998). 
Prostate cancer also has been extensively studied. Pollard et al. (1997) used Lobund-
Wistar rats fed soy protein isolate with high (33.8 mg total isoflavone/kg diet or -12 pimol/kg 
BW/d) or low isoflavone (2.18 mg/kg diet or 0.8 pmol/kg BW/d) dose. Control animals were 
fed casein. MNU (30 mg/kg body weight) was used as a prostate cancer inducer and 
testosterone propionate as a promoter (implanted 7 d after MNU injection). Two designs 
were applied for this study: diets were given to animals 27 d before or 7 d after MNU. 
Animals fed high isoflavone pre-MNU had a 27% increase delay in cancer development 
compared to low isoflavone pre-MNU rats (10 vs. 7.3 months). In addition, rats fed high 
isoflavone intake before MNU had a lower incidence of cancer compared to rats fed 
isoflavones post-MNU (8/24 vs. 18/35), but the time of cancer formation was the same in rats 
fed high or low isoflavone doses post-MNU (10.6 vs. 9.3 months). This study suggests that 
isoflavones were protective against cancer before it occurred but they were not as effective 
once initiation/promotion has started. Therefore, isoflavones may be considered as prostate 
cancer-preventive but not curative compounds. 
Another model to study isoflavones and cancer is the use of transgenic animals 
capable of developing spontaneous tumors in a short period of time, which avoids injection 
of chemicals to promote cancer. With respect to breast cancer, Jin and MacDonalds (2002) 
studied the effect of isoflavones in mouse mammary tumor virus (MMTV)-neu mouse, which 
develops mammary tumors spontaneously due to overexpression of the ErbB-2/neu/HER 
oncogene (cancer gene activated in mammary cancer in both animals and humans). Starting 
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at 7 up to 34 weeks of age, these mice (n=l 8/group) were fed AIN-93G diets containing no 
isoflavones, 250 mg/kg genistein (111 p.mol/kg BW/d), 250 mg/kg daidzein (118 |imol/kg 
BW/d) or Novasoy (equivalent to 250 mg/kg genistein). Latency of tumor development 
increased from 23 weeks of age for control up to 27 weeks of age for all three treatment 
groups (p<0.05). However, by week 34, there was no difference in tumor incidence among 
all groups (-90-100% animals developed tumors). Thus, this study agreed with Pollard et al. 
(1997) that isoflavones were cancer-protective (increased latency of tumor development), but 
they did not stop metastasis once it had started. 
Mentor-Marcel et al. (2001) used a transgenic mouse model of prostate cancer in 
mice (TRAMP model) to mimic prostate cancer. Starting at 5-6 weeks of age up to 28-30 
weeks of age, these mice were fed genistein at 0, 100, 250 and 500 mg/kg diet (0, 44, 111 
and 222 |imol/kg BW/d) (n=25, 10, 17 and 7, respectively). Not only was no toxic effect of 
genistein observed, but also a decrease in poorly differentiated adenocarcinoma was observed 
in a dose dependent manner at 0, 44 and 111 pmol/kg diet BW/d (-30, 20 and 10% animals, 
respectively). The dose of 222 pmol/kg BW/d was similar to 111 pmol/kg BW/d in effect. 
On the other hand, proportions of well-differentiated and moderately differentiated prostatic 
adenocarcinoma were not affected by genistein feeding. The authors concluded that genistein 
had a significant protective effect of genistein on prostate cancer. 
c. In vitro studies 
Studies on in vitro proliferation or inhibition of cancer cell lines by isoflavone were 
conducted to better understand the possible mechanisms of action of these compounds. As in 
animal studies, genistein has been extensively investigated because of its ability to inhibit 
several enzymes necessary for growth and proliferation of cancer cells (Messina et al. 1994). 
Mechanisms of action of daidzein and glycitein with respect to cancer are somewhat more 
obscure and have not been as well investigated as genistein in either animal or in vitro 
studies. 
Hsieh et al. (1998) found that a low concentration of genistein (10 nM) enhanced 
proliferation of human breast cancer cells (MCF-7) while concentration above 20 (iM 
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inhibited the growth (IC50= 16-27 pM). Compared with control, 1 pM genistein produced a 
3-fold greater cell proliferation, while 100 pM genistein decreased cell proliferation by 40%. 
An increase in proliferation was accompanied by an increase in expression of the pS2 gene, 
which is estrogen-dependent and related to cell proliferation. Genistein had a dual effect and 
acted as an estrogen agonist at low concentrations and an antagonist at high concentrations. 
With another breast cancer cell line (MDA-468) that did not contain estrogen receptors, 
Peterson et al. (1991) found an inhibition of proliferation with a similar high dose of 
genistein, but a similar lower dose did not enhance proliferation. Thus, the presence of 
estrogen receptors may be required for genistein to activate cancer cells, while cellular 
inhibition may occur by estrogen receptor-independent mechanisms. 
Akiyama et al. (1987) used epidermal growth factor receptors from cancer A-431 
cells. These receptors are tyrosine-kinase dependent, enzymes necessary for the 
phosphorylation and activation of some cancer-associated genes. The rationale for using 
these cells was that the intricate relationship between EGF receptor, tyrosine kinase and cell 
growth proliferation created a suitable model for inhibition of cell growth by genistein, if the 
mechanisms involved inhibition of tyrosine kinase. Genistein inhibited tyrosine kinase in a 
dose dependent manner (0, 1, 3, 10, 30 and 100 ug/mL; graphical data provided the lowest 
dose with an effect) confirming the hypothesized inhibitory effect. However, these results 
and conclusions were reported from observing blots without statistical analysis. 
Another possible explanation of genistein's inhibitory effect on cancer cells is the 
inhibition of DNA topoisomerase and DNA cleavage. Salti et al. (2000) examined the effect 
of genistein in apoptosis and topoisomerase Il-mediated DNA breakage in colon cancer cells 
(HT-29). Using fluorescent techniques to assess DNA breakage, they found that genistein 
increased DNA breakage in a dose-dependent manner at 10, 30, 100 and 200 pM (DNA 
damage score from ~75 to -150 arbitrary units one hour after treatment, extrapolated from 
graphical data). Apoptotic cells increased by 54 ± 3.5% and 94 ± 1.4% compared to untreated 
cells at 60 and 150 pM genistein, respectively. 
Vissac-Sabatier et al. (2003) focused on how phytoestrogen-rich diets impact 
expression of Brcal and Brca2, two major tumor suppressor genes of human breast cancer. 
They analyzed the expression of these genes in mammary glands of ovariectomized (ovx) 90 
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d old Wistar rats fed different diets for 90 d (n^lO/group; controls were sham operated and 
ovx animals fed the same diet without soy or isoflavones). Diets contained Novasoy (159, 
156 and 33 mg of genistein, daidzein and glycitein/g Novasoy, respectively) at 20, 40 or 80 
mg total isoflavone/kg body weight/day. Soylife contained 5.55, 15.36 and 14.09 mg of 
genistein, daidzein and glycitein/g Soylife, respectively and was given at dose of 4, 8 and 16 
mg total isoflavone/kg body weight/day. None of the treatments increased expression of 
Brcal while doses of 8 mg Soylife and 80 mg Novasoy increased Brca2 expression by a 
factor ~2 and ~3, respectively. In a separate part of the study, comparison of animals fed 40 
and 80 mg isoflavone/kg body weight/day from Novasoy to animals treated with o^-estradiol 
(30 ng/kg body weight) showed that all three groups increased significantly Brcal levels 
compare to sham or ovx control animals. Brca2 levels were significantly increased with 
estradiol and 80 mg isoflavone from Novasoy/kg body weight/day animals. The authors 
concluded that isoflavones from supplements significantly increased the expression of 
cancer-suppressor genes. Different proportions of one isoflavone to the other was not a major 
factor in the outcome measured, thus suggesting that all three isoflavones may work in an 
additive manner to prevent cancer. 
Therefore, isoflavones' mechanisms of action to prevent cancer are multiple and will 
deserve more investigation in animal and possibly human trials. On the other hand, most of 
the published studies on genistein and cancer-associated enzyme inhibition were done with 
pharmacological doses of genistein (greater than the highest dose achievable through a 
normal diet rich in soy products). This calls into question of extrapolating the data to in vivo 
situations (Barnes et al. 1995). 
d. Summary 
Isoflavones as cancer-protective agents are under investigation. Despite 
epidemiological data that showed a correlation between consumption of soy and/or 
isoflavone and lower risk of cancer (Hirayama. 1979; Zheng et al. 1999), animal and in vitro 
studies provided mixed conclusions, especially with respect to the doses necessary to inhibit 
cancer (above dietary levels; Lamartiniere et al. 1995), the apparent dual action of genistein 
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(Hsieh et al. 1998) and the actual modes of action observed in vitro that may not be valid in 
vivo (Akiyama et al. 1987; Markovits et al. 1989; Constantinou et al. 1996). Estrogen-
dependent cancers, such as breast cancer, may be studied separately from estrogen-
independent cancers. As seen in the toxicity section (McMichael-Phillips et al. 1998), there 
also may be a dual action of genistein in humans, where it is inhibitory when administered 
before but stimulatory after cancer development. This would support the conclusion that 
isoflavones might be cancer-protective, but not curative. 
2. Isoflavones and blood lipid profile 
Among all the health-enhancing or protecting effects that have been hypothesized for 
isoflavones, the cholesterol-lowering effect has been one of the most controversial. Many 
studies have been performed in both animals and humans, but the data have led to some 
discrepancies and opposing opinions as to how effective isoflavones are in improving the 
blood lipid profile. 
a. Human studies 
Human studies focusing on the hypocholesterolemic effects of isoflavones have also 
given rise to variable results. Several factors may be considered when analyzing the data: 
age, baseline blood lipid profile, isoflavone source (purified, dietary supplement or part of 
soy protein), dose of isoflavones and duration of the feeding period (Demonty et al. 2003). 
Great variations of these factors from one study to the next make comparative analysis of the 
data a real challenge. According to Goodman-Gruen et al. (2001), one of the major 
disadvantages of providing soy protein when focusing on isoflavones and cholesterol is the 
variety of other bioactive compounds present, such as saponins that might interfere with the 
hypothesized isoflavone cholesterol-lowering effect. It also seems that providing isoflavones 
to individuals with moderate to severe baseline hypercholesterolemia might result in more 
improvements compared with individuals who have normal baseline blood lipid profiles as 
seen in obese v. lean rats (Peluso et al. 2000). 
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An epidemiological study performed by de Kleijn et al. (2002) grouped 939 post­
menopausal women into quartiles according to their isoflavone intake. They found that 
women in the highest quartile of isoflavone intake (>0.9 pmol/kg BW/d) had significantly 
lower plasma triglyceride (1.46 vs. 1.62 mmol/L) and mean cardiovascular risk factor 
metabolic score (1.30 vs. 1.74 score, calculated based on systolic and diastolic blood 
pressure, plasma triglycerides and HDL-C, body mass index and waist-to-hip ratio values for 
each subject) compared to the lowest quartile of isoflavone intake (<0.3 pmol/kg BW/d), 
respectively. Also comparing postmenopausal women (n=208) based on their isoflavone 
consumption, Goodman-Gruen et al. (2001) found that the group with the highest intake of 
genistein (>3.7 |_imol/kg BW/d) had significantly lower BMI (24.5±3.5 vs. 26.2±4.4) and 
greater HDL-C (1.5±0.04 vs. 1.4±0.65 mmol/L) compared to the group with no intake of 
genistein. Another epidemiological study (Ho et al. 2000) done in both Chinese men (n=500) 
and women (n=510) showed that higher soy and isoflavone consumption was negatively 
correlated with total cholesterol (R=-0.225; p~O.O46 and R=-0.283; p=0.033) for men and 
women less than 50 years of age, respectively. Isoflavone consumption also correlated 
negatively with LDL-C for men (R=-0.203; p=0.026) and women < 50 (R=-0.242; p=0.043). 
Women older than 50 years did not show any correlation between blood lipid profile and 
isoflavone intake, because of significantly lower dietary intake of soy and isoflavone 
compared to men (66.3±71.68 mg/wk vs. 101.6±107.5 mg/wk) and women less than 50 years 
of age (66.3±71.68 mg/wk vs.82.4±98.0 mg/wk). For this study, exclusion criteria were not 
listed, but all subjects that received dietary assessment at the hospital were eligible up to 
n=100 per age group (<34, 35-44, 45-54 and >55 years of age). Confounding factors included 
in these analyses were sociodemographic variables of sex, age, marital status and level of 
education. 
These epidemiological studies have led researcher to conclude that isoflavone 
consumption had a positive impact on blood lipid profile in both men and women and that 
there may be a minimum threshold intake required to observe an effect. However, clinical 
trials have showed much more varied and controversial results. 
Crouse et al. (1999) studied the effect of isoflavones in moderately 
hypercholesterolemic men and women (n=156; LDL cholesterol concentrations from 3.62 to 
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5.17 mmol/L). Subjects were divided into 5 groups (n=31) and given beverages containing 
either 25 g casein/day, 25 g ethanol-washed isolated soy protein/day that contained 3mg total 
isoflavones (0.15 |imol/kg BW/d) or 25 g soy protein/day at three levels of isoflavones: 27, 
37 or 62 mg total isoflavones (1.4, 1.95 and 3.3 juimol/kg BW/d) for 9 weeks. Subjects given 
3.3 pmol/kg BW/d had significantly lower levels of total (4% reduction) and LDL 
cholesterol (6% reduction) compared with casein controls. In addition, when subjects were 
divided in two groups (same n) based on their baseline cholesterol values, subjects with 
baseline LDL in the highest half (>4.24 mmol/L) had an even greater decrease in total (9%) 
and LDL cholesterol (10%) compare to casein. An 8% decrease was also observed in total 
and LDL-cholesterol of baseline-high LDL subjects fed 1.95 pmol/kg BW/d compare to 
casein group. Thus, this study showed not only a threshold effect of isoflavones in order to 
improve blood lipid profile but also that more severely hypercholesterolemic subjects had 
greater benefit from isoflavone than did moderately hypercholesterolemic subjects. 
An interesting aspect of cholesterol metabolism in pre-menopausal women was 
investigated by Merz-Demlow et al. (2000). They found that the baseline blood lipid profile 
differed in the different phases of the menstrual cycle (early follicular, midfollicular, 
periovulatory and midluteal phases). Consequently, they used a cross-over study to 
investigate the effect of no (<10 mg; 0.5 pmol/kg BW/d), low (-65 mg; 3.4 gmol/kg BW/d) 
and high (-130 mg/d; 6.8 pmol/kg BW/d) isoflavones diet from soy protein isolate, each 
applied during a full menstrual cycle (n=13). Women given the low isoflavone dose did not 
differ from the controls (no isoflavone) in any blood lipid value for any menstrual cycle 
phases. However, women fed the high isoflavone diet showed significantly lower LDL-C 
compare to control in the midfollicular (2.20±0.04 vs. 2.38±0.04 mmol/L) and periovulatory 
(2.07 ± 0.05 vs. 2.3 ± 0.05 mmol/L) phase. Also in the periovulatory phase, the high 
isoflavone diet improved the total:HDL-C ratio (2.91 ± 0.06 vs. 3.24 ± 0.05) and LDL-
C:HDL-C ratio (1.69 ± 0.05 vs. 1.96 ± 0.04) compare to control. Regardless of the menstrual 
phase, it seemed that a 3.4 pmol/kg BW/d dose of isoflavones was not sufficient to improve 
the blood lipid profile in pre-menopausal women, while a dose of 6.8 nmol/kg BW/d was 
effective. The same results were obtained in hypercholesterolemic postmenopausal women 
(n=18; time of study=93 d, crossover design with the same doses of isoflavones applied) by 
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Wangen et al. (2001). LDL-C cholesterol was significantly lower during high isoflavone 
intake compared to control (3.01±0.05 vs. 3.22±0.05 mmol/L). The low isoflavone feeding 
gave an intermediate result that was not different from control or high isoflavone (3.05±0.05 
mmol/L). While a dose of 3.3 (imol/kg BW/d was enough to produce significant results in 
Grouse et al. (1999) study (men and women), it seemed that in women (pre- or 
postmenopausal), a higher threshold isoflavone dose (-6.8 pmol/kg BW/d) was needed to 
obtain significant results (Merz-Demlow et al. (2000); Wangen et al. (2001)). Therefore, men 
and women may differ in the minimum dose required to obtain significant improvement in 
blood lipid profile. This could be partly explained by the fact that men and women differ in 
baseline blood lipid profile values. Freedman et al. (2004) compared plasma lipoprotein 
levels in men and women as part of the analysis of the Framingham study. They found that, 
when adjusted for age, men had significantly higher concentrations of triglycerides (mean 
0.24 g/L difference between men and women; pO.OOl) and LDL-cholesterol (mean 0.06 g/L 
difference; pO.OOl) while women had significantly higher HDL-C (mean 0.12 g/L 
difference; pO.OOl). Thus, women have lipid profiles less prone to cardiovascular disease, 
so that a higher dose of isoflavones is required to exert a significant impact on their blood 
lipid profile. 
Baseline cholesterolemia is also a crucial factor when designing this type of study. To 
accentuate the controversy surrounding the possible role of isoflavone in decreasing 
cholesterol, several studies have concluded that isoflavones do not improve the blood lipid 
profile. For example, Jenkins et al. (2002) examined the effect of a control (no soy products), 
high (73 mg; 3.8 nmol/kg BW/d) and low (10 mg/d; 0.8 (imol/kg BW/d) isoflavone 
containing soy protein diet (cross-over design; each diet=l month) involving 41 
hypercholesterolemic men and post-menopausal women. Guidelines to design the diets were 
followed from the National Cholesterol Education Program Step II. Regardless of the 
isoflavone dose, soy protein significantly decreased LDL-C, improved the total:HDL 
cholesterol ratio, the LDL:HDL cholesterol ratio and coronary artery disease risk. This study 
demonstrated that soy protein improved blood lipid profile but the role of isoflavone in this 
mechanism was not clearly established, probably due to some design-related issues. No 
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group was provided any soy protein, nor were groups given isoflavone without a soy protein 
matrix included, thus producing controversial conclusions. 
Isoflavone without a soy protein matrix was also investigated. Dewell et al. (2002) 
provided 36 moderately hypercholesterolemic post-menopausal women (mean total 
cholesterol =6.6±1.3 mmol/L) with 150mg isoflavone supplement/day (7.9 pmol/kg BW/d; 
n-2O) or placebo (n=16) for 2 months. Isoflavone tablets contained 90% aglycones/10% 
glucosides; analysis of other bioactive components found in the supplement was not 
performed. No significant differences were found between baseline and two months for the 
isoflavone fed group in total cholesterol and HDL-cholesterol. No differences were found in 
total cholesterol and HDL cholesterol between placebo and isoflavone groups. It is possible 
that in this study, despite a dose that should have been high enough to produce an effect, 
baseline moderate hypercholesterolemia may not be high enough to observe an effect as seen 
by Grouse et al. (1999). 
Similar results to Dewell et al. (2002) were found by Hodgson et al. (1998) with 46 
men and 13 postmenopausal women (all normocholestrolemic) given either a placebo or 
isoflavone (55 mg; 2.9 pmol/kg BW/d) tablets (analysis of other bioactive components found 
in the supplement was not performed) for one month, after adjustment for age, gender, 
weight or urinary excretion of isoflavones. In this case, the dose of isoflavones applied along 
with normal baseline cholesterol levels might have led to non-significant effects. 
To clarify the dose necessary for isoflavones to decrease LDL-C, Zhuo et al. (2004) 
performed a meta-analysis of 8 human studies with no, low and high isoflavone-containing 
soy protein treatments. They concluded that a minimum dose of 50 g soy protein (96 mg 
isoflavone/d; ~5 pmol/kg BW/d) was required to observe an effect. Both normo- and 
hypercholesterolemic subjects showed significant decreases LDL-C with 96 mg isoflavone 
(0.14 and 0.18 mmol/L decrease, respectively). However, those with baseline 
hypercholesterolemia showed an even greater p value (0.0008) in decreasing LDL-C 
compared to those with baseline normocholesterolemia (p=0.03). 
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b. Animal studies 
Animal studies on soy protein and isoflavones with respect to cholesterol-lowering 
effects have been investigated in a few animal models. Golden Syrian hamsters have been 
one of the most extensively studied because cholesterol metabolism in Golden Syrian 
hamsters closely resembles that of humans and hypercholesterolemia can be induced in a 
short period of time in this animal model (Bravo et al, 1994). 
Song et al. (2003) fed male and female Golden Syrian hamsters (n=10/sex/group; 6-8 
weeks of age) a high fat diet containing 130 [imol/kg BW/d of purified daidzein for 10 
weeks. Total cholesterol was significantly reduced by -24% and non-HDL cholesterol by 
-35% in both sexes. The fact that only daidzein was fed in its purified form make 
extrapolation to humans difficult considering that dietary isoflavones are consumed in a food 
matrix with different proportions of each isoflavone. 
Lin et al. (2004) fed male hamsters (n=20/groups; 5 weeks of age) for 5 weeks 30% 
fat, 0.08% cholesterol Western-type diets containing either casein, plant sterol esters, soy 
isoflavones from Novasoy® and different combination of these four diet components. 
Hamsters fed isoflavones (-80 pmol/kg BW/d) did not differ from the casein control for total 
cholesterol, triglycerides or HDL-cholesterol (p>0.05). This study disagrees with Song et al. 
(2003), but major differences in study design make comparisons almost impossible. Song et 
al. (2003) fed both sexes at a higher dose/kg diet of purified daidzein (130 pmol/kg BW/d), 
while Lin et al. (2004) used only male fed Novasoy at a dose of 80 nmol/kg BW/d. 
Therefore, both sexes should be included for such a design and a minimal isoflavone dose 
expected to produce significant results should be considered as well. 
Blair et al. (2002) examined male (n=75) and female (n=74) Golden Syrian FIB 
hybrid hamsters (12 weeks of age) fed either casein, soy protein with (450 mg isoflavone/kg 
diet or 166 nmol/kg BW/d) or without (10 mg total isoflavone/kg diet or 3.7 |imol/kg BW/d) 
isoflavone, isoflavone-deprived soy protein and casein to which an isoflavone supplement 
(325 mg total isoflavone/kg diet or 120 (imol/kg BW/d) was added. All diets were 
extrapolated in composition to mimic a typical Western diet (high saturated fat from lard, 
beef tallow, and butter and high sugar from sucrose). After 16 weeks, none of the treatments 
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lowered LDL+VLDL-cholesterol (C) in females whereas in males, the three soy protein-
based diets, but not the casein+isoflavone diet reduced LDL+VLDL-C significantly (-25 to 
50%). Plasma LDL+VLDL-C was positively correlated with plasma isoflavone in females 
(r=0.65; p=0.02) but not in males (r=0.47; p=0.28). HDL-C was significantly higher in 
females fed soy protein with or without isoflavone (-25%) while males did not show any 
improvement in HDL-C after soy feeding. This study showed a clear gender-related effect 
associated with soy protein, but isoflavone as part of soy protein or supplement did not show 
any positive effect in improving blood lipid profile. On the other hand, animals in Blair et al. 
(2002) were older than in the Lin et al. (2004) and Song et al. (2003) studies. Differences in 
background diet composition may also alter the outcome. For example, the main source of 
saturated fat in Song's study was coconut oil while in Blair's study, lard, beef tallow and 
butter were used. This may have had an influence in raising cholesterol levels in the animals 
so that induction of hypercholesterolemia and choices of diets were important factors to 
consider when designing such a study. Control diets may have also contributed to the results 
obtained. While Blair et al. (2002) used a control diet where soy protein was replaced by 
casein, Song et al. (2003) used the same diet as the treatment without isoflavone. Therefore, a 
control diet closer to that of the treatment may be more appropriate than a control diet with 
changes in major nutritional factors, such as the protein source. 
Using a rat model, Peluso et al. (2000) examined the effect of isoflavone in male 
obese Zucker rats and male lean Sprague-Dawley rats. Diets were casein, low isoflavone soy 
protein (38 mg/kg diet or 14 p.mol/kg BW/d) or high isoflavone soy protein (578 mg/kg diet 
or 214 ^mol/kg BW/d). All diets were formulated to contain 18.6% protein, 69.4% 
carbohydrate and 12.0% fat. Plasma and liver total cholesterol was significantly reduced in 
rats fed both soy protein diets (21 and 29% for low and high isoflavone doses, respectively) 
compared with casein fed control obese animals. Liver total triglyceride level, liver 
cholesteryl ester and liver weight were significantly lower in high vs. low isoflavone diet 
(p<0.05; numerical data not available), which indicated a possible greater effect on 
cholesterol metabolism when isoflavones were present. In lean animals, no treatment diets 
improved plasma total cholesterol and triglyceride. However, feeding a high isoflavones diet 
significantly decreased liver total cholesterol and cholesteryl ester levels compare to casein 
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feeding but not low isoflavones feeding. This study produced mixed conclusions about the 
role of isoflavone in cholesterol metabolism. However, it seemed that results were more 
significant in obese than lean animals, suggesting that baseline cholesterol profile is an 
important factor to consider. Higher starting total cholesterol concentrations may be 
necessary for isoflavones to exert a significant effect compared to a more "healthy" baseline 
blood lipid profile. 
c. Mechanisms of cholesterol lowering by isoflavones 
Despite conflicting results of isoflavone on cholesterol metabolism, a few studies 
have focused on the possible mechanisms by which isoflavones interact with lipoproteins. 
One possible mechanism is a decrease in oxidation of LDL, which decreases uptake by 
macrophages in the arterial wall, thereby leading to a decrease in plaque formation. This 
mechanism may not be a cholesterol-lowering effect per say, but cardiovascular disease and 
blood lipid profile are highly correlated with each other. Jenkins et al. (2000) looked at the 
effect of a low-fat diet vs. a low-fat diet + 33g soy protein (86 mg isoflavone/d; 4.5 pmol/kg 
BW/d) fed for 1 month to 31 hyperlipidemic subjects. Mean total cholesterol and LDL-
cholesterol decreased significantly between control and soy diets (-0.38 ± 0.07 mmol/L and -
0.27 ± 0.07 mmol/L decrease for total and HDL-C, respectively). In addition, ex vivo 
oxidized LDL, expressed as conjugated dienes (-7 ± 2 pmol/L) and conjugated dieneszLDL 
ratio (-0.7 ± 0.4) decreased significantly from control to soy treatment. The author concluded 
that isoflavone-rich foods improve blood lipid profiles, partly because of a decrease in LDL 
oxidation. However, a soy treatment without isoflavones was not included in this study, so 
that the actual role of isoflavones vs. other bioactive components found in soy protein in 
decreasing LDL oxidation and improving blood lipid profiles has not been fully proved. In a 
cross-over design of 2 menstrual cycles with placebo and 2 menstrual cycles of red clover 
tablets supplementation (43 mg/d; 2.2 (amol/kg BW/d), Samman et al. (1999) did not find any 
significant changes in blood lipid profile or in ex vivo copper-induced LDL oxidation (lag 
time of 32.9 ±3.1 vs. 30.4 ± 2.9min for placebo and supplement, respectively) from plasma 
sample obtained from the subjects (14 premenopausal women) in either study design. 
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Therefore, isoflavone without a protein matrix did not improve LDL oxidation but the dose 
of supplementation may have been below a threshold level. 
LDL uptake by the liver is due to a higher presence of LDL receptors, thereby 
reducing LDL-C. Baum et al. (1998) studied for 24 weeks 66 hypercholesterolemic 
postmenopausal women fed soy protein containing either 56 mg or 90 mg total isoflavones/d 
(2.9 and 4.7 pmol/kg BW/d) and a control group fed a casein-based diet. Both doses of 
isoflavones increased significantly expression of LDL receptor (127 ± 17.7 and 175 ± 31% of 
baseline measurements for 2.9 and 4.7 |j.mol/kg BW/d groups, respectively), as reflected by a 
higher mononuclear cell LDL receptor mRNA concentrations compared to the control group 
(74 ± 7.8 % of baseline). Also focusing on LDL receptor, Kirk et al. (1998) used mice that 
lacked LDL-receptor (LDL-null) and wild type C57BL/6 mice, each type fed a diet 
containing either high (-350 mg total isoflavone/kg diet; 155 pmol/kg BW/d) or low (-35 
mg/kg diet; 15 pmol/kg BW/d) levels of isoflavones for 6 weeks. Plasma cholesterol and 
LDL oxidation were similar between the two diets in the LDL-null animals, whereas in wild 
type mice, high isoflavones decreased total cholesterol by 30% and atherosclerotic lesions by 
50% compared to the low isoflavone diet. This study not only showed a significant effect of 
isoflavones on cholesterol metabolism, but also the important relationship with LDL 
receptors in achieving these effects. A greater increase in LDL receptor expression in the 
highest compared to the lowest dose of isoflavones in wild type mice also suggested the 
possibility of a dose-response up-regulation effect However, regression and correlation 
analysis to test this hypothesis were not performed in that study and deserved further 
investigations. 
d. Summary 
From the studies selected throughout this review, isoflavones may have a positive 
action on blood cholesterol. The most important factors to consider are gender, dose (-100 
mg isofiavone/d or 5.3 jimol/kg BW/d), baseline cholesterol (hypercholesterolemia) and time 
(1 month minimum) in order to obtain significant improvement in blood lipid profiles. With 
respect to animal models, uncertainty factors between humans and animals and higher doses 
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(-10 to 15 folds) required to observe similar effects (as seen in cancer section) would led to 
the hypothesis that if a dose of -5 ^.mol/kg BW/d is required to observe an effect in humans 
with relevance to dietary intake, a dose of - 50-75 pmol/kg BW/d applied to animals 
producing significant results would be considered for extrapolation to humans. Higher doses 
would be classified as pharmacological (use of supplements; dose not achievable with diet 
only) and results observed deserve further investigation to ameliorate relevance to humans. 
3. Isoflavones and immune function 
Among all of the possible health-related effects that may be associated with 
isoflavone, enhancement of immune function has been demonstrated, but the number of 
studies published is somewhat more limited compared to other health effects. Zhang et al. 
(1999a) compared isoflavone aglycones and glucuronides, the two main forms found in 
plasma after ingestion, with respect to modulation of human natural killer cells. 
Concentrations of 0.1 to 10 pM of daidzein and genistein glucuronides activated NK cells in 
vitro by -30% and toxicity was not observed with isoflavone glucuronide concentration up to 
50 p.M. Genistein (aglycone) activated NK cells at 0.1 to5 pM but inhibition was observed at 
10 nM. Consequently, isoflavones glucuronides were as efficient, but less toxic than their 
aglycone equivalent in benefiting NK activity. Guo et al. (2001) used an in vivo model to 
study isoflavone and immune function. B6C3F1 mice were gavaged for 28 d with different 
doses of genistein (0, 2, 6 or 20 mg/kg body weight; 0, 7.4, 22 or 74 pmol/kg BW/d; 
n=12/group), injected with 105 B16F10 melanoma cells 24h after the last dose of genistein 
and killed 18 d after cancer cells injection. Host resistance to cancer formation and cytotoxic 
T cells activity were proportional to the dose of genistein fed. After killing, in vitro basal NK 
activity was not affected by genistein while IL-2-stimulated NK activity was significantly 
increased in animals originally fed 20 mg genistein/kg body weight (effector:target ratio was 
25:1). Splenic B-cell percentage and IgM and IgG antibody cell response were not affected 
by genistein. This study showed that genistein was tumor protective, probably due to an 
increase in immune function and resistance. Guo et al. (2002) also studied the effect of 
genistein intake in a two-generation rat model. Sprague-Dawley rats (F0) were fed three 
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doses of genistein: low (25 ppm; 9 ^mol/kg BW/d), medium (250 ppm; 92 pmol/kg BW/d) 
or high (1250 ppm; 462 nmol/kg BW/d) starting at d 7 of pregnancy to postpartum d 51. 
Control animals received a diet deprived of any isoflavone. F1 animals (males and females) 
received the same genistein doses as their mothers up to 64 d after birth. F0 animals did not 
have any significant changes in proportions or amounts of T-cells, B-cells or NK cells. NK 
activity was significantly higher in the medium (111% increase) and high group (133% 
increase). In F1 male rats, significant increases in numbers of splenocytes, T cells, T-helper 
cells and cytotoxic T-cells were observed at all 3 doses of genistein. NK cell number was 
unaffected but the proportion of NK to other types of splenic cells was significantly lower 
than the control at all 3 doses. NK activity showed a significant increase at 462 pmol/kg 
BW/d genistein with 200:1 effectontarget ratio only. F1 female animals also showed 
increases in T cells numbers (462 pmol/kg BW/d), T helper cells (9 and 462 |imol/kg BW/d) 
and cytotoxic T cells (92 and 462 |imol/kg BW/d 1250ppm). Decrease in % NK cells was 
observed for 9 and 462^imol/kg BW/d genistein. Splenocyte IgM antibody-forming cell 
response to T-dependent antigen sheep RBC was increased by 122% at 462 nmol/kg BW/d, 
while no significant data were found for the male F1 animals. Lastly, NK activity was 
enhanced only at 462 pmol/kg BW/d with 100:1 effectontarget ratio. The authors concluded 
that genistein did not have similar effects in F0 compared to F1 animals. In addition, male 
and female F1 rats did not produce the same results, suggesting that immunomodulation by 
isoflavone may have a gender-specificity, although the authors mentioned that the underlying 
mechanisms to explain these differences are still unknown (Guo et al. 2002). Different 
baseline immune functions and profiles, along with hormonal modulation of immune 
response probably specific to each gender could be hypothesized to be partly responsible for 
the observed data. Effects of isoflavones in vivo, particularly in humans, need further 
investigation. The possible relationships between isoflavones, tumor formation and immune 
system also deserve further investigations. 
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4. Isoflavones and osteoporosis 
Osteoporosis is defined as a "disease characterized by low bone mass and 
microarchitectural deterioration of bone tissue leading to enhanced bone fragility and a 
consequent increase in fracture incidence" (Melton and Riggs. 1983). This disease affects 35 
million humans around the world and is more prevalent in women than men, especially after 
menopause which causes a lack of estrogen, leading to a decrease in bone formation and an 
increase in bone resorption (Melton et al. 1992). While drugs, such as raloxifene have a 
positive effect in preventing bone loss because of its weak estrogenic effect that partially 
replaces the loss of estrogen after menopause (Delmas et al. 1997), other estrogen-like 
dietary compounds, such as isoflavones contained in soy products, have been studied as 
osteoporosis-preventing compounds. 
a. Human studies 
Fewer studies focusing on isoflavones and osteoporosis have been performed in 
humans than in animals. Dalais et al. (1998) performed a double-blind, randomized, entry-
exit, cross-over study in which they provided postmenopausal women (n=44) different diets 
for 12 weeks, containing either 45 g soybean grits (53 mg total isoflavone; 2.8 pmol/kg 
BW/d) or 45 g wheat. Bone mineral content increased by 5.2% (p<0.04) and 3.8% (non 
significant) for the soy and wheat diet, respectively compared to baseline. No changes were 
detected in bone mineral density. Dalais and colleagues concluded that isoflavones may have 
an impact in improving bone health in postmenopausal women, but further investigation 
would be needed. 
Also in 1998, Potter et al. compared the effect of 2 doses of isoflavones using isolated 
soy protein (40 g/day for 6 months) as part of a parallel-group, double-blind trial in 
postmenopausal women. The two doses were 55 and 90 mg total isoflavones/d (2.9 and 4.7 
Hmol/kg BW/d). Another group received casein as a control. The increase in lumbar spine 
bone mineral density and bone mineral content between baseline and 24 weeks was 
significantly greater in the 4.7 jimol/kg BW/d group (0.892 ± 0.114 vs. 0.912 ± 0.119 g/cm2 
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and 49.6 ± 8.3 vs. 50.8 ± 8.7 g/cm2 at time 0 and 24 weeks for bone mineral density and bone 
mineral content, respectively) compare to casein (0.940 ±0.159 vs. 0.934 ±0.153 g/cm2 and 
56.0 ±11.0 vs. 55.4 ± 10.3 g/cm2 at time 0 and 24 weeks for bone mineral density and bone 
mineral content, respectively), while the group receiving 2.9 pmol/kg BW/d did not show 
significantly improved bone density and mineral content compare to casein. While this study 
suggested a minimal daily dose required for isoflavone to exert an effect on bone, 
interpretation of the data is somewhat confusing, considering that baseline values were 
different among groups and not taken into account in the analysis. Since there was no 
difference between time 0 and 24 weeks for each group, this study does not clearly 
demonstrate an effect of isoflavones on bone density. 
Another study published by Alekel et al. (2000) focused on 69 perimenopausal 
women given 40 g of soy protein isolate with isoflavones SPI+ (80.4 mg total 
isoflavones/day or 4.2 gmol/kg BW/d; n-24) or with reduced isoflavone content SPI- (4.4 
mg/day; n=24). Another group (n=21) was given whey control protein (40 g/d). Both SPI+ 
and SPI- groups maintained their bone mineral density and content, while significant 
decreases were observed for both in the control group. Analysis of covariance showed that 
there was a treatment effect on bone mineral content. Multiple regression taking into account 
baseline values as well as other confounding factors, like body weight, showed that only 
SPI+ treatment contributed positively from the control for bone mineral density (5.6%; 
p=0.023) and bone mineral content (10.1%; p=0.0032). This study clearly showed that soy 
protein without isoflavones did not fully prevent bone loss, thereby demonstrating that 
isoflavones exerted an effect on bone density. 
Despite the fact that these studies are over a short-term period (<1 year), they do 
provide some basis for future investigations that would either confirm or refute the potential 
role of isoflavones in preventing bone loss. On the other hand, the study of Ho et al. (2001) 
was conducted over 3 years with 132 women (30-40 yoa). Measurements at baseline and at 3 
years included bone mineral density using DXA, soy food intake and other key nutrients, 
such as calcium. Consumption of isoflavones was divided in quartiles (0 to 0.15 (imol/kg 
BW/d, n=37; 0.15 to 0.23 |imol/kg BW/d, n=21; 0.23 to 0.39 pmol/kg BW/d, n=29; 0.39 to 
2.5 pmol/kg BW/d, n=29) and the loss of bone mineral density was significantly less in the 
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highest quartile of intake (1.1%) compare to the lowest (3.5%), when confounding factors 
were included in the regression analysis. Overall, isoflavones accounted for 24% of the 
variance of the bone density regression slope obtained with individual values at time 0 and 3 
years. This long-term study with sufficient power provided evidence that soy foods 
containing isoflavones help prevent bone loss in 30 to 40 years old women. However, 
subjects selected were not postmenopausal, which could lead to conduct additional studies 
with respect to the design of Ho et al (2001). It would be very instructive to follow 
premenopausal women who consume soy through menopause to determine the effects 
b. Animal studies 
Animal studies focusing on soy and osteoporosis were mostly performed as short-
term studies with ovarectomized (ovx) animals, a procedure that is arguably relevant to 
menopause in women (Thompson et al. 1995). 
Using ovariectomy to mimic menopause in 95 d-old Sprague Dawley rats 
(n=8/group), Aqmandi et al. (1996) found that ovx animals fed soy protein isolate (SPI) (227 
g/kg diet; isoflavone content not mentioned) for 30d had significantly higher mean bone 
density of the right femur (-1.5 vs. -1.3 g/cm3 bone volume; pO.OOl) and the fourth lumbar 
vertebra (-1.45 vs -1.3 g/cm3 bone volume; p0.05) compared to ovx animals fed casein. 
The ovx group fed casein also had significantly greater serum concentrations of 1,25-
dihydroxy-vitamin D, a marker of bone resorption, compared to animals fed SPI. Aijmandi 
and colleagues concluded that soy is effective in preventing bone loss due to ovarian 
hormone deficiency. However, they could not conclude if it was soy or isoflavones 
themselves that were responsible for the positive effect observed on bone density. 
To understand the specific role that isoflavones may play in bone density, Arjmandi 
et al. (1998) conducted another study in which 48 Sprague-Dawley rats (90 d-old) were 
divided in 4 groups: 1 sham and 1 ovx group fed casein; 2 ovx groups fed a diet with SPI 
containing either normal (+; 473 mg total isoflavones as aglycone/kg diet) or reduced (-; 45 
mg/kg diet) isoflavone content. The different diets were given for 35 d after surgery. Serum 
alkaline phosphatase, a nonspecific marker of bone formation, was significantly higher in the 
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SOY+ group (84 ± 16.2 U/L) compared to sham animals (106 ± 12.6 U/L). In addition, 
SOY+ animals had a mean right femur density (1.497 ± 0.030 g/cm3 bone vol) similar to the 
sham group (1.522 ± 0.041), but significantly higher than ovx (1.449 ± 0.044) or soy- (1.452 
± 0.030) groups, which indicated that isoflavones prevented bone loss after ovx. 
To understand which isoflavones play a role in bone density, Picherit et al. (2000) 
compared the effect of daidzein and genistein on ovx 12 month old female Wistar rats. 
Controls included sham operated and ovx animals fed a soy-free diet with no isoflavone 
supplementation (n= 13/groups; feeding period= 90 days). Daidzein and genistein were given 
orally in the diet at a dose of 10 mg or 37 pmol/kg BW/d. They found that bone mineral 
density of lumbar vertebrae, femur and its metaphyseal (cancellous bone) and diaphyseal 
(cortical bone) zones analyzed by DEXA were not different between the daidzein and sham 
groups, while genistein and sham groups were not significantly different in the diaphyseal 
bone mineral density only (numerical data not available). No difference in bone turnover 
markers was observed between the groups. Overall, Picherit and colleagues concluded that 
daidzein was more efficient in preventing bone loss than genistein. This study was also of 
great interest because isoflavones were fed as pure compounds without a soy protein matrix, 
which clearly established the importance of isoflavones in preventing bone loss in the rat 
model. Another study from the same group published in 2001 looked at a dose response in 
the same animal model. Ovx Wistar rats (10/groups) were fed 0, 20, 40 or 80 mg isoflavones 
(0, 74, 148, 296 pmol/kg BW/d from Novasoy®) for 91 days. Ten sham-operated animals 
fed no isoflavones served as a control. Total and diaphyseal bone mineral density of the 
femur was not significantly different between sham controls and rats fed 74, 148 and 296 
pmol/kg BW/d whereas the rats fed 148 and 296 pmol/kg BW/d had non significantly 
different metaphyseal femoral bone mineral density compared to sham operated animals and 
compared to each other. Urinary pyroxidinoline, a marker of bone resorption was also similar 
between sham, 148 and 296 pmol/kg BW/d groups while significantly lower in the 74 
^mol/kg BW/d group (numerical data not available). On the other hand, rats fed 296 nmol/kg 
BW/d showed a somewhat toxic effect with a significantly higher mean uterine weight (0.40 
± 0.04g) compared to the other isoflavone doses (0.18±0.01, 0.19±0.02 and 0.22 ± 0.03g for 
the rats fed 0, 74 and 148 pmol/kg BW/d, respectively). Therefore, the optimal dose of 
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isoflavones to prevent bone loss without noticeable adverse effects has been established at 
148 pmol/kg BW/d in the ovx Wistar rat model. In humans, with an uncertainty factor of 10-
15 described in the cancer section, a dose of efficacy in humans to exert significant bone-
sparing effect should be between 15 and 20 (imol/kg BW/d, which exceeds at least by a 
factor 3 the normal doses obtained from diet only. Isoflavone consumed as a supplement to 
achieve such doses would then have to be considered in future human clinical trials. 
Considering these data and conclusions altogether, isoflavones do have a positive effect in 
preventing bone loss and further replication of these data with relevance to humans could 
lead to consider isoflavones as bone-sparing compounds. 
c. Summary 
As observed with cancer, isoflavones may offer osteoporosis protection. In this case, 
pre-, peri- or postmenopausal women as well as the dose of isoflavone, baseline bone mineral 
density and bone mineral content, and time of treatment should be carefully selected to 
investigate solely the role of isoflavones in preventing this chronic disease. 
5. Isoflavones and menstrual cycle and menopause 
Isoflavones have received much attention related to estrogen-dependent diseases and 
their mechanisms, because of the structural similarities that these compounds have with 
estrogen (Figure 3). Thus, isoflavones and some of their metabolites have been studied for 
binding to estrogen receptors (Setchell and Adlercreutz, 1988). 
Isoflavones have among many other mechanisms, a weak estrogenic mode of action, 
and they can act as an agonist or antagonist compared to estrogens, depending on the tissue 
or organ reached and receptor bound (Jordon, 1990; Brann et al. 1995). Song et al. (1999) 
compared the estrogenic activity and estrogen receptor affinity of daidzein, genistein and 
glycitein compare to 17p-estradiol (the main estrogen hormone in premenopausal women) 
and diesthylstilbestrol DES (synthetic estrogen). Using a mouse uterine enlargement assay 
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and estrogen receptor relative affinity, they found that l?P-estradiol and DES were the most 
potent compounds and that isoflavones act as weak estrogens. They showed a relative affinity 
for the estrogen receptor that is 200, 3700 and 3600 times lower than 17[3-estradiol for 
genistein, daidzein and glycitein, respectively. In addition, daidzein estrogenic relative 
potency was known to be lower than that of genistein by a factor of 5 (Farmakalidis and 
Murphy. 1985), but the relative potency of glycitein was found to be 3 times higher than 
genistein. Although glycitein is found as in minor proportions in soyfoods, this stronger 
estrogenic activity deserve further attention (Song et al. 1999). 
Estrogens and estrogen-like compounds bind to two families of estrogen receptors, 
ER a and p, the second being recently discovered as being a receptor bound mostly by 
isoflavones and non-steroidal estrogens (Kuiper et al. 1997&1998). ERa is found in great 
proportions throughout the human body, especially in the adrenal gland, kidney, breast, 
uterus, ovaries and testes. The presence of ER|3 has been shown in the brain, thymus, lung, 
bladder, bone, breast, uterus, ovaries and prostate (Setchell and Cassidy. 1999). The 
discovery of this receptor, along with the dual action of isoflavones in organs possessing 
either one or both receptors led to endless possibilities about the metabolic and health-related 
mechanisms of action of isoflavone. 
Two of the main processes in women depending on estrogen metabolism that have 
been investigated with regard to isoflavones are menstrual cycle and menopause. 
Figure 3: Chemical structure of isoflavone. 
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Figure 3 (continued): Chemical structure of estradiol 
a. Menstrual cycle 
Cassidy et al. (1994) examined the effect of 1 month supplementation of soy protein 
(60 g protein or 45 mg isoflavone/d; 2.4 pmol/kg BW/d) compared to a control diet without 
isoflavone on the menstrual cycle of 6 premenopausal women (mean age 24 years). 
Significantly delayed menstruation (1 to 5 d in 5 subjects) and increased follicular phase (2.5 
± 1,6d) but not luteal phase was observed with isoflavone intake. LH and FSH levels were 
significantly lower (21.2 ± 12.7 vs. 7.1 ± 2.6 U/L and 14.6 ± 5.6 vs. 7.8 ± 4.6 U/L for LH and 
FSH levels of control vs. soy diets, respectively). Plasma estradiol also increased 
significantly during the luteal phase of the soy treatment. These results showed that 
isoflavones act as an anti-estrogen with respect to menstrual cycle. Cassidy also mentioned 
epidemiological data showing that Asian women have longer menstrual cycles and lower 
rates of breast cancer compare to Caucasian women (Treolar et al. 1970), suggesting a 
possible connection between hormonal modulation induced by isoflavones and prevention of 
breast cancer. 
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Lu et al. (2000) also examined hormonal levels of premenopausal women (n=10; 
mean 30 years of age) during a month supplementation of soy milk providing an average of 
150 mg total isoflavone/day (7.9 nmol/kg BW/d). They found a significant decrease in 17(3-
estradiol (25%) and progesterone (45%) compare to baseline measurements previous to the 
study. No changes in LH, FSH or menstrual cycle length were found, although the increase in 
follicular phase was marginally significant (p=0.06). As observed in Cassidy et al. (1994), 
the range of urinary excretion was very large and varied from 9.1 to 37.6% of ingested dose. 
Secondary analysis showed that decrease in 17(3-estradiol was proportional to urinary 
excretion of isoflavones, which in turn was influenced by age. 
Considering that there is a difference in mean age between the studies of Cassidy et 
al. (1994) and Lu et al. (2000) and that urinary isoflavones and possibly hormonal levels may 
be influenced by age, this could explain why some significant results found in Cassidy's 
study were not reproduced in Lu's study. High levels of circulating 17(3-estradiol have been 
associated with increased risks of breast cancer (Hankinson et al. 1995), suggesting that 
isoflavones may protect against breast cancer by modulating sexual hormone profiles. 
Isoflavone intake and its consequences in hormonal levels and menstrual cycle length 
tested over several menstrual cycles also need further investigation. Duncan et al. (1999) 
examined the effect of no (control: 0.15 mg or 0.5 pmol/kg BW/d), low (1 mg or 3.7 
|imol/kg BW/d) or high (2 mg or 7.4 pmol/kg BW/d) isoflavone intake (from soy protein 
powder) in 10 pre-menopausal women. In a randomized cross-over design, each diet was 
consumed for 3 menstrual cycles. Compared to control, the low isoflavone diet significantly 
decreased plasma LH (26.6 ±1.8 vs. 19.1 ± 2.0 IU/L; p=0.009) and FSH (4.62 ± 0.2 vs. 3.92 
± 0.2 IU/L; p=0.04). The high isoflavone diet significantly reduced DHEA-S (4566 ±521 vs. 
4408 ± 476 nmol/L; p=0.02) and free T3 (3.46 ± 0.1 vs. 3.27 ± 0.11 pmol/L; p=0.02). 
Moreover, isoflavone consumption did not influence endometrial thickness as assessed by 
histology (no detailed data provided). The authors concluded that isoflavone may not be the 
primary factor responsible for altering the hormonal profile and decreasing the risk of cancer 
in premenopausal women. In another study from the same group (Xu et al. 2000a), the 
hypothesis that isoflavones may decrease estrogen metabolites (16a-(OH) estrone, 4-(OH) 
estrone and 4-(OH) estradiol) possibly related to an increase in cancer risk was investigated. 
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Using the same study design and diets as Duncan et al. (1999), 18 premenopausal women 
were assessed for urinary metabolites of estrogen. They used gas chromatography-mass 
spectrometry to analyze urine collected for 72 h at baseline and during the last 3 days of each 
feeding period. Compare to control, the low isoflavone diet (3.7 |j.mol/kg BW/d) significantly 
increased the l/16a-(OH) estrone ratio (3.82 ± 0.33 vs. 5.09 ± 0.38) while consumption of 
3.7 or 7.4 |4.mol/kg BW/d decreased urinary 4-(OH) estrone (1.93 ± 0.10; 1.63 ± 0.10; 1.51 ± 
0.10 nmol/24h urinary excretion for control, low and high isoflavone diet, respectively). 
Compared with baseline values, all three soy protein diets significantly increased the ratio of 
urinary 2/4-(OH) estrone ratio (3.80 ± 0.11; 4.67 ± 0.24; 5.14 ± 0.25 and 5.05 ± 0.24 for 
baseline, control, low and high isoflavone diets, respectively) and significantly decreased 
genotoxic/total estrogens ratio (0.16 ± 0.01; 0.14 ± 0.01; 0.12 ± 0.01 and 0.13 ± 0.01 for 
baseline, control, low and high isoflavone diets, respectively). The authors concluded that 
isoflavones along with other components found in soy protein exerted a cancer-protective 
effect by decreasing the amount of genotoxic estrogen metabolites. However, isoflavones per 
se may not have been the major components responsible for these effects. 
When studied over a short period of time (1 month), it seemed that isoflavones 
exerted a significant effect in modulating hormonal profile towards a cancer-protective 
effect. However, more elaborate studies done over several menstrual cycles did not give 
significant results about the role of isoflavones in improving premenopausal estrogenic 
profile. Thus, the actual role of isoflavones in modulating hormonal profile is still 
controversial and deserves further investigation. 
b. Menopause 
The effects of isoflavone in postmenopausal women have showed modestly 
promising data, suggesting that isoflavone may be a potential candidate as an alternative to 
hormone therapy (HT, including estrogen and progesterone different from Estrogen therapy 
or ET that contains only estrogens), which has been associated with a 50% decrease in 
coronary heart disease risk (Stampfer and Colditz, 1991), but also with an increase in risk of 
breast cancer. Possible associations between soy intake and decreased risk of cancer, 
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atherosclerosis or osteoporosis are described in their respective sections. In addition, other 
menopausal-related symptoms have been studied with respect to soy and isoflavone intake. 
Using a double-blind, randomized, cross-over study (12-weeks long), Dalais et al. (1998) 
compared the effect of soy, linseed and wheat-based diets on several factors associated with 
menopause. Compared to baseline measurements, hot flushes were reduced by 22%, 41% 
and 51% for soy, linseed and wheat, with the last two being statistically significant. Only soy 
produced a significant increase in vaginal cytology maturation index (-103%, based on 
graphical data) and bone mineral density (5.2%). Reduction of hot flushes by wheat was not 
expected. In addition, the authors found 10 to 30-fold difference in urinary isoflavone 
excretion, but did not analyze the data based on apparent absorption, which could have 
resulted in different conclusions. The lack of further analysis based on urinary excretion 
limited the interpretation of the data. 
More recently, Crisafully et al. (2004) examined the effect of 1 year of dietary 
genistein supplementation (45 mg/d; 2.4 pmol/kg BW/d; other bioactive compounds not 
mentioned) on menopausal syndromes compare to estrogen progesterone therapy and placebo 
(n=30/group). Compared to a placebo, they found a decrease of hot flushes by 22 and 53% 
after 3 months, 29 and 56% after 6 months and 24 and 54% after 12 months for genistein and 
estrogen therapy treatments (overall p<0.01 for both treatment groups at all time points), 
respectively. In addition, endometrial thickness was similar in all 3 groups after 12 months. 
This study showed the positive impact of genistein on menopausal symptoms, without a 
negative impact on endometrial thickness. 
In 2000, Pino et al. looked at the relationship between isoflavone supplementation 
and sex hormone binding globulin (SHBG) levels, also known to decrease with menopause. 
Ten postmenopausal women were provided 69mg isoflavones/d (3.65 |imol/kg BW/d) for 10 
weeks, while 10 others were given a placebo. SHBG levels were compared to circulating 
plasma isoflavone concentrations, which is a better way to assess outcomes related to these 
compounds where bioavailability is widely different from one subject to another. They found 
a direct correlation between plasma isoflavones and percent increase in SHBG (r=0.84; 
pO.OOl). In addition, all women with circulating isoflavone concentration above 0.6 p.mol/L 
had at least a 30% increase in SHBG level. However, not all studies have shown a positive 
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impact of isoflavone on menopausal symptoms. Penotti et al. (2003) fed 10 postmenopausal 
women for 6 months a daily dose of 72 mg isoflavone or 3.8 pmol/kg BW/d (controls, n=10, 
were fed placebo) and found no significant difference in hot flush reduction, endometrial 
thickness or pulsatility index of uterine arteries. 
Duration of the studies, mean age of the subjects, isoflavone sources and doses may 
have contributed to the disparate conclusions of the studies described above. Statistical 
power may also be of importance. Crisafully et al. (2004) found significant results with 30 
subjects while Penotti et al. (2003) found no effect with 10 subjects. Nevertheless, 
isoflavones seem overall to exert a positive health effect on post- or peri-menopausal women 
and no signs of toxicity have been reported. Hence, isoflavones may indeed be a good 
candidate as an alternative to HT, but more research is needed. 
6. Isoflavones and infant health 
Short- and long-term health effects as well as toxicity of isoflavone intake by infants 
and children have also been the focus of several studies. Murphy et al. (1997) analyzed 
isoflavone concentration in several soy-based formulas and found a range of 214 to 267 ug/g 
dry weight of isoflavones expressed as aglycone, which correspond to a daily intake of 5 to 
12 mg/kg body weight (18 to 44 pmol/kg BW/d) depending on the volume consumed by 
infants. The use of soy-based infant formula started more than 100 years ago to children with 
immunoglobulin E-mediated cow's milk allergy, lactose intolerance, galactosemia and as a 
vegetarian human milk substitute (Merritt and Jenks. 2004). 
Prenatal exposure of isoflavone has been assessed in one study done by Adlercreutz 
et al. (1999). Asian pregnant women consuming a traditional diet (mean plasma isoflavone 
concentration was 233 nmol/L) showed that fetuses were exposed to significant 
concentrations of isoflavone as reflected in the cord blood (299 nmol/L) and amniotic fluid 
(223 nmol/L), which demonstrated that isoflavone can pass the placental barrier. 
Setchell et al. (1997) found that in 4-month-old infants consuming soy-based formula, the 
mean daily intake of total isoflavone was 16 to 29 pmol/kg BW. On the other hand, 
isoflavone concentration in breast milk of women consuming soy foods was 5.6 ± 4.4ug/L, 
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which caused minimal exposure of infants to isoflavones (<0.01 jjmol/kg BW/d) (Setchell et 
al. 1998). 
Isoflavone intake from soy-based formula in infants per kg body weight was higher 
than in adults consuming soy products (30 g soy protein/d) by a factor 6 to 11 (Setchell et al. 
1997; Franke et al. 1998) as reflected in plasma samples of soy formula fed infants (mean 
980 ug/L; range 552 to 1775 ug/L). The greater apparent absorption has been hypothesized to 
be related to an immature gut microflora (lower bacterial degradation), a lower renal 
clearance (longer plasma half-life), but also partly to a more continuous feeding of greater 
proportion of isoflavones coming from soy formula solely (Setchell et al. 1998). 
Because of these bioavailability data and the fact that isoflavones have potent 
estrogenic or anti-estrogenic activity, special attention has been brought to toxic or greater 
health-promoting effects of isoflavones in infants with respect to growth, reproductive, 
neurobehavioral and immune development as well as thyroid metabolism. However, no 
epidemiological studies have shown that pre- and neo- natal exposure to isoflavones resulted 
in toxicity signs. Asian women consuming high levels of isoflavone have been reported to 
carry normal pregnancy and delivery, while babies fed soy formula have not shown any 
clinical signs of disease or toxicity that could be associated with isoflavone intake (Badger et 
al. 2002). A follow-up study performed by Strom et al. (2001) showed that adults (-20-30 y; 
n=811) that were fed either soy (n=248) or cow's milk (n=563) as infants (0 to 4mths of age) 
did not show any significant difference in pregnancy outcomes, height, weight, age of sexual 
maturation, menstrual cycle length or missed period. Reproductive and non-reproductive 
parameters were also similar between the two groups. Neurobehavioral parameters, 
expressed by educational outcome (highest degree obtained) were not significantly different 
between the two groups. This showed that soy intake at a young age did not affect growth 
and development, and did not carry any long-term effect in young humans. The downside to 
that study was that subjects were too young (20-30 years of age) to develop chronic diseases 
so that the effects of isoflavone on cancer, diabetes, menopausal symptoms could not be 
evaluated, but deserve to be investigated. 
In animals, Badger et al. (2001) found that rats injected with genistein (1850 (imol/kg 
BW/d) at days 2,4 and 6 after birth developed significantly less mammary tumors induced by 
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DMBA than controls over 110 d (30% decrease). If extrapolated to humans, this study 
showed that early exposure to isoflavones may indeed protect against chronic disease later in 
life. Actual human studies need to be done to confirm these data. 
7. Isoflavone toxicity 
Very few studies have concluded that isoflavone may be show signs of toxicity. In 
animals, Hartley et al. (2003) fed isoflavones (150 mg/kg diet; 55 (j.mol/kg BW/d) to male 
Wistar rats (n=16) for 18 d (14d as a group + 4 d in individual housing). Controls followed 
the same protocol and fed a diet without isoflavone. Animals fed isoflavones spent 
significantly less time in active social interaction measured as a social interaction test based 
on time spent grooming, sniffing, following, boxing and wrestling. In addition isoflavone 
intake was correlated with significantly higher stress-induced plasma corticosterone (100 vs. 
30 mg/mL) and stress-induced plasma vasopressin concentration (~6 vs. 1 pmol/L).Stress 
was induced using an elevated plus-maze apparatus with 2 open and 2 closed arms. 
Therefore, it seemed that isoflavone had a negative behavioral effect on animals. 
Yellayi et al. (2002) showed that isoflavones may have a negative impact on thymus. 
Subcutaneous injection of genistein (2, 8, 20, 80, 200 mg/kg body weight or 7.5, 29, 74, 296 
and 740 jxmol/kg BW/d) in ovariectomized C57BL/6 mice decreased thymus weight compare 
to control in a dose response manner with the 4 highest doses being significantly different 
from the control (17 to 78% decrease) which had a subsequent negative effect on immune 
function, especially humoral immunity. Only 7.5 and 29 (jmol genistein/kg BW/d doses have 
a relevance to humans in terms of dietary doses. Thus, since most of the toxic effects were 
observed with 74 and 296 |imol/kg BW/d, doses that were injected subcutaneously, the 
relevance of these data to human may not be of significance. 
McMichael-Phillips et al. (1998) looked at 48 women with benign or malignant breast 
disease. Subjects were divided in two groups, one control and one fed 60 g ground texture 
vegetable protein containing 45 mg isoflavone for 14 d. Soy-fed subjects had a significant 
increase in proliferation of breast tissue (0.91 ± 0.9 vs. 1.74 ± 1.72 labeling index for control 
vs. soy, respectively), which is associated with increased risk of breast cancer. Progesterone 
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receptors were also higher in the soy vs. control group (19.32 ± 9.04 vs. 14.85 ± 8.62 
labeling index). This agonist effect of isoflavone is in agreement with Pollar et al. (1997) in a 
study in rats focusing on prostate cancer. Isoflavones were cancer-protective before cancer 
occurs while they were cancer-enhancing when cancer is already present. Indeed, isoflavone 
(33.8mg total isoflavone/kg diet) fed after cancer initiation did not produce a significant 
protective effect compare to the same treatment applied before cancer initiation. 
In addition, Hargreaves et al. (1999) studied 84 premenopausal women fed control or 
soy (45 mg isoflavone/d) for 14 d. Even though breast cell proliferation was not increased 
with soy, pS2 (marker of estrogenic response) levels significantly increased while nipple 
aspirate levels of apolipoprotein D decreased in the treatment group confirming the weak 
agonist estrogenic activity of isoflavone on cancer once it has already developed. 
Another study done by Bloedon et al. (2002) focused on postmenopausal women 
(n=24). Four single doses of isoflavone based on genistein content (2, 4, 8 and 16 mg/kg 
body weight or 7.4, 14, 29 and 59 pmol/kg BW/d) were used in two preparations, both 
containing mostly isoflavones in their aglycone form. Isolated episodes of edema, nausea and 
breast tenderness have been hypothesized by the authors to be linked to isoflavone intake, 
mostly because these events occurred a short period of time after ingestion of treatment diets. 
From one of the isoflavone preparations, subjects experienced (regardless of the dose 
ingested) an average of 7% increase in systolic and diastolic pressure along with a 32% 
average decrease in neutrophil counts 24 h after isoflavone ingestion. The conclusions of 
possible toxicity may be irrelevant considering that isoflavone were fed at pharmacological 
and not dietary doses (a high isoflavone intake associated with a typical Japanese diet may 
not exceed 1 mg/kg body weight/d (Munro et al. 2003)). The doses fed here may be 
achievable through supplement intake, but the studies on health-related effects described in 
this review were based on isoflavone intake coming from the diet and not supplements. 
Studying health-effects of high doses of isoflavones related to individuals consuming 
supplements may lead to a whole new set of studies, hypothesis and rules that could lead to 
totally different conclusions. This has not been investigated yet, but certainly would deserve 
attention, considering the growing popularity of these compounds. 
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C. Isoflavone metabolism and bioavailability 
1. Overview of isoflavone metabolism 
The actual process of isoflavone absorption is still somewhat obscure. The structure 
of isoflavone aglycones (MW=254, 270 and 284 g/mol for daidzein, genistein and glycitein, 
respectively) is neither hydrophilic nor lipophilic and there is no evidence that they are 
absorbed by facilitated or active transport. Due to their low molecular weight, isoflavones 
could then be absorbed through diffusion, but this remains to be verified (Birt et al. 2001). 
To investigate cellular uptake and absorption of isoflavone aglucons and glucosides, 
Murota et al. (2002) used Caco-2 cell monolayers as a model of human intestinal epithelium. 
When incubated with 10 pmol/L of either daidzein or genistein on the apical (i.e., mucosal 
side), 20% and 15% of the dose applied for genistein and daidzein, respectively were found 
on the baso-lateral side after 2 h of incubation and the presence of glucuronides and sulfate 
conjugates indicated that isoflavones may be conjugated right after absorption and not 
exclusively in the liver. The same incubation performed with daidzin and genistin revealed 
that only daidzein and genistein as well as their conjugates were found at the baso-lateral 
side, supporting the idea that isoflavone glucosides cannot be absorbed intact. Moreover, 
only 1.5% of the applied dose was found on the basolateral side, meaning that glucosides 
absorption may be slower than aglycones (data based on 0-2 h only after isoflavone 
injection). The overall percentage of the applied dose found on the basolateral side was not 
included in the study which focused only on 0-2 h incubation. 
In vivo, Setchell et al. (2002) failed to find any isoflavone glycoside at 1, 2 or 8 h in 
plasma samples collected from 12 women ingesting 50 mg of either daidzin or genistin. Due 
to a fast appearance of isoflavones in plasma after ingestion (maximum plasma peak reached 
at 6 h or sooner in humans; Setchell et al. 2002; Xu et al. 1994), it was hypothesized that 
isoflavone glycosides were cleaved by human intestinal enzymes and absorbed in the small 
intestine. Indeed, Day et al. (2000) found that lactase phlorizin hydrolase, a membrane-
bound, family 1 {3-glycosidase found on the brush border membrane of mammalian small 
intestine, was able to cleave the sugar moiety of daidzin and genistin with a greater Vmax for 
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genistin (-2.8 U/mg LPH) than daidzin (~0.9 U/mg LPH). This cleavage process apparently 
delayed the absorption compared to ingested isoflavone aglycones. Setchell et al. (2001) 
found in humans a peak plasma concentration of 5.2 and 6.6 h for genistein and daidzein, but 
it took 9.3 and 9.0 h for genistin and daidzin to appear in the plasma as their respective 
aglycone and conjugates forms. Plasma area under the curve was similar between glucosides 
and aglycones. Zheng et al. (2004) also found no significant difference in urinary excretion 
of women fed soygerm (-94% glucosides; 50.8 ± 5.6% urinary total isoflavone as percentage 
of ingested dose) or fermented soygerm flour (-88% aglycones; 51.5 ± 6.1% urinary total 
isoflavone as percentage of ingested dose). These in vivo data are in agreement with the data 
observed in vitro by Murota et al. (2002). 
In animals, Andlauer et al. (2000a) used an ex-vivo rat small intestine model. Doses 
of 5.9, 12.0 and 23.8 prnol genistin were applied to the luminal side. About 15% injected 
dose was found on the basolateral side, mostly as glucuronide (11.6%) with small amounts of 
genistein (1.9%) and genistin (1.3%). The latter finding was surprising, but considering this 
ex-vivo model, it was possible that a leak in the system could have resulted in the passage of 
intact genistin to the basolateral side. Despite this ambiguous situation, the authors concluded 
that cleavage of the glucosidic form seemed required to facilitate a greater absorption and 
that conjugation of isoflavone was a process also occurring at the intestinal level. 
Distribution of isoflavones in the different tissues and organs of the body occurs 
rapidly, but storage in organs or tissue is virtually nonexistent. In an in vivo system, Coldham 
and Sauer (2000) used [14C]-genistein fed at a dose 4 mg/kg body weight (14 pmol/kg BW) 
to 5 male and 5 female Wistar rats. At 24 h after ingestion of the genistein dose, no 
significant radioactivity was detected in heart, lung, brain, testes or ovaries, bone, fat or 
thymus. 
After absorption, isoflavones undergo endogenous biotransformation by UDP-
glucuronosyltransferase (UGTs) and sulfotransferases in the intestinal mucosa, liver and 
other organs (Barnes et al. 1998), which modifies its chemical structure and solubility, 
thereby influencing its distribution, storage and excretion (Birt et al. 2004). Glucuronide and 
sulfate conjugates made up about 70-80% and 20% in urine, respectively and 50-60% and 
20-30% in plasma, respectively in women fed soymilk (n=6) (Zhang, 2000). In addition, 
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greater amounts of isoflavone aglycone were recovered from 0-24 h plasma samples (-20-
25% ingested dose) compared to 0-24 h urinary excretion (<10% ingested dose). The fact 
that the amounts of total isoflavones recovered from urine vs. plasma as percentage of the 
ingested dose somehow do not match may be due to enterohepatic circulation (Sfakianos et 
al. 1997), where more than half of the ingested isoflavone was excreted in the bile after 
conjugation. Limited evidence and further investigation are crucial to confirm this 
hypothesis. Sfakianos et al. (1997) used anesthetized female rats with biliary cannulas to 
measure isoflavones biliary excretion. Genistein infused into the duodenum was recovered as 
7-O-P-genistein glucuronide and 75% of the infused dose was recovered within 4h. Moreover 
infusion of genistein glucuronide in the duodenum resulted in a slower biliary excretion of 
the same compound, indicating that like glucosides, isoflavones endogenously conjugated 
have to be cleaved prior to reabsorption, either by intestinal or microbial enzymes. 
Back in the intestine, isoflavones are deconjugated by gut microbial glucuronidase 
and sulfatase to release the aglycone form, part of it being possibly reabsorbed through 
enterohepatic circulation (Sfakianos et al. 1997). Isoflavones not undergoing this process are 
submitted to microbial degradation and metabolite formation, some of which can also be 
absorbed to exert weak estrogenic or anti-estrogenic effects, while the rest undergoes fecal 
excretion (See figure 4; from Hendrich and Murphy, 2001). 
From the data described above, humans and animals share great similarities in 
absorption, biotransformation and excretion of isoflavones. Plasma kinetics and urinary 
distribution of isoflavones (bioavailability) as well as microbial metabolism of these 
compounds are discussed in the next section. 
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Figure 4: Overview of metabolism (adapted from Hendrich and Murphy. 2001) 
2. Overview of isoflavone bioavailability 
Bioavailability is defined as the proportion of a compound that appears in plasma 
over time when the compound is administered orally. It is also defined nutritionally as the 
proportion excreted in the urine and feces compared to the amount ingested (Birt et al. 2001). 
Depending on the chemistry of the molecule (fat- or water-soluble), bioavailability may also 
be affected by storage, especially in fat, when the compound is lipid-soluble. Considering 
that isoflavones are conjugated after absorption, they become more water soluble and storage 
of these compounds may then be very little or none (Birt et al. 2004). Consequently, 
bioavailability of isoflavones focuses mostly on plasma and urinary kinetics as well as 
microbial metabolism. Food matrices in which isoflavones are found and chemical 
differences that separate daidzein, genistein and glycitein (Figure 1) have also been studied 
with respect to possible variations in isoflavone bioavailability (Birt et al. 1994; Xu et al 
2002). 
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a. Animal models 
To study bioavailability of isoflavones with possible extrapolation to humans, a valid 
animal model needs to be established. So far, rats have been one of the most investigated 
animal models to study kinetics and fate of isoflavones. Using isolated rat small intestine as 
an ex vivo animal model, Andlauer et al. (2000b), studied the absorption rate and 
biotransformation of isoflavones daidzin and genistin derived from pre-digested tofu (1184 
nmol genistein expressed as aglycone/g tofu and 572 nmol daidzein expressed as aglycone/g 
tofu). Tofu also contained small amounts of malonyl-isoflavone and isoflavone aglycone. Of 
these compounds, 8% genistein and 8.9% daidzein appeared at the vascular side, either as 
aglycone, glucuronide and glucoside. A3- and 2-fold increase in the aglycone genistein and 
daidzein, respectively was found at the luminal side. However, no sulfate conjugate were 
found in this experiment. In another experiment with only genistin applied in an isolated rat 
small intestine, Andlauer et al. (2000b) found an absorption rate of about 15%, with 
glucuronides>aglucons>glucosides found on the vascular side. These two studies showed 
that daidzein and genistein absorption rate are similar and that biotransformation occurs 
during the absorption process. However, the absence of sulfate conjugate indicated that rat 
may not be able to produce this conjugate, or this process is restricted exclusively to the liver. 
The presence of isoflavone glucoside on the vascular side was surprising and lead to the 
conclusion that rat may be capable of absorbing isoflavone glucoside without cleavage. On 
the other hand, the very small proportion of isoflavone glucosides found may have been 
related to a leakage in this ex vivo system. 
In an in vivo system, Coldham and Sauer (2000) used [14C]-genistein fed at a dose 4 
mg or 14 |imol/kg body weight in 5 males and 5 females Wistar rats. Mass balance of 
radioactivity showed that 67 and 66% [14C] were recovered in the urine and 30 and 36% in 
the feces for males and females, respectively. In the first 2.5 h, male rats had significantly 
higher isoflavone concentration and showed a higher secondary plasma peak at 6-8 h after 
ingestion compared to females. On the other hand, females showed a higher liver [14C] at 2h 
and 7 h compare to males; this could explain the lower plasma levels found in females. Mass 
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spectrophotometry analysis showed that glucuronides and sulfate conjugates were present in 
both sexes. No glucosides were found in plasma so some of the ex vivo data obtained by 
Andlauer at al. (2000b) were not reproducible in vivo. This study is of importance, because it 
showed several similarities between rats and humans bioavailability of isoflavones 
(absorption process, conjugation and plasma kinetics and gender difference). However, only 
mass balance was measured in urine and feces so that radioactivity from metabolites 
produced by gut microorganisms was not separated from the radioactivity of "intact" 
isoflavones aglycones and conjugates. 
King (1998) compared the bioavailability of daidzein and genistein in male Wistar 
rats fed a soy extract providing 74 [xmol genistein and 77 ^moldaidzein/kg BW. 48 h urinary 
excretion of daidzein and genistein were 17.4 ± 1.2% and 11.9 ± 1.1% of the ingested dose, 
respectively, while fecal excretion was 2.3 ± 0.5% and 3.4 ± 0.4%, respectively. As observed 
in humans (Xu et al. 1994 & 1995; Setchell et al. 2003), daidzein is more bioavailable than 
genistein and the range of urinary excretion is comparable to human data. Therefore, not only 
are rats an interesting model to study bioavailability, but also the gut microbial metabolism 
of humans and rats may share some similarities in degrading or metabolizing isoflavones. 
With respect to humans, King et al. (1996) also compared the bioavailability of 
genistein glucoside vs. aglycone (20 mg or 74 nmol/kg BW fed to male Wistar rats). 
Genistein was absorbed faster than genistin as reflected in plasma concentration (11.0 ± 
2.3pmol/L vs. 4.93 ± 0.22 nmol/L of genistein 2 h after genistein or genistin ingestion, 
respectively). As a consequence, genistein-fed animals had a faster urinary excretion. On the 
other hand, 48 h recovery from plasma, urine or feces was similar between the two groups, 
indicating that bioavailability of isoflavone aglycones and glucosides are equivalent. The 
same phenomenon has also been observed in humans (Setchell et al. 2001). So many 
similarities in data between rat and human data could lead to the establishment of rats, or 
rodents in general, as valid models to study isoflavone bioavailability. 
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b. Humans 
Many human studies have focused on understanding how isoflavones are metabolized 
in the body, with special focus on plasma kinetics as well as urinary and fecal excretion. 
Xu et al. (1994) fed 12 women 3 doses of isoflavones (2.5, 4.8 and 7.4 gmol/kg BW from 
soymilk powder; 44% genistein and 56% daidzein). Plasma levels of daidzein and genistein 
were similar to each other at time 6.5 and 24 h following ingestion at all 3 doses. Urinary 
recovery of daidzein and genistein were 21% and 9% of the ingested dose, respectively and 
fecal excretion was 1 -2% ingested dose. The amounts of isoflavone recovered in the urine 
were proportional to the ingested dose (dose-response between amounts fed and those 
recovered in the urine). Total isoflavone excreted in the urine was higher in 0-12 h compared 
to 12-24 h following ingestion by a factor of 2 to 3, meaning that isoflavone absorption and 
metabolism is a fast process, occurring mostly in the first 12 h after ingestion and 
disappearing almost completely after 24 h. Based on urinary excretion, Xu et al. (1994) 
concluded that daidzein was more bioavailable than genistein. Setchell et al. (2003) also 
came to the same conclusion using [13C]-labeled isoflavones and found a urinary recovery of 
30.1% and 9.0% of the ingested dose (0.4 mg of [13C] daidzein or genistein, n=16 
premenopausal women) for daidzein and genistein, respectively. 
Xu et al. (1995) performed a similar study to that of Xu et al. (1994) with three doses 
of isoflavones fed (3.4, 6.9 and 10.3 fxmol isoflavones/kg body weight; n-7 women), but 
looked at the individual results and found that 2 subjects had significantly higher fecal 
excretion of isoflavones compare to the 5 others (about 6% vs. 0.6% of the ingested dose, 
respectively and regardless of the dose fed). Forty eight hours urinary recovery was 16 ± 4% 
and 10 ± 4% of the ingested dose for daidzein and genistein, respectively in the 5 subjects 
with low fecal excretion. The two subjects with high fecal excretion had 32 ± 5% and 37 ± 
6% urinary recovery expressed as a % ingested dose. As for plasma, subjects with high fecal 
and urinary excretion had plasma isoflavone level 2.5-fold higher compare to subjects who 
were low isoflavone excreters. This study established the principles of phenotypes of 
isoflavone bioavailability, in which people can be grouped as high apparent absorbers (high 
urinary, plasma and fecal isoflavone contents) or low apparent absorbers. Moreover, high 
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apparent absorbers do not seem to have as much gut microbial activity degrading isoflavones, 
because they are excreted intact and in greater level in the feces those subjects. The role of 
the gut microflora in determining the extent of isoflavone bioavailability became then a 
factor that could not be overlooked. These two studies performed by Xu et al. (1994 & 1995) 
did not consider bioavailability of glycitein, a minor, but still important soy isoflavones. 
By feeding soymilk (4.5pmol total isoflavone/kg BW) to 14 subjects (7 males, 7 
females), all in vitro fecal moderate degraders, Zhang et al. (1999b; erratum 2001) found that 
plasma genistein concentration was higher than that of daidzein, which in turn was higher 
than that of glycitein at both 6 and 24 h after ingestion by males (1.29 ± 0.5, 1.78 ± 0.83 and 
0.22 ± 0.08 pMol at time 6h for daidzein, genistein and glycitein respectively) or females 
(1.04 ± 0.61, 1.70 ± 1.01, 0.20 ± 0.08 (iMol at time 6 h for daidzein, genistein and glycitein 
respectively). However, urinary excretion of glycitein was the highest, followed by daidzein 
and genistein (48.6 ± 23.1, 27.6 ± 20.7 and 55.3 ± 26.0 % ingested dose over 48h after 
ingestion in males and females together for daidzein, genistein and glycitein, respectively). 
No significant difference was found in bioavailability data between males and females. This 
study showed that isoflavones were absorbed to a great extent, but urinary data supported the 
idea that genistein may be more susceptible microbial degradation compared to daidzein, so 
that less genistein is re-absorbed and found in the urine. In other words, overall absorption of 
daidzein is apparently greater than that of genistein. Lower glycitein plasma concentration 
was probably due to lower doses of that isoflavone fed, but high glycitein urinary excretion 
may be related to a low microbial degradation/high reabsorption phenomenon as 
hypothesized for daidzein. The presence of the methoxyl group on the glycitein molecule 
could be in part responsible for the data observed in this study, underlying the hypothesis that 
glycitein may be less susceptible to microbial degradation. 
In another study, Lu and Anderson (1998) focused on sex and long-term (1 month) 
soymilk intake (200 mg total isoflavone/d or ~10 pmol/kg BW/d) with regard to urinary 
excretion of isoflavones and metabolites. They found that women (n=6) excreted 24% and 
66% of the ingested dose of genistein and daidzein respectively, while men (n-6) excreted 
only 15% and 47%. After one month, women excreted less daidzein (14%) and genistein 
(45%) than at time 0 in the urine, while in men, isoflavone urinary excretion levels were 
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stable. With respect to equol production one man and one woman were capable of producing 
equol from daidzein at time 0. Moreover, 3 additional women but no additional men 
developed the capability to produce equol over the one month study. This study showed a sex 
difference in isoflavone bioavailability and the fact that in women, chronic exposure to soy 
may alter the gut microflora, leading to a higher degradation of isoflavones (thus less urinary 
excretion), and the production of new metabolites, such as equol. Men may have a more 
stable microflora, explaining the stability of urinary excretion and the absence of new 
subjects developing the capability to produce equol. 
Separate studies conducted in men in women provided additional data to plasma 
kinetics of isoflavones. In women, Xu et al. (1994) found similar daidzein and genistein 
concentration in plasma 6.5 and 24 h after ingestion of soymilk. In men, Watanabe et al. 
(1998) observed a peak of genistein in plasma at 6h after ingestion of baked soybean powder, 
peak that was two-fold higher than the peak observed for daidzein. Plasma half-lives of 
daidzein and genistein were 7.75 h and 7.77 h in women (Setchell et al, 2003), and 8.36 h 
and 5.79 h in men (Watanabe et al. 1998), respectively. Unfortunately different isoflavone 
composition, subject numbers, handling of plasma samples and analysis differed from one 
study to the next, making comparison across studies impossible to make. Only Zhang et al. 
(1999b; erratum 2001) studied both sexes within the same study and found no gender 
difference in overall isoflavone bioavailability. 
In summary, bioavailability of isoflavones is now fairly well understood, and data on 
plasma kinetics, urinary and fecal excretion are reproducible from one study to the other. 
Isoflavone absorption is a rapid process, in men or women, with a maximum plasma peak 
occurring within 6 h after ingestion. Only traces of isoflavone are detected in the urine after 
48h, meaning that most of the isoflavones ingested are being excreted within 24-48 h. The 
data obtained from animal and human studies are also comparable, so that potential animal 
models could be validated to study isoflavone bioavailability and/or health related effects 
observed with these compounds in more detail. On the other hand, in both humans and 
animals, urinary plus fecal excretions are not equal to 100% of the ingested dose and most of 
the studies have found a cumulative urinary and fecal excretion not exceeding 60% (in many 
studies, even much less than that), suggesting that a great amount of isoflavones disappear in 
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this process. There is now good evidence that gut microorganisms are greatly involved in the 
process of bioavailability, as described in the following section. 
c. Isoflavones and gut microorganisms 
Gut microorganisms play an important part in isoflavone bioavailability. Several 
aspects of the absorption/metabolism/degradation processes may be influenced by the 
presence of the gut microflora. 
In order to be reabsorbed after biliary excretion, isoflavone conjugates must be 
cleaved. The same applies to any isoflavone glucosides that might have arrived intact in the 
ileum or large intestine. Bacteria play an important role in this cleavage process through P-
glucosidase or ^-glucuronidase activity. Previous in vitro work done by Hawksworth et al. 
(1971) showed that a variety of bacteria possess these enzymatic activities using in vitro 
incubation of groups of bacteria with various sugars, all differing in their glycosidic bonds 
from one another and measuring the different sugar breakdown over time (sucrose added for 
(3-glucosidase acivity, substrate of (^-glucuronidase not provided). P-glucosidases have been 
found in Enterococci and to a lesser extent in Lactobacilli, Clostridia, Bacteroides and 
Bifidobacteria strains. P-glucuronidase activity is mostly due to Enterobacteria and to a 
much lesser extent by Clostridium and Bacteroides. 
Xu et al. (1995), while studying bioavailability of isoflavones in 7 subjects, found that 
2 individuals excreted significantly higher amounts of isoflavones in their urine and had 
significantly higher peak plasma concentration. This was the first indication that isoflavone 
bioavailability was not the same in all individuals. The role of the gut microflora in 
degrading more isoflavones in those who excreted less of it the urine have been hypothesized 
and confirmed by Hendrich et al. (1998). Men and women (n=20) were screened for in vitro 
fecal isoflavone degradation. After cluster analysis, they found three phenotypes of 
degradation for daidzein: high (n=5; k=0.299), moderate (n=10; k=0.055) and low (n=5; 
k=0.012). When rechecked after 10 months, the high (n=5; k=0.326) and moderate (n=4; 
k=0.073) phenotypes shown greater stability compare to low degradation phenotype (n=5; 
k=O.O53). The same phenotypic profile was observed for genistein. High (n=5), moderate 
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(n=10) and low (n=5) degraders showed degradation rate constants of 0.299, 0.163 and 
0.023, respectively. After 10 months, high (n=5), moderate (n=4) and low (n=5) degraders 
had mean degradation rates of 0.400, 0.233 and 0.049, respectively. Overall, 12/14 subjects 
who were re-examined after 10 months showed stability in their phenotyping. Subjects 
switching from one phenotype to another, along with greater k observed for each phenotype 
and isoflavone after 10 months were indicative of variation in the microflora, which probably 
would affect isoflavone bioavailability over time. In addition, genistein was overall degraded 
faster then daidzein, as reflected in mean rate constant values (0.023 vs. 0.163 for daidzein 
and genistein, respectively). 
This difference observed in vitro could partly explain the difference observed in 
urinary excretion. Urinary excretion of daidzein is greater, apparently because of a lower 
degradation in the gut. Chemical structures of both isoflavones could also explain this 
difference: daidzein has 2 hydroxyl groups, while genistein has 3 at key positions (C-5,7,4) 
that makes it theoretically more susceptible to degradation. Griffiths and Smith (1972) 
compared microbial degradation of several phenolic compounds, including isoflavones, and 
found that the presence of a hydroxyl group in the 5 position was associated with greater 
microbial degradation. Genistein, but not daidzein, possesses a 5-OH group, which would 
then make it more susceptible to microbial degradation and in agreement with in vivo and in 
vitro data. As for glycitein, no published data on phenotypes of degradation or urinary 
excretion is available, but one would assume that this compound would be degraded or 
excreted among subjects according to phenotypes. Moreover, urinary excretion values of 
glycitein close to that of daidzein (Zhang et al. 1999b; erratum 2001) may lead to the 
hypothesis that both compounds would have similar patterns of gut microbial degradation. 
Finally, degradation phenotypes and bioavailability of glycitein in animals has not been 
elucidated yet. 
Identification of isoflavone-degrading microorganisms has not been done yet. There 
have been a few studies focusing on single strains and their ability to degrade these 
compounds, but so far, no study has focused on the colonic/fecal microflora as a whole. 
Winter et al. (1989) showed that Clostridial strains were capable of cleaving the C-ring of the 
flavonoids quercitin, kaempferol and naringenin. Clostridial species may also be involved in 
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degrading daidzein. Hur et al. (2002) found that a Clostridium sp. isolated from human fecal 
samples (200 different unknown bacterial colonies cultured from fecal sample and each 
incubated with daidzein) was capable of transforming daidzein (400 pM) into ODMA (112 
jxM) over a 3d incubation. Eubacterium limosum, a strict anaerobe from the human intestinal 
tract, has been showed to transform glycitein (100 ^M) to 6,7,4'-trihydroxyisoflavone (Hur 
and Rafii. 2000). However, the amount of metabolite produced and the time to produce it 
were not mentioned, leading to a difficult extrapolation to humans. Schoefer et al. (2002) 
found that a pure strain of Eubacterium ramulus degraded 0.5 mM genistein completely in 4h 
into 6 ' -hydroxy-ODMA and 2-(4-hydroxyphenyl)-propionic acid. Daidzein was degraded 
over 12 h by E. ramulus to yield ODMA at an amount equal to 70% of the daidzein initially 
present. The metabolites produced were in agreement with those observed in vivo (Joannou et 
al. 1995) so that E. ramulus may degrade isoflavones. However, bacterial competition and 
colonic environment were not considered, despite being of great importance when studying 
gut bacterial degradation of isoflavones. 
d. Gut microbial metabolites of isoflavones 
Gut microflora are also responsible for converting isoflavones to metabolites, but the 
bacteria responsible for metabolizing these compounds as well as biological effects 
associated with these metabolites remain to be identified. Daidzein catabolism has been 
proposed to yield the metabolite dihydrodaidzein, itself transformed into O-
desmethylangolesin (O-DMA) or equol. As for genistein, its microbial metabolism has been 
associated with the formation of dihydrogenistein, itself catabolized to 6 ' -hydroxy-O-DMA 
(Joannou et al. 1995). Most of these metabolites have not been fully understood and/or 
ivestigated from a microbial or health-related standpoint. Chemical structures of daidzein, 
genistein and their respective metabolites can be found on the next pages. 
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Chemical structures of daidzein, dehydrodaidzein and O-desmethylangolesin (O-DMA) 
according to the first possible pathway of daidzein microbial degradation 
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Chemical structures of daidzein, dehydroequol and equol according to the second possible 
pathway of daidzein microbial degradation 
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6 ' -hydroxy-O-Demethylangolensin 
Chemical structures of genistein and its microbial metabolites: dihydrogenistein and 6'-
hydroxy-ODMA. 
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One of these metabolites has brought some attention because of its weak estrogenic 
activity: equol, derived from daidzein. Lampe et al. (1998) showed that -35% of subjects 
(n=60; 30 men and 30 women) are capable of producing equol after eating soybean for 3d 
and the range of equol production varied by a factor 10. Women who were equol producers 
had a significantly higher intake of energy from carbohydrate, plant protein, soluble and 
insoluble fibers. These correlations were not found in men. In addition, Lu et al. (1996) 
found that chronic soy exposure in women (n=6) resulted in 1 subject producing equol at 
baseline vs. 4 subjects one month later. Therefore, it is possible that chronic soy intake may 
modify the microflora or activate some bacterial enzymes responsible for equol production. 
The same study performed in men (Lu et al. 1995) showed that one subject was equol 
producer at baseline, but no additional subjects produced equol over a month chronic soy 
exposure. Therefore, equol production seems more susceptible to be activated in women than 
in men by chronic soy exposure. This sex-difference also suggests that the microflora of men 
may be more stable than that of women. Despite some attention brought to equol, its health 
or toxic effects still remain to be fully investigated. Selvaraj et al. (2004) studied the 
estrogenicity of equol in ovariectomized C57BL/6 mice (n=5/group; 30 d old) injected daily 
for 12 d with 0,4, 8, 12 or 20 mg equol/kg BW/d (0, 16, 33, 50 and 83 pmol/kg BW/d) or fed 
0, 500, 1000 ppm equol (0, 400, 800 jjmol/kg BW/d) in AIN-93G diet. None of the dietary 
treatments had an effect on uterine weight while injected doses of 50 and 83 nmol/kg BW/d 
increased significantly uterine weight by a factor 2 and 4, respectively compare to control. 
Dietary and injected equol both induced a dose dependent increase in endometrial thickness 
(~7 [Am in control up to 40 |jm with 83 pmol/kg BW/d injected and 30 fim with 800 pmol/kg 
BW/d; approximation from graphical data). The same phenomenon was observed with 
uterine epithelial proliferation (up to 90-fold and 20-fold increase with highest dose injected 
or fed compare to control, respectively). The authors concluded that equol was a weak 
estrogen, but extrapolation of injected doses to an in vivo human situation is impossible to 
make. On the other hand, the authors found concentrations of ~8 pM plasma equol when fed 
orally at 800 pmol/kg BW/d and compared it to normal human plasma levels of equol 
producers (only 1 pM). Therefore, the dose of equol applied was too high to extrapolate these 
results to humans with significance. Likewise, no soy products contain such doses of equol. 
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Only microbial degradation of daidzein is responsible for equol appearance in plasma and 
urine, which is one of the reasons why equol is such a difficult compound to work with to 
obtain significant extrapolable data. One of the few studies looking at equol and health 
related benefits in humans was done by Duncan et al. (2000). Premenopausal women who 
produced equol (n=5) were compared to non-equol producers (n=9) for plasma hormone and 
sex hormone binding globulin (SHBG) levels. They found that equol production was 
significantly associated with overall lower concentrations of testosterone (p<0.01), 
dehydropiandrosterone (p<0.01), Cortisol (p=0.03), midluteal estrone (p=0.004) and higher 
levels of SHBG (p=0.02) and midluteal progesterone (p=0.002). The authors concluded that 
equol producers had hormonal profiles consistent with reduced risk of breast cancer so that 
equol might directly (or indirectly) influence hormone production in a beneficial way. 
In addition to the metabolites identified by Joannou et al. (1995), other by-products of 
isoflavone gut microbial metabolism have been identified. In Wistar rats, King (1998) found 
equol and 4-ethyl phenol to be the main metabolites from daidzein and genistein, 
respectively. However, equol was mostly produced 24-48 h after isoflavone ingestion while 
4-ethyl phenol was produced between 0-24 h and reached a plateau between 24 and 48 h. 
This showed that metabolite production does not occur at the same time or at the same level, 
meaning that gut microorganisms metabolize each of the isoflavones differently. Using [14C] 
labeled genistein also in Wistar rats, Coldham and Sauer (2000) found that genistein can be 
metabolized into 4-hydroxyphenyl-2-propionic acid in males and dihydrogenistein in 
females. However, proportions of these metabolites as percentages of the ingested dose were 
not calculated in either study (King 1998; Coldham and Sauer. 2000) so that there are still 
some uncertainties as to how important these new identified metabolites actually are from 
metabolic and physiologic standpoints. 
e. Factors influencing isoflavone bioavailability 
Bioavailability has been extensively studied in both animals and humans, as described 
above. However, there may be factors that influence the extent to which isoflavones are 
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apparently absorbed or degraded. Diet, food matrix, food processing or gut transit time may 
be involved in modulating this process. 
In animals, Uehara et al. (2001) studied the effect of supplementing a diet with 5% 
fructooligosaccharides (FOS, a mixture of indigestible and fermentable sugars) for 7 d in 
Sprague-Dawley rats. Controls were fed the same diet without FOS. Isoflavones (40 mg or 
148 pmol/kg BW) were given on d 5 of the feeding using a gastric tube. Plasma kinetics 
showed that in FOS-fed animals, genistein and daidzein concentrations from tail blood was 
significantly higher in the 48 h following FOS ingestion compared to controls and 24-48 h 
urinary genistein recovery was also higher in FOS-fed animals. Even though not significantly 
different, there was also a trend toward increased total 48 h urinary genistein excretion in 
FOS- compared to control-fed animals (14.5 ± 1.2% vs. 11.6 ± 1.5% ingested dose). Urinary 
excretion of daidzein over 48h was similar in treatment and control groups (23.0 ± 2.4% vs. 
22.7 ± 3.3%). This study shows that FOS modified and possibly delayed absorption of both 
daidzein and genistein. Despite similar amounts excreted in the urine over 48 h the 
proportion of isoflavone excreted in 0-24 h was higher in controls whereas 24-48 h excretion 
was higher in FOS fed animals. With a higher power (here, n-5-6), 0-48h urinary genistein 
excretion values could also have been significantly different between treatments 
Also in rats, Piskula (2000) looked at genistein plasma kinetics and conjugation in 
rats either fed or food deprived (24 h fasting, n=5/group, 7.9 jimol isoflavone/kg BW injected 
using a gastric tube). In food-deprived rats, plasma daidzein and genistein reached a 
maximum concentration of 20.9 ± 4.4 pmol/L and 11.4 ± 3.1 jimol/L, respectively less than 
10 min after ingestion). Fed rats reached a maximum plasma daidzein concentration of 2.4 ± 
0.8pmol/L 2 h after ingestion while genistein plasma level reached 1.8 ± 0.2pmol/L 4 h after 
ingestion. Genistein was dissolved in Na^COs, which increased gastric pH and improved 
absorption in fasted animals compared to fed animals that probably maintained a lower 
gastric pH due to digestion. More interestingly, the proportion of sulfate conjugates was 
significantly higher throughout the study in food-deprived rats, while glucuronide conjugates 
were dominant in fed rats. This phenomenon could be due to biotransformation activities in 
the liver that differ between fasted and fed states. 
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These two studies (Uehara et al. 2001; Piskula. 2000) showed that bioavailability in 
animals can be modified using dietary factors, such as insoluble fibers that may have an 
impact on gut transit time. Moreover, isoflavones ingested as part of a regular diet showed a 
different pattern of bioavailability compared to fasting. These findings deserve more 
investigation, with the goal of finding a factor that could improve significantly isoflavone 
bioavailability with relevance to humans, thereby enhancing possible health-promoting 
effects. 
In humans, Tew et al. (1996) found that a high wheat fiber diet (40 g/d) had a 
negative impact on isoflavone bioavailability compared to a low fiber diet (15 g/d). Using a 
cross-over design and tofu or texturized vegetable protein (TV?) as sources of isoflavones, 
Tew et al. found that a high fiber diet decreased significantly plasma concentration (55% 
decrease at time 24 h; p<0.05) as well as urinary excretion (20% decrease; p<0.03) of 
genistein, which disagreed with Uehara et al. (2001) findings in animals. Different fiber diets 
may have different modes of action in modifying isoflavone bioavailability. On the other 
hand, Tew et al. did not find any difference in urinary recovery of daidzein or genistein 
expressed as % ingested dose from tofu or TVP, regardless of the fiber dose. Food matrix in 
this study did not influence overall apparent absorption. 
Xu et al. (2000b) also concluded that food matrix or background diet did not 
influence isoflavone bioavailability. There was no difference in urinary excretion or plasma 
kinetics in subjects fed either a basic diet, a self-selected diet eaten at specific times or a self-
selected diet eaten ad libitum. No difference was also observed when isoflavones were fed as 
part of tofu, tempeh, cooked soybeans or TVP. 
With respect to gut transit time, Zheng et al. (2003) looked at in vitro disappearance 
of isoflavones and in vivo genistein urinary excretion and gut transit time in 35 Asian and 33 
Caucasian females. Asians with low genistein in vitro fecal degradation had a significantly 
shorter mean gut transit time and greater genistein urinary excretion compared to Asians with 
rapid in vitro fecal genistein degradation (GTT was 40 ± 8 h vs. 63 ± 5 h and genistein 
urinary excretion was 11.0 ± 2.7% vs. 4.0 ± 1.7% of ingested dose from soymilk for low and 
high genistein degraders, respectively). This was not observed in Caucasian subjects, 
probably because Caucasian low genistein degraders had a mean gut transit time significantly 
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higher than Asian subjects with the same phenotype (86 ± 10 h vs. 40 ± 8 h, respectively). 
Zheng concluded that a rapid gut transit time coupled with a low in vitro genistein 
disappearance resulted in greater bioavailability as reflected in urinary excretion. 
D. Identification of isoflavone-metabolizing and degrading microorganisms: 
use of genomic techniques 
Microbial ecology of a specific environment has been a challenge to assess both 
quantitatively and qualitatively. The numerous species present within the same environment 
creates such a complexity that techniques used over the past 30 years or more, such as plate 
count, has not given completely accurate data with regard to the original sample studied 
(Amman et al, 1995). New approaches to study microbial diversity were developed based on 
molecular biology techniques. One of them, namely polymerase chain reaction coupled with 
denaturing gradient gel electrophoresis (PCR-DGGE) was developed in 1993 by Muyzer et 
al. This technique was based on targeting and multiplying by PGR the DNA sequences 
coding for the V3 region of 16S rRNA with primers designed to match the conserved regions 
of the 16S rRNA gene. This sequence is different from one species to another and highly 
conserved within the same species. Consequently, the 16S rDNA sequence becomes an ID 
for the corresponding micro-organism. Theoretically, PGR products of the 16S rDNA 
sequences of a bacterial community should still represent the original population, both in a 
quantitative and a qualitative manner. In practice, this technique allows the amplification of 
all the major species present originally in the sample (species that represent 1% or more of 
the total community), but minor ones may not be represented accurately on the gel (Muyzer 
et al, 1993). DGGE allows the separation on an acrylamide gel done with a gradient of urea 
and formamide of the different PGR products sequences obtained based on their GC content 
and melting temperature (Tm). During migration on the acrylamide gel, when a DNA 
sequence reaches its Tm, its helical structure partially melts, stopping the migration process 
through the gel (Muyzer and Smalla, 1998). Since PGR of fecal DNA creates a mixture of 
different DNA sequences, each one will stop at a different distance of migration, creating a 
banding pattern within the same lane. Depending on the primers used, the PGR products 
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varied in length from 200 to 400 bp (Fromin et al, 2002). Band patterns within the same lane 
or profile represent the bacterial composition of the sample studied. Muyzer et al. (1995) 
established that one band should represent only one sequence, which is consequently the 
representation of a single species. Moreover, the intensity of the band obtained after staining 
should represent the frequency of the species in the original sample studied (Murray et al, 
1996). In other words, a band of strong intensity should represent a micro-organism present 
in greater quantity compare to a micro-organism that corresponds to a band of weak 
intensity. However, some studies have showed that within the same band, 2 sequences were 
found because of a strong similarity in their sequence and GC content (Vallaeys et al, 1997). 
This raises the question of applying different gradients of acrylamide and different time of 
electrophoresis to obtain an optimal separation of the different PGR products (Muyzer and 
Smalla, 1998). Considering the possible pitfalls of PCR-DGGE (multiple species within the 
same band, presence of heteroduplexes and chimeric molecules (Ferris and Wards, 1997), 
inaccuracy in representing on the gel the original population diversity), it has been suggested 
that if all the samples are treated exactly the same way, one would assume that possible 
biases are normalized between samples, making the comparison of profiles and bands quite 
accurate (Fromin et al, 2002). On the other hand, advantages of PCR-DGGE include 
easiness, reproducibility, reliability and speed (Muyzer and Smalla. 1998). Indeed, 
considering the greater accuracy of this technique compare to standard microbiology 
techniques, such as plate count and sub-culturing of microbial samples, many studies have 
used PCR-DGGE to study microbial ecology from various samples. This technique can be 
applied to bacterial communities from soil and rhizosphere (Smalla et al. 2001), water 
(Murray et al. 1996), feces from animals (Simpson et al. 1999) or humans (Walter et al. 
2001). Depending on the primers used, it also allows to study the microbial population as a 
whole, but primers specific for groups or families of bacteria have also been developed to 
study only a sub-set of the original samples. For example, Walter et al. (2001) used primers 
specific for lactic acid-producing bacteria of the genera Lactobacillus, Pediococcus, 
Leuconostoc and Weissella, which is useful to assess the colonization of the colon by 
probiotics fed along with dairy products. PCR-DGGE becomes then an important tool in 
assessing the stability of a defined microflora over time or space (Muyzer and Smalla, 1998). 
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Any increase or decrease in bands intensity would then reflects greater or lower amounts of 
the corresponding-micro-organisms, respectively. Depending on the outcome studied, one 
would focus on the whole profile or only on specific bands of interest. 
With regard to gut microbial metabolism of isoflavones, the PCR-DGGE technique 
has not been applied yet, but could be useful in identifying the species responsible for 
metabolizing and degrading these compounds. Indeed, comparing gut microbial profile of 
subjects or animals with significantly different in vitro fecal degradation rates could lead to a 
correlation between degradation rates and intensity of one or more bands present among all 
profiles. In addition, variation in degradation rate within the same subject or animal over time 
could lead to compare profiles at different time points and assess changes in bands intensity 
that correlate with the change in degradation rate. Ultimately, the bands of interest 
correspond to bacterial species that could be involved in degrading isoflavones in the large 
intestine. 
E. Human gut microorganisms 
1. Composition of the colonic/fecal microflora in humans 
Microflora of the large intestine is composed of a complex balance of bacterial strains 
needed for human health. Up to 500 different strains have been identified, but only 30-40 
species are thought to compose more than 99% of this microflora, (table 2). (Hooper et al. 
2002; Mai. 2004) 
Most, if not all the strains identified in the human microflora are anaerobes. 
Facultative anaerobes include Streptococcus, Enterococcus, Staphylococcus, Enterobacterial 
Yeast and Lactobacillus. Obligate anaerobes include Bifidobacterium, Bacteroides, 
Fusobacterium, Eubacterium, Veillonella, Clostridium, Peptostreptococcus and Prevotella 
Turner et al. (2003). 
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Bacteroides Eubacteria Bifidobacteria Others 
B.fragilis E. aerofaciens 1 B. adolescentis Enterococcus faecium 
B. vulgatus E. aerofaciens 2 B. longum Fusobacterium prausnitzii 
bacteroides FB E. rectale 1 B. infantis Ruminoccus gnavus 
B. thetaiotaomicron E. rectale 2 Ruminoccus bromii 
B. tmiformis E. biforme Ruminococcus obeum 
Bacteroides FO E. eligens Ruminococcus albus 
B. stercocis E. lentum Escherichia coli 
B. caccae Peptostreptococcus productus 
B. distasonis 
Table 2: Most prevalent species identified and cultured from human fecal sample (adapted 
from Finegold et al. 1974 and Moore and Moore. 1995) 
Most of the studies about the gut microflora actually focused on analysis of fecal 
samples. To verify the physiological and microbiological relevance of the fecal ecology to 
the large intestine, Moore and Moore (1988) analyzed the bacterial composition of feces, 
ascending, transverse, descending colon and rectum of cadavers within 4 h of death. They 
found that microbial composition of the different segments of the large intestine were similar 
to feces, assuring then that fecal bacterial profile is of physiological relevance to the large 
intestinal physiology. 
With special focus on ethnicity and diet, Moore and Moore (1995) analyzed the fecal 
flora from subjects of different ethnicities (Caucasian (n=17), Asian (n~22), African (n=16)). 
Regardless of ethnicities, they found that 371 taxa accounted for 96.7% of the total bacterial 
population, but 177 of these taxa were seen only once over analysis of 88 fecal samples, 
which meant that a limited number of taxa accounted for most of the fecal flora. The other 
3.3% were assumed to be linked to minor taxa. They also found that Eubacterium 
earofaciens type 1 was the most prevalent strain with 8.43% total bacterial population, 
followed by Bacteroides vulgatus at 7.79%. The bacterial composition with respect to 
ethnicities is described in the next section. 
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In the past 10 years, new techniques involving molecular biology have been 
developed to assess with more accuracy fecal bacterial profile and dynamics, both 
qualitatively and quantitatively. One of the techniques, PCR-DGGE, was reviewed in the 
previous section. Another variation of that technique involves the multiplication of 16S 
rDNA sequence coupled with cloning of the sequences using competent E.coli DHI cells. 
Using a moderate heat shock treatment, target DNA is inserted into E.coli cells as plasmids 
and multiplied using E.coli enzymatic and metabolic activities. DNA of colonies that 
contained a sequence were reamplified, enzymatically digested and sequenced. Using this 
technique along with more classical microbiology methods, like plate counts, Suau et al. 
(1999) looked at the 16S rDNA sequences obtained from fecal sample from one 40-year-old 
man. Microbiological techniques showed that 60-80% bacteria observed by staining could 
not be cultivated by classic bacterial culture techniques. Cloned 16S rDNA sequences 
showed 284 different clones that were grouped into 82 molecular species, themselves 
grouped into 3 phylogenetic groups: the Bacteroides-Prevotella group, the Clostridium 
coccoides group and the Clostridium leptum group. However, only 24% of the clones could 
be matched to sequences already known and available through genomic libraries. The 
Bacteroides-Prevotella group included several genuses such as Porphyromonas, Bacteroides 
or Prevotella. Clostridium coccoides and Clostrium leptum groups included mostly 
Clostridium, Ruminococcus and Eubacterium species (See table 3). According to Suau et al. 
(1999), the species identified are the most prevalent ones in the human gut microflora and 
constitute up to 95% of total bacterial count. However, only 1 subject was screened and a 
higher power could have lead to the identification of a greater number of species. The fact 
that 76% of the clones matched with unidentified strains showed how complex the colonic 
microflora is and how only a little is actually understood about gut microbial identification, 
diversity and metabolism. 
Harmsen et al. (2002) used a more extensive technique (dot blot hybridization and 
fluorescent in situ hybridization or FISH) with the development of 7 fluorescent probes, each 
specifically designed to match one group of bacteria: Phascolarctobacterium and relatives, 
Veillonella, Eubacterium hallii and relatives, Lachnospira and relatives, Eubacterium 
cylindroides and relatives and 2 probes for Ruminococcus and relatives. After incubation 
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with each of these probes, fluorescent bacteria were counted. These groups were chosen, 
because their 16S rDNA sequences are known and they are considered major groups of 
bacteria in the feces. Total bacterial counts among 7 subjects (ethnicity not mentioned) 
selected for that study ranged from 8.6*1010 to 3.7*10u cells/g dry weight. In addition, there 
were major differences in bacterial counts of the different groups among the 7 subjects. For 
example, the Eubacterium cylindroides group, targeted to bind E. cylindroides, biforme, 
tortuosum and dolichum, Clostridium innocuum and Streptococcus pleomorphus varied from 
7.8*107 to 9.3*109 cells/g dry weight. In addition, Veillonella group went undetected in 4 
subjects up to 4.3* 109 cells/g dry weight in another subject. This study showed the great 
inter-individual microbial diversity among humans, but confirmed that many strains may 
indeed be found ubiquitously in all subjects. 
Using the same FISH and specific probes technique Franks et al. (1998) looked at 
several bacterial groups: Bacteroides fragilis-Bacteroides distasonis, Clostridium 
lituseburense, Clostridium histolyticum, Clostridium coccoides-Eubacterium rectale and 
Streptococci-Lactobacilli. Bacterial counts using FISH showed again large variations from 
one subject to the other (n=7). For example, Bacteroides varied from 3.1*1010 to 11.6*1010 
cells/g dry weight. Compare to bacterial staining and counting, 90-100% bacteria were 
identified and counted using FISH. Average bacterial count of Bacteroides was 20% of the 
total flora while the Clostridium coccoides-Eubacterium rectale group accounted for 29% of 
the total flora. Percentages of other groups were not given. In addition, subjects were 
followed over 8 months and the Bacteroides jragilis and Bifidobacterium groups showed the 
greatest inter- and intra-individual variability over time, while the Clostridium coccoides-
Eubacterium rectale group showed greater stability. This study confirmed that Bacteroides 
and Clostridium are two of the major groups of the gut microflora. Inter-individual variability 
was also confirmed while intra-individual variability (without any apparent changes of diet or 
lifestyle) showed that some bacterial groups may be more unstable over time, thus 
questioning the actual overall stability of the gut microflora. 
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Bacteroides-Prevotella 
group 
Clostridium coccoides 
group 
Clostridium leptum 
group 
Porphyromonas Clostridium Eubacterium 
P. salivosa C. herbivorans E. siraeum 
P. catoniae C. populeti E. plautii 
P. gingivalis C. coccoides E. desmolans 
P. endodontalis C. nexile 
C. oroticum Ruminococci 
Bacteroides C. clostridiiforme R. bromii 
B. putredinis C. celerecrescens R. flavefaciens 
B. splanchinus C. xylanolyticum 
B. vulgatus C. symbiosum Clostridium 
B.jragilis C. aminovalericum C. sporosphaeroides 
B. stercoris C. aminophilum C. leptum 
B. uniformis C. viride 
B. eggerthii Eubacterium 
B. caccae E. xylanophylum Others 
B. ovatus E. ventriosum Fusobacterium 
B. thetaiotaomicron E. eligens Termitobacter aceticus 
B. forsythus E. formicigenerans 
B. distatonis E. contortum 
B. Merdae E. rectale 
E. hadrum 
Prevotella E. halii 
P. pallens E. ramulus 
P. veroralis 
P. denticola Ruminococcus 
P. oulora R. obeum 
P. oris R. hansentii 
P. veroralis R. productus 
P. ruminicola R. torques 
R. gnavus 
Table 3: Most prevalent species from the 3 major groups of bacteria identified in human fecal 
sample (adapted from Suau et al. (1999) and Fuller and Perdigon (2003)) 
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As a summary of the data obtained from the different studies using FISH, Fuller and 
Perdigon (2003) reported inter-individual variability in bacterial groups from fecal samples 
of 15 healthy adult humans. Variations expressed as % of total fecal microflora were 
obtained using FISH: 
Bacteroides - Prevotella: 1.5 - 96.3 
Bifidobacterium: 0.4 - 44.6 
Atopobium-Eggerthella-Colinsella: 0.1 —23.0 
Eubacterium rectale-Clostridium coccoides: 6.2 - 69.0 
Clostridium leptum: 0.5 - 38.5 
This study confirmed the results found by Harmsen et al. (2002) and Franks et al. (1998). 
Tremendous inter-individual variability was observed and the Bacteroides/Prevotella and E. 
rectale/C. coccoides are the two groups that reached the highest % of the total fecal flora, 
thus being the two most prevalent groups in the fecal flora. However, new groups, like 
bifidobacterium can account for a large % total flora. Precise quantification of bacterial 
groups is needed to produce elaborate and physiologically relevant data. 
Finally, Matsuki et al. (2002) used a combination of culture of fecal suspension on 
non-specific aanaerobic agar, DNA extraction of selected colonies and PCR with group-
specific probes. The primers were designed for B. fragilis, Prevotella, Bifidobacterium and 
C. coccoides groups. Among the 6 subjects selected, Prevotella were only detected in two of 
them while the number of different strains of the B. fragilis group varied from 1 to 45, 
depending on the fecal sample studied. The major issue with this technique is that culturing 
fecal sample resulted in an average 54% decrease in bacterial count. Therefore, the number 
of isolated strains from one bacterial group may be biased by the loss of micro-organisms. 
Moreover, the techniques involving 16S rDNA and probes rely on known DNA sequences 
and corresponding micro-organisms. They give a more accurate estimate of the fecal 
bacterial profile compared to classic microbiological methods but identification of new 
strains cannot be done following this protocol. 
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2. Determinants of secondary metabolism of bacterial species 
- Bacterial metabolism and enzymatic activities 
Depending on the efficacy of nutrient absorption in the small intestine, bacteria 
composing the gut microflora depend on the host's non-absorbed nutrients to survive and 
compete with other bacteria. The following list describes the types and quantities of nutrients 
arriving in the large intestine that bacteria can metabolize (From Fuller and Perdigon. 2003): 
Resistant starch: 8-40 g/d 
Non-starch polysaccharides: 8-18 g/d 
Unabsorbed sugars: 2-10 g/d 
Oligosaccahrides : 2-8 g/d 
Dietary protein: 3-9 g/d 
In addition, these substrates are not metabolized the same way by micro-organisms that show 
a substrate-specificity so that certain end-products measured in the gut microflora reflect the 
presence of certain bacterial activities and bacterial groups. For example, with respect to 
carbohydrate metabolism, Bacteroides can produce acetate or propionate while butyrate 
formation can be linked to the presence of Clostridium or Fusobacterium (non-exhaustive 
list) (Fuller and Perdigon, 2003). The presence of bacterial groups can also be related to 
detection of other and-products of carbohydrate metabolism, such as ethanol, succinate, 
lactate, pyruvate or hydrogen. 
- Factors influencing the gut microbial composition 
A few studies about factors affecting gut microbial profile have showed some 
interesting results. However, many of these studies looked at by-products or other endpoints 
of bacterial metabolism that reflect a change in the flora but they lacked a microbial analysis 
in identifying which actual strains are affected by these parameters. Below are a few studies 
that did look at changes in colonic ecology with respect to stress, ethnic background, diet, 
prebiotics and probiotics. 
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Holdeman et al. (1976) studied the fecal microflora of 3 astronauts during a 3-phase 
treatment: normal housing and normal diet, normal housing and Skylab diet (designed for 
food while in space), and confined housing and Skylab diet (stress period). Total microscopic 
counts and culture of the colonies using agar plates showed that the Skylab diet applied for 
3.5 months did not have an effect on the gut microbial composition. However, the diet 
associated with confined housing provoked a rise in Bacteroides fragilis subsp. 
thetaitaomicron (~3 to ~8.5 isolates/person/sample) while Peptostreptococcus productus II 
counts decreased significantly to almost no isolate found (5.3 to 1.5 isolates/person/sample). 
Results were normalized among subjects and fecal samples. This showed that stress (~2 
months period), but not diet was a factor in modifying some of the major species of the gut 
microflora. However, technical difficulties to culture the microorganisms, the low power and 
particularity of the subjects and protocol made it difficult, even impossible to extrapolate to 
the general population. On the other hand, these early studies yielded some interesting 
hypotheses that could lead to more relevant data today, considering the enormous advances 
made to culture and analyze the gut microflora. Starvation, considered as a stress, has been 
studied mostly in animals (rats, mice, pigs) and all concluded that starvation significantly 
decreased lactobacilli counts (Tannock. 1997). 
One of the early studies on diet and gut microflora was done by Finegold et al. 
(1974). They looked at 15 Japanese fed a traditional Japanese diet and 18 Caucasian fed a 
typical Western diet. Microbiologic counts and bacterial cultivation of microorganisms using 
selective media revealed that counts of Streptococcus faecalis var. faecalis (9.83 vs. 8.46 
log 10 microorganisms/g feces), Eubacterium contortum (9.58 vs. 0), Eubacterium lentum 
(10.20 vs. 10.07) and Peptostreptococcus sp. 1-25 (8.29 vs. 4.64) were significantly higher 
(p<0.05) in stool samples of Japanese vs. Caucasian, respectively. Only Bifidobacterium 
infantis was higher in Caucasian compare to Japanese (10.29 vs. 0 log 10 microorganisms/g 
feces). However, the species more prevalent in one ethnicity compare to the other were not 
studied for correlation to a specific food item. In the discussion, Finegold et al. also 
mentioned that due to diet (or ethnicity), Clostridium species are more prevalent in Japanese 
than Americans while the opposite may be true for Fusobacterium species. It is therefore 
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possible that diet do influence gut microbial profile and that long-term changes in dietary 
regimen could lead to significant changes in types and amounts of bacterial strains. 
More recently Moore and Moore (1995) analyzed the fecal microflora from subjects 
of different ethnicities (Caucasian (n=17), Asian (n=22), African (n=16)). They found that, 
even though many of the bacterial strains were present among all ethnicities, their 
proportions varied tremendously (table 4 & 5). 
This study showed that ethnicity, probably influenced by dietary factors as well as 
genetic background, is a major factor in the composition of the fecal/colonic flora. However, 
nutritional intervention to modify gut microbial profile in humans (short or long-term) have 
not been performed yet, so that diet associated with ethnicity could play an indirect role in 
determining the bacterial profile, but direct evidence is still lacking. 
Caucasians Japanese Africans 
Total Eubacterium 24.6 11.3 28.1 
Total Bacteroides 17.3 26.4 15.2 
Total Ruminococcus 8.3 2.8 7.2 
Total Peptostreptococcus 6.4 2.5 1.5 
Total Lactobacillus 1.1 2.7 3.9 
Total Clostridium 0 0 5.6 
Total Bifidobacterium 4.8 5.5 3 
Total Fusobacterium 3 3.3 4.7 
Others 5.5 5.1 3.7 
Table 4: Distribution of the major bacterial groups as % isolates in the fecal flora of healthy 
Caucasians on a western-type diet, rural native Japanese and rural native Africans. (Adapted 
from Moore and Moore. 1995). 
Another way to modify the gut microbial profile is the introduction of probiotics 
(ingestion of living bacteria to improved gut health) and prebiotics (non-bacterial factor 
found to influence the gut microflora to improve health). Despite interesting finding about 
changes in specific strains in gut microflora (breast milk significantly increases 
Bifidobacteria population. Fuller and Perdigon. 2003), the effects of pre- and probiotics have 
been related to other endpoints that reflect a modification of the gut microflora, such as 
volatile fatty acids profile. On the other hand, significant changes in the gut profile as a 
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whole have not been fully investigated and/or understood yet. Table 6 is a non-exhaustive list 
of the major pre and probiotics used to improve gut health. 
Caucasians Japanese Africans 
Eubacterium aerofaciens 1 8.5 7.5 15.2 
Eubacterium aerofaciens 2 1.5 3.8 4.2 
Eubacterium rectale 1&2 8.8 2.1 
Eubacterium rectale 3 2.4 2.9 
Eubacterium biforme 1.9 1.1 
Eubacterium elizens 1.5 
Eubacterium BN 2.6 
Bacteroides vuleatus 8.2 7.5 
Bacteroides FB 6 2.3 
Bacteroides thetaitaomicron 1.4 3.2 1 
Bacteroides fraeilis 2.5 8.7 
Bacteroides ovatus 2.4 
Bacteroides uniformis 1&2 2.4 1.9 1.2 
Bacteroides stercoris 1.6 1.5 
Bacteroides FO 1 1.4 
Bacteroides caccae 1.4 
Bacteroides distasonis 1.3 2 
Ruminococcus CE 1.5 
Ruminococcus enavus 1.5 
Ruminococcus bromii 5.2 1.3 3.9 
Ruminococcus obeum 1.6 2.1 
Ruminococcus flavefaciens 1.2 
Peptostreptococcus Droductus 4.2 1.2 
Pevtostrentococcus DZ 2.2 1.3 1.5 
Lactobacillus salivarius 1.7 
Lactobacillus acidovhilus 5 1.1 1 2.2 
Lactobacillus S06 1.7 
Clostridium verfrineens 1.8 
Clostridium ramosum 3.8 
Bifidobacterium adolescentis 2.2 5.5 3 
Bifidobacterium loneum 2.6 
Fusobacterium AB 1 
Fusobacterium vrausnitzii 3 3.3 3.7 
Covrococcus comes 1.4 
Streptococcus S03 1.5 
Enterococcus faecium 3.6 
Gemmieer formicilis 1.6 1.4 
Escherichia coli 1.2 2.3 
Butwibrio crossotus 1.3 
Table 5: Distribution of the predominant species as % isolates in the fecal flora of healthy 
Caucasians on a western-type diet, rural native Japanese and rural native Africans. (Adapted 
from Moore and Moore. 1995). 
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Prebiotics Probiotics 
Lactulose Lactobacillus acidophilus 
Innulin Lactobacillus casei 
Fructooligosaccharides Lactobacillus bulgaricus 
Galactooligosaccharides Bifidobacterium adolescentis 
Lactosucrose Bifidobacterium bifidum 
Isomaltooligosaccharides Bifidobacterium breve 
Glucooligosaccharides Bifidobacterium longum 
Xylooligosaccharides Bifidobacterium infantis 
Table 6: Commonly used prebiotics and families of prebiotics and probiotics in humans. 
(From Fuller and Perdigon. 2003; Tannock. 1995). 
3. Summary 
Despite significant findings in the overall knowledge of gut microbial composition 
and metabolic activities, many aspects remain to be studied. Minor species that may vary 
among individuals have not been identified yet in spite of new accurate molecular biology 
techniques. Additionally, factors influencing composition of the gut microflora have been 
investigated from a metabolic point of view, but the actual changes in proportions of the 
different microbial species were not a research objective in these studies. Ethnicity-related 
gut microbial composition studied by Moore and Moore (1995) and Finegold et al. (1974) 
gave significant basis with relationship to diet for further studies, but long-term changes in 
dietary habits and how they would affect composition and metabolic activities of the colonic 
microflora remain until now a major knowledge gap that must be investigated in the near 
future. In addition, other factors supposedly influencing the gut microflora deserve more 
attention (gut transit time, sex and age). 
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ISOFLAVONE EXCRETION PHENOTYPES INFLUENCE PLASMA 
CHOLESTEROL IN GOLDEN SYRIAN HAMSTERS 
To be submitted to Journal of Nutrition 
Mathieu Renouf, Sun-Ok Lee and Suzanne Hendrich 
ABSTRACT 
We hypothesized that hamsters sorted into high and low isoflavone excreter phenotypic 
categories would show significant differences in plasma cholesterol status, the high 
isoflavone excreters having lower cholesterol. One-year old hamsters were fed either 1.18 
mmol total isoflavones/kg diet (5 males, 5 females) or 1.77 mmol total isoflavones/kg diet (5 
males, 4 females) for 10 d. Urine and feces were collected for 24 h in metabolic cages, and 
blood collected at euthanasia after 16h fast. According to a cluster analysis, hamsters sorted 
into two distinct urinary isoflavone phenotypes: high and low excreters with mean total 
isoflavone excretion of 44 ± 5% v. 14 ± 7%; daidzein excretion of 30 ± 7% v. 8 ± 3%; 
glycitein excretion of 84 ± 6% v. 28 ± 13% and genistein excretion of 35 ± 7% v. 8 ± 4% of 
the ingested dose, respectively. Urinary excretion of all isoflavones was strongly correlated 
(0.93<r<0.98; p<0.001). Fasting plasma total cholesterol was significantly lower in high 
versus low excreters (e.g., based upon total isoflavones, 6.1 ± 1.9 mmol/L v. 8.3 ± 1.5 
mmol/L, respectively), regardless of sex. Although females had significantly better 
bioavailability than males for total isoflavones (33 + 18% v. 17 + 9%), daidzein (24 + 14% v. 
11 + 6%) and genistein (27 + 15% v. 10 + 6%), cholesterol concentrations were not 
significantly different by sex, probably because of the great interindividual variability in 
isoflavone bioavailability. These data support our hypothesis. Golden Syrian hamsters may 
be good models to study the link between bioavailability and cholesterol-lowering effects of 
isoflavones because they sort into isoflavone bioavailability clusters similar to what has been 
noted previously in humans. 
Key words: isoflavone, hamsters, bioavailability, phenotypes, cholesterol. 
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Dietary isoflavones are found almost exclusively in soybeans and soy products 
(Murphy et al., 1997) and have an estrogen-like chemical structure (Setchell and Adlercreutz 
1988). Evidence suggest that they may prevent chronic diseases such as breast cancer 
(Lamartiniere et al., 2002), but the health effects of these compounds are highly variable 
among individuals and their bioavailability is not well understood. In humans, 1 to 25% of 
the ingested dose of isoflavones is excreted in the urine, mostly as glucuronide conjugates, 
whereas less than 1% is recovered in the feces. The great proportion of isoflavones not 
recovered or disappearing has been linked with microbial metabolism and degradation (Hur 
et al. 2000; Xu et al. 1995). When isoflavones were incubated in vitro with human feces, they 
disappeared within 48 h. Fecal isoflavone degradation rates differed among individuals with 
degradation rates sorted into statistically significant clusters: high, moderate or low (Zheng et 
al. 2003). Low degraders seemed to have greater apparent absorption (urinary excretion) of 
isoflavones whereas high degraders had lesser urinary excretion (Xu et al. 1995). Zheng et al. 
(2003) found that Asian female low isoflavone degraders had more rapid gut transit time 
(GTT) and threefold greater urinary genistein excretion than did Asian high isoflavone 
degraders or Caucasian low or high isoflavone degraders. Caucasians had significantly longer 
GTT than did Asians. 
Valid animal models need to be established to facilitate long-term study of dietary 
modulation of chronic diseases. In the case of cholesterol metabolism, Golden Syrian 
hamsters may be used to study the hypocholesterolemic effects of isoflavones, because 
cholesterol metabolism in hamsters is similar to that of humans (Bravo et al, 1994). Dorfman 
et al. (2003) found that the most appropriate protocol in using hamsters as a 
hypercholesterolemic model with relevance to humans was to feed Golden Syrian hamsters a 
diet containing 10% saturated fat and 0.1% cholesterol for 10 weeks. Song et al., (2003) 
showed that Golden Syrian hamsters fed 1.3 mmol daidzein/kg diet for 10 weeks had 
significantly lower concentrations of total cholesterol and non-HDL cholesterol compared 
with control hamsters fed a casein-based diet high in saturated fat. Isoflavone bioavailability 
has not been established yet in this animal model. Our hypotheses are that hamsters, like 
humans, cluster into significantly different isoflavone bioavailability phenotypes. 
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Furthermore, in hamsters these isoflavone bioavailability phenotypes correspond to the 
cholesterol-lowering efficacy of isoflavones. 
MATERIALS AND METHODS 
Chemicals and diets 
Isoflavones were purchased as Novasoy® from ADM (Decatur, IL). Isoflavone 
composition was determined by HPLC (Murphy et al., 1997). Total isoflavone concentration 
was 1.18 mmol/g Novasoy® and daidzein, genistein and glycitein were 37%, 53% and 10% 
of total isoflavones respectively. The diet was high in saturated fat, casein-based with 10% 
sucrose in partial replacement of rice flour as a source of carbohydrates (Song et al., 2003). 
Diets were formulated to contain 1.18 mmol (320 mg) or 1.77 mmol (480mg) of total 
isoflavone/kg diet. Other chemicals used for isoflavone extraction and analysis were 
purchased from Fisher Scientific (Pittsburg, PA) and Sigma (St Louis, MO). 
Animals 
The animal experimental protocol was approved by the Iowa State University 
Committee on Animal Care. Fifteen male and 14 female Golden Syrian hamsters (-12 weeks 
of age), were obtained from Harlan-Teklad (Madison, WI). They were housed individually in 
the same room in a temperature-controlled room (23°C) with a 12h light:dark cycle. 
Hamsters were maintained on a standard rodent chow diet until they reached 1 year of age. 
Males and females were randomly assigned to one of two diets containing either 1.18 mmol 
total isoflavone/kg diet (n=5 males, 5 females) or 1.77 mmol total isoflavone/kg diet (n=5 
males, 4 females). Animals were fed ad libitum for 10 days and urine collected over 24 hours 
in metabolic cages. Urine was stored at -20°C until analysis. After 24h in metabolic cages, 
diets were withdrawn from hamsters 14-16h before euthanizing them under CO2. Blood was 
collected using cardiac puncture and plasma samples were obtained by centrifugation at 5000 
g for 10 min at 4°C and frozen at -20°C until analysis. 
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Urinary isoflavone analysis 
Isoflavone extraction from urine samples was done following a modified protocol 
established by Zhang et al. (1999). Five mL of urine were incubated with 50 pL of 0-
glucuronidase-sulfatase (Sigma, Saint Louis, MO) at 37°C for 20 h to obtain the aglycone 
form of isoflavones. Fifty pL of 2,4,4'-trihydroxydeoxybenzoin (THE) was also added prior 
to the incubation as an internal standard. Incubation mixtures were loaded on Extrelut (TM) 
QE columns (EM Science, Gibbstown, NJ) and extracted with ethyl acetate. The eluent 
obtained was collected, dried using a roto-evaporator (Buchï, Flawil, Switzerland) and 
dissolved in 9.8 mL of 20% ethanol and 0.2 mL of IN HCL. Five milliliters of this solution 
was loaded on a pre-wetted Sep-pak CI8 cartridge (Waters, Rainin, Wobum, MA), washed 
twice with 2mL of distilled deionized water and eluted with 2 mL of 80% methanol. 
Samples were stored at 4°C until HPLC analysis (Zhang et al., 1999). Urinary isoflavone 
excretion was expressed as a percentage of the dose ingested over 24 h, to normalize data 
across variations in food intake and body weight. 
Plasma total cholesterol analysis 
Plasma total cholesterol analysis was performed using a standard diagnostic kit 
(Sigma Chem. Co., St Louis, MO). Each sample was measured in duplicate on a Beckman 
DU 500 spectrophotometer (Beckman Coulter, Fullerton, CA). 
Statistical analysis 
Statistical analysis was performed using SAS (SAS Institute, version 6.12; 1998, 
Cary, NC). Phenotypes were established using a cluster analysis. Blood cholesterol and 
urinary excretion among the clusters, sexes and isoflavone doses were compared by one-way 
and two-way ANOVA and correlation between urinary excretion of isoflavones was done by 
a regression test. All results were considered significant at p<0.05. 
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RESULTS 
Urinary isoflavone excretion 
Females fed 1.18 mmol/kg diet did not show any significant difference (p>0.05) in 
urinary excretion of daidzein, genistein, glycitein and total isoflavone compared with the 
group fed 1.77 mmol/kg diet (32 ± 21% vs. 35 ± 17%; 25 ± 16% vs. 23 ± 12%; 57 ± 37% vs. 
69 ± 33% and 25 ± 18% vs. 29 ± 14% ingested dose for total isoflavone, daidzein, glycitein 
and genistein at 1.18 and 1.77mmol/kg diet, respectively). On the other hand, males fed 1.77 
mmol/kg diet had significantly less urinary excretion of daidzein (16 ± 6% vs. 7 ± 3%; 
p=0.027) and genistein (14 ± 7% vs. 5 ± 2%; p=0.024) compared with males fed 1.18 
mmol/kg diet (Table 1). Urinary excretion of total isoflavone and glycitein did not differ 
between the two doses in males (22 ± 9% vs. 12 ± 7% and 48 ± 20% vs. 36 ± 26% ingested 
dose for total isoflavones and glycitein at 1.18 and 1.77 mmol/kg diet (p>0.05), respectively). 
Comparison of males and females fed the same dose of isoflavone showed that at 
1.18 mmol/kg diet, no significant difference were found in urinary excretion of individual 
and total isoflavone (22 ± 9 vs. 32 ± 21, p=0.37; 16 ± 6 vs. 25 ± 16, p=0.28; 48 ± 20 vs. 57 ± 
37, p-O.66; 14 ± 7 vs. 25 ± 18, p-0.23 expressed % ingested dose for total isoflavone, 
daidzein, glycitein and genistein, of males vs. females respectively; table 1). On the other 
hand, a sex-difference was found between males and females fed 1.7 7mmol/kg diet in 
urinary excretion of total isoflavone (12 ± 7 vs. 35 ± 17%; p=0.03), daidzein (7 ± 3 vs. 23 ± 
11; p=0.02) and genistein (5 ± 2 vs. 29 ± 14%; p=0.008). Glycitein urinary excretion was not 
significantly different (36 ± 26 vs. 69 ± 33%; p=0.08) (table 1). 
When sexes were combined, there was no significant effect of dose for daidzein (20 ± 
12 vs. 14 ± 11; p=0.32), glycitein 53 ± 29 vs. 50 ± 33; p=0.87), genistein (20 ± 14 vs. 16 ± 
15; p=O.55), or total isoflavones 27 ± 16 vs. 23 ± 17; p=0.57) (Table 1). 
When doses were combined, females had significantly greater urinary excretion of 
total isoflavone (33 ± 18% vs. 17 ± 9%; p=0.026), daidzein (24 ± 14% vs. 11 ± 6%; p=0.018) 
and genistein (27 ± 15% vs. 10 ± 6%; p=0.005) compared with males while glycitein was not 
statistically different between sexes (62 ± 34% vs. 42 ± 23%; p=0.14) (Table 1). 
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Regardless of the dose of isoflavone fed or sex, glycitein bioavailability was 
significantly higher than that of daidzein (52 ± 30% vs. 17 ± 12%; pO.OOl) and genistein 
(52 ± 30% vs. 18 ± 14%; pO.OOl). Mean urinary excretion of daidzein and genistein were 
not significantly different (17 ± 12% vs. 18 ± 14%; p=0.9). 
Urinary excretion of all animals, regardless of gender or dose, was ranked from the 
greatest to the least. Cluster analysis indicated the presence of high and low excreter 
(apparent absorber) phenotypes for all isoflavones. Mean urinary isoflavone excretion of low 
excreters was statistically different from that of the high excreters. Moreover, the range of 
urinary excretion showed large differences between the greatest and the least excreters. For 
example, female #2 fed 1.18 mmol total isoflavone/kg diet excreted only 4% of the ingested 
dose for total isoflavone whereas female #1 also fed 1.18 mmol total isoflavone/kg diet 
excreted 53% of the ingested dose for total isoflavone. Table 2 summarizes the range of 
excretion for each category of isoflavone; figure 1 gives an example of the different values 
and clusters obtained for total isoflavones (graphs not shown for daidzein, glycitein and 
genistein). 
Correlation between urinary excretions of isoflavone 
Excretions of each or total isoflavone were correlated, and all of these correlations 
showed an r value of 0.93 or greater. Moreover, regression analysis showed that all the 
correlations were statistically significant (pO.Ol). Total isoflavone urinary excretion was 
significantly correlated with daidzein (r=0.93), glycitein (r=0.97) and genistein (r=0.98). In 
addition, daidzein urinary excretion showed a significant correlation with genistein (r=0.97) 
and glycitein (r=0.98) while genistein and glycitein urinary values were significantly 
correlated (r=0.93). 
Plasma total cholesterol 
Females fed 1.18 and 1.77 mmol/kg diet had similar cholesterol levels (7.7 ± 0.9 vs. 
5.7 ±1.8 mmol/L; p=0.19). Similar results were found between males fed 1.18 and those fed 
1.77 mmol/kg diet (7.5 ± 2.2 vs. 8.8 ± 1.1 mmol/L; p=0.29). Comparison of mean plasma 
total cholesterol of animals fed the same dose of isoflavone did not show significant 
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differences between males and females (p=0.82 and 0.08 for 1.18 and 1.77 mmol/kg males 
vs. females-fed animals, respectively) Despite sex differences observed in isoflavone urinary 
excretion, total cholesterol based only on sex did not show a significant difference in plasma 
total cholesterol (6.8 ±1.3 vs. 8.1 ± 1.6 mmol/L for male vs. females, respectively; p=0.18) 
(Table 1). 
Based on phenotypes of urinary excretion (regardless of sex or dose fed), mean plasma total 
cholesterol level of high excreters was significantly lower than that of low excreters for total 
isoflavones (6.1 ±1.9 vs. 8.3 ±1.5 mmol/L; p-O.Ol9), daidzein (6.1 ±1.9 vs. 8.3 ±1.5 
mmol/L; p=0.019) and genistein (6.3 ± 1.5 vs. 8.4 ± 2.0 mmol/L; p-0.03). Plasma cholesterol 
did not differ between glycitein excretion phenotypes (6.4 ±1.6 vs. 8.3 ± 2.0 mmol/L; 
p=0.054, Table 3). 
DISCUSSION 
This study demonstrates that the clustering of individuals according to apparent 
isoflavone absorption as reflected in urinary excretion may predict the efficacy of isoflavone-
containing products with respect to their cholesterol lowering ability. A hamster model may 
be useful in such studies because of similarities with humans in isoflavone bioavailability 
phenotypes. 
Urinary excretion of the two isoflavone doses was not significantly different in 
females, whereas males fed 1.77 mmol total isoflavone/kg diet had lower bioavailability of 
daidzein (16 ± 6% vs. 7 ± 3%; p=0.027) and genistein (14 ± 7% vs. 5 ± 2%; p=0.024) than 
males fed 1.18 mmol total isoflavones/kg diet. Because the percentage urinary excretion is 
similar between the 2 doses fed to females but not males, we therefore concluded that a 
positive dose response occurred in females while males displayed a somewhat "inverse dose 
response". Although this phenomenon has not been observed in Golden Syrian hamsters 
previously, a similar pattern has been observed by Janning et al. (2000) in female DA/Han 
rats fed by gavage a single dose of 10 or 100 mg daidzein/kg body weight (or 37 vs. 370 
pmol/kg body weight). Plasma area under the curve, another way to assess bioavailability of 
a component, was 9.7% and 2.2% for 10 and 100 mg dose, respectively. The authors 
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hypothesized some differences in kinetics related to the dose fed, but no explanation was 
provided. In the present study, the difference between the two doses fed (-118 vs. 177 
pmol/kg body weight, chronic intake) were not as great as in Janning et al. (2000) (37 vs. 
370 gmol/kg body weight of pure daidzein, acute intake) and it occurred only in males. In 
our study, although animals were distributed among groups at random, there may have been a 
greater proportion of low urinary excreters among the males fed the higher isoflavone dose, 
whereas high urinary excreters predominated among male fed the lower isoflavone dose. 
Randomization of females seemed to have produced a more even distribution of animals of 
each excretion phenotype in each dose fed, thus not observing a dose-related effect on 
urinary excretion. This unfortunate randomization of male animals could also explain the 
lack of difference in isoflavone excretion observed between males and females fed 1.18 
mmol isoflavones/kg diet (Table 1), whereas significant sex difference in urinary isoflavone 
excretion occurred in animals fed 1.77 mmol isoflavones/kg (Table 1). This was also 
reinforced by analysis of gender and dose using a two-way ANOVA that did not give a 
significant p value (0.2). 
With respect to sex differences observed here in animals, Lu et al (1998) observed in 
humans lesser isoflavone bioavailability in men than in women. During a one month 
intervention study, women (n=6) excreted 24 and 66% of the ingested doses of genistein and 
daidzein, respectively, whereas men (n=6) excreted 15 and 47% as genistein and daidzein 
respectively. Compared with Lu et al. (1998) study, male hamsters had urinary genistein 
excretion quite similar to men (15% and 10% of the ingested dose for men and male 
hamsters, respectively), but urinary excretion of daidzein was much less in male hamsters 
(47% and 11.8% for men and male hamsters, respectively). The same pattern of urinary 
excretion was also observed in women compared with female hamsters. Genistein levels 
were comparable (24% and 27.5% for women and female hamsters, respectively) but 
daidzein urinary excretion levels differed (66% and 24.5% for women and female hamsters, 
respectively). This showed that apparent absorption of genistein may be more similar 
between humans and hamsters compared with that of daidzein. When comparing 
different animal models, Bayer et al. (2001) investigated daidzein bioavailability in Fisher 
244 male (n=4) and female (n=4) rats fed 100 mg daidzein/kg diet. Despite not finding sex 
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difference in urinary excretion as we did in this study, daidzein urinary excretion levels in 
rats were more similar to the ones found in the present study. Indeed, daidzein was excreted 
at 8.8 ± 3.1 and 8.2 ± 2.8% ingested dose for males and females respectively. Levels of 
daidzein metabolites in urine (ODMA and equol) accounted for less than 5% of ingested 
dose, so that the idea that daidzein is extensively converted into metabolites, especially 
equol, which would partly explain the low bioavailability of unchanged daidzein, was not 
confirmed in this study. In Janning et al. study (2000), plasma area under the curve was 
9.7% and 2.2% for 10 and 100 mg daidzein, respectively in female DA/Han rats fed daidzein 
by gavage as a single dose and equol detection was so small that it was not accurately 
quantifiable. The possibility that that low daidzein bioavailability may be due to significant 
transformation of daidzein into equol is not supported by the data obtained from other animal 
studies. In the present study, we have not been able to detect the presence of equol in urine, 
possibly because the samples were partly diluted with drinking water when animals were in 
metabolic cages and only 5 mL were used for analysis. In addition, our limit of detection for 
equol using a UV detection method would not be likely to detect the seemingly small 
amounts of equol that may have been present. On the other hand, daidzein bioavailability 
data established in other rodent models confirmed the data obtained in our study. Janning et 
al. (2000) examined at plasma area under the curve, which indicated how much daidzein was 
absorbed over time, but it was still an indirect evidence of how much of the compound was 
likely to be excreted in the urine. 
In humans, Lu et al. (1998) did not assess glycitein bioavailability, which was one of 
the main points of the present study. In humans, Zhang et al (1999; erratum, 2001) found that 
moderate degraders (n=14,7 males and 7 females) had 52.4 ± 19.6%, 37.0 ± 25.9% and 47.6 
± 18.1% urinary recovery of the ingested dose of daidzein, genistein and glycitein, 
respectively. Urinary excretion of genistein was significantly less than that of daidzein and 
glycitein whereas urinary excretion of daidzein and glycitein were not statistically different. 
These results taken altogether indicated that glycitein and daidzein were more absorbable 
than was genistein in humans. In the present hamster study, daidzein and genistein had 
similar patterns of urinary excretion (females showed 24% and 27% and males 11% and 10% 
for daidzein and genistein, respectively), whereas glycitein urinary recovery was higher (62% 
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and 42% for females and males, respectively). Urinary excretion of glycitein was greater and 
excretion of daidzein less in hamsters compared with humans who were moderate fecal 
isoflavone degraders (Zhang et al 1999). On the other hand, urinary excretion of genistein in 
hamsters who were high excreters was close to that of moderate human degraders. These 
differences may be due to a different gut microbial profile with presumably less glycitein-
degrading and more daidzein-degrading microorganisms in hamsters compared with humans. 
We also hypothesized that sex differences could be due to a gut microbial adaptation over 
time in males that did not occur in females, but this remains to be identified specifically. 
Phenotypes of bioavailability based on in vitro fecal isoflavone degradation have 
already been established in humans, who can be categorized as low, moderate or high 
isoflavone degraders (Zheng et al, 2003). In the present study we established our isoflavone 
bioavailability phenotypes based on urinary isoflavone excretion instead of in vitro fecal 
isoflavone degradation because we have not yet performed in vitro isoflavone incubations 
with hamster fecal or cecal contents. Zheng et al. (2003) showed that low urinary genistein 
excretion (and hence apparent absorption) corresponded with a high in vitro fecal 
degradation of genistein in Asian women, and this pattern was influenced by a significantly 
longer gut transit time. Considering that in the present study, genistein bioavailability in 
hamsters seemed to be more relevant to humans, it could then be considered as the trademark 
isoflavone when considering relationships between urinary, fecal excretion and in vitro 
degradation with relevance to humans. In order for hamsters to be a fully useful model to 
study bioavailability and health-promoting effects of isoflavones, it is crucial in future 
studies to evaluate the relationship between in vitro fecal degradation and urinary excretion 
of these compounds. 
In previous studies (Zheng et al. 2003; Zheng et al 2004), a low bioavailability of 
daidzein tended to correspond with a low bioavailability of genistein and vice-versa. 
Correlation of daidzein or genistein with glycitein in humans has not been established yet, 
but unpublished data from our laboratory suggest that glycitein bioavailability was positively 
correlated with that of daidzein and genistein, although these correlations were not as strong 
as observed in hamsters. These data showed an additional common feature between hamsters 
and humans, namely that bioavailability phenotypes were generally consistent across the 
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different isoflavones. Indeed, there was a strong relationship among urinary excretion of all 
isoflavones so that a hamster being a high daidzein excreter was also a high genistein and 
glycitein excreter. 
Because isoflavones are thought to be health-promoting compounds, we measured 
plasma total cholesterol as an endpoint in order to relate bioavailability to health. We chose 
plasma total cholesterol because lipid metabolism in Golden Syrian hamsters is close to that 
of humans and hypercholesterolemia can be induced in a short period of time in this animal 
model (Bravo et al, 1994). Our study showed that, regardless of sex and dose, total 
isoflavone, daidzein, genistein and to some extent glycitein had an effect on total cholesterol. 
Animals excreting low amounts of isoflavone had greater total cholesterol than those 
excreting large amounts. Greater isoflavone bioavailability was associated with a greater 
decrease in total cholesterol. This result is consistent with a previous study in hamsters 
showing the efficacy of daidzein in lowering cholesterol. Song et al. (2003) fed a high fat 
diet containing 1.3mmol/kg diet of purified daidzein to hamsters for 10 weeks, resulting in. 
significantly lower levels of total cholesterol by -24% and non-HDL cholesterol by -35% in 
both sexes. There was no gender difference in improving blood lipid profile, which is in 
agreement with the present study. On the other hand, Lin et al. (2004) fed male hamsters 
(n=20/groups) for 5 weeks different diets containing either casein, plant sterol esters, soy 
isoflavones from Novasoy® or different combination of these four diet components. 
Hamsters fed isoflavones (-0.8 mmol total isoflavones/kg diet) did not differ from the casein 
control for total cholesterol, triglycerides or HDL-cholesterol. These results do not agree with 
the present study, but we fed both sexes higher doses of isoflavones than did Lin and 
colleagues, which suggest the possibility of a threshold dietary dose necessary to observe 
physiological effects. Lin et al. (2004) did not attempt to sort individuals according to 
isoflavone bioavailability. The great range of apparent isoflavone absorption (as reflected in 
excretion; from 2% of the ingested dose for genistein, up to 95% of the ingested dose for 
glycitein in the present study) could interfere with the effect of isoflavones on cholesterol 
metabolism. Thus, studies of health endpoints influenced by isoflavones should cluster 
individual endpoint variables relative to isoflavone bioavailability to appropriately relate to 
the health effect. 
104 
Human studies focusing on the hypocholesterolemic effects of isoflavones have also 
given variable results. Age, baseline blood lipid profile, isoflavone source (purified, dietary 
supplement or part of soy protein), dose of isoflavone and duration of the intervention varied 
from one study to another so that comparisons of protocols and results are difficult to make. 
According to Goodman-Gruen et al. (2001), one of the major disadvantages of providing soy 
protein is the variety and amounts of other bioactive compounds, such as saponins that might 
interfere with or mask isoflavone actions on cholesterol metabolism. It also seems that 
providing isoflavones to individuals with moderate to severe baseline hypercholesterolemia 
would produce more significant results in contrast to normocholesterolemic individuals. 
Grouse et al. (1999) studied the effect of isoflavones in moderately hypercholesterolemic 
men and women (n=156; LDL cholesterol levels 3.62 to 5.17 mmol/L). Subjects were 
divided into 5 groups (n=31) and given beverages for 9 weeks containing either 25 g 
casein/day, 25 g ethanol washed isolated soy protein/day that contained 3 mg total 
isoflavones or 25 g soy protein/day at three levels of isoflavones: 27, 37 or 62 mg total 
isoflavones. Subjects who consumed 62 mg isoflavones/day had significantly lower levels of 
total (4% reduction) and LDL cholesterol (6% reduction) compared with casein controls. In 
addition, subjects with baseline LDL in the highest range (>4.24 mmol/L) had a greater 
decrease in total (9%) and LDL cholesterol (10%) compared to casein. An 8% decrease was 
also observed in total and LDL-cholesterol of baseline-high LDL subjects given 37 mg 
isoflavones compare to casein group. Thus, this studied showed a threshold effect of 
isoflavones in order to improve blood lipid profile and more severely hypercholesterolemic 
subjects showed a greater benefit than did moderately hypercholesterolemic subjects. Dewell 
et al. (2002) gave 36 moderately hypercholesterolemic post-menopausal women (mean total 
cholesterol^ 6.6 ± 1.3 mmol/L) with 150 mg isoflavones/d (n-20) or placebo (n=16) for 2 
mos. No significant differences were found in total and HDL-cholesterol over this time 
period in the isoflavone group. No differences were found between placebo and isoflavone 
groups in total and HDL cholesterol. The fact that studies of isoflavone efficacy vary 
significantly in their results suggests that screening for isoflavone bioavailability might 
permit more successful examination of the health effects associated with these compounds. 
Individuals with high urinary excretion/apparent absorption of isoflavones could have 
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significantly improved blood lipid profiles compared with those with lower urinary 
excretion/apparent absorption, as observed in hamsters. 
The present study establishes the partial validity of Golden Syrian hamsters as an 
animal model to study bioavailability of isoflavones and their possible health-promoting 
effects. Great inter-individual variability in urinary excretion, grouping of animal in 
phenotypes of isoflavone bioavailability and strong correlations among types of isoflavones 
excreted are characteristics similar to what has been observed in humans. Our data, along 
with previously published data (Song et al. 2003; Grouse et al. 1999) showed benefits of 
isoflavones on cholesterol concentrations. On the other hand, differences in urinary excretion 
level of isoflavones between humans and hamsters are a major disadvantage. Glycitein was 
excreted in greater amounts in hamsters compared to humans, while daidzein showed an 
opposite pattern. Only genistein was similar between humans and hamsters. Based on these 
conclusions, health-related effects of genistein in Golden Syrian hamsters would then be 
relevant to humans, while more caution should be taken with respect to daidzein and 
glycitein when using of a rodent model. In addition, Golden Syrian hamsters could be 
considered as an animal model to study isoflavones bioavailability and their 
hypocholesterolemic effects with possible relevance to humans. Reproducibility of the 
results using both sexes with greater sample size, a single dose of isoflavones given and 
taking into account the role of variation in gut microbial ecologies would help in determining 
the observed hamster bioavailability phenotypes. This may provide useful insights into the 
effects of microbial/host interactions on chronic disease prevention. 
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Table 1 Mean isoflavone urinary excretion expressed as % ingested dose (± standard 
deviation) and corresponding mean plasma total cholesterol (mmol/L ± standard deviation) in 
Golden Syrian hamsters, based on sex and/or dose of isoflavone. 
Isoflavone 
mmol/kg Total Plasma total 
diet isoflavone8 Daidzein® Glycitein2 Genistein3 cholesterol15 
females 
(n=5) 1.18 32 ±21 25 ±16 57 ±37 25 ± 18 7.7 ±0.9 
females 
(n=4) 1.77 35 ± 17 23 ± 12 69 ±33 29 ± 14 5.7 ± 1.8 
p value 0.80 0.90 0.63 0.76 0.19 
males 
(n=5) 1.18 22 ±9 16 ± 6 48 ±20 14.6 ±7.0 7.5 ± 2.2 
males 
(n-5) 1.77 12 ± 7 7 ± 3 36 ±26 5.5 ± 2.1 8.8 ± 1.1 
p value 0.11 0.02 0.42 0.02 0.29 
(n=10) 1.18 27 ±16 20 ± 12 53 ±29 20 ± 14 7.6 ± 1.5 
(n=9) 1.77 23 ±17 14 ± 11 50 ±33 16 db 15 7.4 ± 2.7 
p value 0.57 0.32 0.87 0.55 0.84 
males 
(n=5) 1.18 22 ±9 16 ± 6 48 ±20 14.6 ±7.0 7.5 ±2.2 
females 25.9 ± 
(n=5) 1.18 32 ±21 25 ± 16 57 ±37 18.3 7.7 ± 0.9 
p value 0.37 0.28 0.66 0.23 0.82 
males 
(n=5) 1.77 12 ±7 7 ± 3 36 ±26 5 ± 2 8.8 ± 1.1 
females 
(n=4) 1.77 35 ± 17 23 ±12 69 ±33 29 ± 14 5.7 ± 1.8 
p value 0.03 0.021 0.13 0.008 0.08 
females 
(n=9) 33 ±18 24 ±14 62 ±34 27 ± 15 6.8 ± 1.3 
males 
(n=10) 17 ± 9 11 ±6 42 ±23 10 ± 6 8.1 ± 1.6 
p value 0.02 0.01 0.14 0.01 0.18 
(a) Values are expressed as mean percentage of the dose ingested ± standard deviation 
(b) Values are expressed as mean plasma total cholesterol level (mmol/L) ± standard 
deviation 
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Figure 1 Individual values of urinary excretion of total isoflavone and clusters of high and 
low excreter phenotypes. 
X-axis: Low dose (L), 1.18 mmol total isoflavone / kg diet; High dose (H): 1.77 mmol 
total isoflavone / kg diet; F: female; M: male. 
White bars correspond to low urinary isoflavone excreters and black bars to high urinary 
isoflavone excreters. 
100 
e 80 
S 60 
« 
a 40 
High excreters 
0 
Low excreters 
s 3 g B g s 
I l l  
Table 2 Mean of urinary excretion of low and high excreter phenotypes and range of urinary 
excretion, regardless of sex or dose fed. 
Mean low 
excreter a 
14.0 ±7.1 Total 
isoflavone 
Daidzein 
Glycitein 
Genistein 
8.6 ± 3.8 
28.7 ± 13.7 
8.2 ± 4.6 
Mean high 
excreter a 
44.8 ± 7.3 
30.5 ± 7.0 
84.3 ± 6.8 
35.6 ± 7.6 
Range of 
excretion b 
4.0-53.5 
2.9-39.9 
8.9-95.6 
2.4-47.6 
(a) Values are expressed as mean percentage of the dose ingested ± standard deviation 
(b) Values are expressed as percentage of the dose ingested. 
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Table 3 Plasma total cholesterol level of high versus low isoflavone excreters 
Total 
isoflavone 
Daidzein Glycitein Genistein 
High excreters 6.12 ±1.99 6.12 ±1.99 6.47 ± 1.66 6.35 ± 1.5 
Low excreters 8.36 ± 1.56 8.36± 1.56 8.32 ±2.08 8.4 ±2.08 
P value 0..019 0.019 0.054 0.03 
Plasma total cholesterol levels are expressed in mmol/L ± standard deviation. 
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BIOAVAILABILITY OF SOY ISOFLAVONES IN GOLDEN SYRIAN HAMSTERS 
To be submitted to Journal of Nutrition 
Mathieu Renouf and Suzanne Hendrich 
ABSTRACT 
Our hypothesis in this study was that Golden Syrian hamsters display similar patterns of 
bioavailability of isoflavones compared to humans in terms of apparent absorption, urinary 
excretion and gut microbial degradation. Two separate studies were conducted to test this 
hypothesis: one focusing on fecal (study #1) and the other on cecal (study #2) microbial 
degradation of isoflavones. Urinary excretion was significantly lower by 2-4 fold in males 
compared to females in both studies. Fecal isoflavone excretion was not significantly 
different between sexes or isoflavones (study #1) and showed low levels of excretion (<0.5% 
ingested dose). In vitro fecal degradation rates from study #1 showed low degradation levels 
and no significant correlation with urinary and fecal isoflavone excretion. However, cecal 
isoflavone degradation rates (study #2) were much higher than fecal isoflavone degradation 
rates (study #1) and were statistical correlated with urinary excretion of daidzein (r=0.90; 
p=0.01) and genistein (r=0.93; p=0.004) but not glycitein (r=0.50; p=0.3). Compared to 
published human data, female hamsters may be more relevant than males to study 
bioavailability of isoflavones, but strong sex differences deserve more attention. The lack of 
correlation and stability in glycitein bioavailability along with very little human data on this 
isoflavone suggest that more investigation is needed. 
Key words: isoflavone, hamsters, bioavailability, cecal microflora. 
Dietary isoflavones are found mainly in soybeans and soy products (Murphy et al., 1997) 
and have an estrogen-like structure (Setchell and Adlercreutz 1988). Evidence suggest that 
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they may prevent chronic diseases such as breast cancer in animal models (Lamartiniere et 
al., 2002), but the health effects of these compounds are highly variable among individuals 
and their bioavailability is not well understood. In humans, 1 to 25% of the ingested dose of 
isoflavones is excreted in the urine, mostly as glucuronide conjugates, whereas less than 1% 
is recovered in the feces. Women clustered into high and low urinary and fecal isoflavone 
excreters with different patterns of isoflavone bioavailability; high excreters had more similar 
availability of genistein and daidzein than did low excreters (Xu et al. 1995). The great 
proportion of isoflavones not recovered or disappearing has been linked with microbial 
metabolism and degradation (Hur et al. 2000; Xu et al. 1995). When isoflavones were 
incubated in vitro with human feces, they disappeared within 48h. Fecal isoflavone 
degradation rates differed among individuals. Degradation rates sorted into statistically 
significant clusters: high, moderate or low (Zheng et al. 2003). Zheng et al. (2003) found that 
Asian female low isoflavone degraders had more rapid gut transit time (GTT) and threefold 
greater urinary genistein excretion than did Asian high isoflavone degraders or Caucasian 
low or high isoflavone degraders; Caucasians had significantly longer GTT than did Asians. 
Valid animal models need to be established to facilitate long-term study of dietary 
modulation of chronic diseases. Rats have been studied with respect to bioavailability of 
isoflavone (King et al. 1998). However, Golden Syrian hamsters deserve some attention 
because of the use of this animal model to study the hypocholesterolemic effect of 
isoflavones with relevance to humans. Bravo et al. (1994) showed that cholesterol 
metabolism in humans and hamsters are similar each other. Thus, to demonstrate even 
greater relevance, hamsters and humans would also have to share similarities in terms of 
apparent absorption, urinary excretion and gut microbial degradation. Our hypothesis in this 
study is that gut microbial disappearance of isoflavones in fecal or cecal samples from 
Golden Syrian hamsters predicts apparent absorption (urinary excretion) of isoflavones as 
previously shown in humans. To test this hypothesis, two separate studies were conducted: 
one focusing on fecal and the other on cecal microbial degradation of isoflavones. 
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MATERIALS AND METHODS 
Chemicals and diets 
Isoflavones were purchased as Novasoy® from ADM (Decatur, IL). Isoflavone 
composition was determined by HPLC (Murphy et al., 1997). Total isoflavone concentration 
was 963 (amol/kg diet and daidzein, genistein and glycitein were 36%, 51.5% and 12.5% of 
total isoflavones respectively. The diet was formulated to contain 0.1% cholesterol and high 
level saturated fat from coconut oil (10%). The diet was casein-based as the main source of 
protein and formulated to mimic a typical Western-type diet (Song et al., 2003). Other 
chemicals used for isoflavone extraction and analysis were purchased from Fisher Scientific 
(Pittsburg, PA) and Sigma (St Louis, MO). 
Animals and study designs 
The animal experimental protocols for both studies were approved by the Iowa State 
University Committee on Animal Care 
Study #1: 20 males and 20 females Golden Syrian hamsters (~4 weeks of age) were 
obtained from Harlan-Teklad (Madison, WI). They were housed individually in the same 
room in a temperature-controlled room (23°C) with a 12 h light:dark cycle. Hamsters were 
maintained on a standard rodent chow diet for 2 weeks. Males and females were then fed ad 
libitum the isoflavone, casein-based diet for 2 weeks and put in metabolic cages for 24 h to 
collect urine and feces. Body weight and food intake were monitored every day until the end 
of the experiment. Urine analysis was performed within 48 h after collection and animals 
euthanized under CO2 less than 48 h after isoflavone extraction and HPLC analysis of all 
urine samples. During that time, animals were fed the same isoflavone, casein-based diet, 
which was withdrawn 12 h before euthanizing them under CO2. Contents from the large 
intestine of the 4 highest and lowest urinary excreters were collected for in vitro fecal 
incubation. 
Study #2: 10 males and 10 females Golden Syrian hamsters (—4 weeks of age) were 
obtained from Harlan-Teklad (Madison, WI). Protocols and design of this study were similar 
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to study #1, except that cecal instead of fecal contents from the three highest and lowest 
urinary excreters were collected for in vitro incubation. In addition, only urinary, but not 
fecal excretion analysis was performed in this study. 
Urinary isoflavone analysis 
Isoflavone extraction from urine samples was done following a modified protocol 
established by Zhang et al. (1999). Five mL of urine were incubated with 50 pL of P-
glucuronidase-sulfatase (Sigma, St Louis, MO) at 37°C for 20 h to obtain the aglycone form 
of isoflavones. Fifty pL of 2,4,4' -trihydroxydeoxybenzoin (THB) were also added prior to 
the incubation as an internal standard. Incubation mixtures were loaded on Extrelut (TM) QE 
columns (EM Science, Gibbstown, NJ) and extracted with ethyl acetate. The eluent obtained 
was collected, dried using a roto-evaporator (Buchï, Flawil, Switzerland) and dissolved in 9.8 
mL of 20% ethanol and 0.2 mL of IN HCL. Five milliliters of this solution was loaded on a 
pre-wetted Sep-pak CI8 cartridge (Waters, Rainin, Woburn, MA), washed twice with 2 mL 
of distilled deionized water and eluted with 2 mL of 80% methanol. Samples were stored at 
4°C until HPLC analysis (Zhang et al., 1999). Urinary isoflavone excretion was expressed as 
a percentage of the dose ingested over 24 h, to normalize data across variations in food intake 
and body weight. In both studies, urine analysis was performed within 48 h after collection in 
order to identify the highest and lowest urinary excreters for further colonic or cecal in vitro 
incubation. 
Fecal isoflavone analysis 
Fecal excretion of isoflavones was analyzed on 2 g of ground fecal sample mixed with 10 
mL acetonitrile and 2 mL of 0.1 mol/L HC1. The mixture was stirred for 3 h, and then filtered 
through No. 1 Whatman filter paper. The eluent was collected in a round bottom flask and 
evaporated using a roto-evaporator (Buchi, Flawil, Switzerland). The dry residue was 
dissolved in 2 mL ethanol, 7.8 mL ultrapure water and 200 pL of 1 Mol HC1. Five mL were 
loaded onto a pre-wetted Sep-Pak CI8 cartridge (Waters, Rainin, Woburn, MA), washed 
with 2 mL of distilled deionized water and eluted with 2 mL of 80% methanol. Samples were 
stored at 4°C until HPLC analysis. 
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Fecal and cecal in vitro isoflavone analysis 
At the end of each study, animals were euthanized under CO2 and the content of the colon 
(study #1) or cecum (study #2) of the 3 or 4 highest and lowest urinary excreters placed in 15 
mL of anaerobic brain heart infusion media or BHI (Fisher, Chicago, IL). BHI was prepared 
with 50 mL sodium bicarbonate/L media as a buffer and cysteine sulfide (Sigma, St Louis) as 
an oxygen indicator. After collection, contents were vortexted for -15 sec to be homogenized 
and aliquoted by 5 mL volume in 20 mL of new anaerobic BHI media to which isoflavones 
were added to obtain a final concentration of 50 (iM for each isoflavone. Isoflavones were 
synthesized chemically according to Chang et al. (1994) and Lang'at-Thoruwa et al. (2003). 
Duplicate tubes were prepared for each colonic or cecal sample obtained as well as a 
negative control (feces only). After adding isoflavone, each tube was then vortexed for 10 sec 
to homogenize feces and isoflavone and duplicate samples taken immediately afterwards and 
frozen at -60°C to measure isoflavone concentration at time 0. Tubes were placed at 37°C 
and isoflavones concentration over time was assessed by taking duplicate samples from each 
tube at time 3, 6, 9 and 12 h. All the samples taken were put at -60°C until isoflavone 
extraction and HPLC analysis. By flushing tubes with CO2 and close them tightly, incubation 
tubes were maintained anaerobically during this process to preserve bacterial quality. To 
reduce isoflavone contamination in control fecal or cecal samples, diets were withdrawn ~12 
h before euthanizing animals. 
Statistical analysis 
Statistical analysis was performed using SAS (SAS Institute, version 6.12; 1998, 
Cary, NC). Phenotypes were established using a cluster analysis. Fecal and urinary 
excretions among the clusters were compared by one-way ANOVA and correlations among 
the bioavailability data for the different isoflavones were done using linear correlation 
analysis. All results were considered significant at p<0.05. 
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RESULTS 
Body weight and food intake 
Study #1: Initial mean body weights were similar (p=0.1) between males (122 ± 9 g) and 
females (117 ± 10 g). Despite similar food intake between males and females (7.1 ± 0.7 g/d 
and 7.3 ± 0.5 g/d, respectively; p=0.3), females gained significantly more weight on a daily 
basis (1.0 ± 0.3 g/d) compared to males (0.7 ± 0.2 g/d; p=0.01). 
Study #2: Mean initial body weight was similar (p=0.09) between males (114 ± 4 g) and 
females (119 ± 7 g). Food intake between male (7.6 ± 0.5 g/d) and females (7.7 ± 0.4 g/d) 
were similar (p=0.4). Average daily body weight gain was statistically less (p=0.001) in 
males (0.8 ± 0.2 g/d) than females (1.1 ± 0.1 g/d). 
Urinary isoflavone excretion 
Study #1: Males and females differed greatly in urinary excretion of isoflavones (Figure 
1). In males, daidzein and glycitein excretion were similar (18.2 ± 7.8% vs. 15.8 ± 6.3% 
ingested dose; p=0.3), while urinary excretion of genistein was significantly lower (7.8 ± 
6.2% ingested dose) than that of daidzein (pO.OOl) or glycitein (pO.OOl). In females, mean 
glycitein and genistein urinary excretion were similar (31.4 ± 11.2% vs. 26.7 ± 11.5% 
ingested dose; p=0.2), while mean daidzein urinary excretion was significantly higher (44.2 ± 
13.7% ingested dose) compared to that for glycitein (p=0.003) and genistein (p<0.001). 
Males were lower urinary excreters compared to females for daidzein (pO.OOl), glycitein 
(pO.OOl) and genistein (p<0.001). Consequently, clustering of animals as high or low 
excreters based on their individual urinary isoflavone excretion values showed that females 
were mostly high excreters while males were mostly low excreters (Figure 3; data not shown 
for daidzein or glycitein). Regardless of sex, correlations between urinary excretions of the 
different isoflavones were all significant. Urinary daidzein correlated with both glycitein and 
genistein (r=0.97 and r=0.96; pcO.OOl), as well as between glycitein and genistein (r=0.97; 
pO.OOl). 
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Study #2: In males, daidzein and glycitein excretion were similar (13.6 ± 7.6% vs. 11.0 ± 
5.1% ingested dose; p=0.4), while genistein urinary excretion was significantly lower (6.7 ± 
4.5% ingested dose) than that of daidzein (p=0.03) but not glycitein (p=0.07). In females, 
mean glycitein and genistein urinary excretion were similar (18.2 ± 8.0% vs. 15.8 ± 9.4% 
ingested dose; p=0.54), while mean daidzein urinary excretion was significantly higher (29.6 
± 13.4% ingested dose) compared to glycitein (p=0.03) and genistein (p=0.01). Males were 
lower urinary excreters compare to females for daidzein (p=0.005), glycitein (p=0.03) and 
genistein (p=0.01) (Figure 2). As observed in study 1, clustering of animals as high and low 
urinary excreters showed that females were phenotyped as high excreters while males were 
mostly low excreters (Figure 4; data not shown for daidzein or glycitein). 
Fecal isoflavone excretion 
In study #1, fecal isoflavone excretion was analyzed for each animal. Males and females 
showed less than 0.5% ingested dose present in the feces. There was no significant difference 
between isoflavones within and between sexes (Data not shown). Moreover, fecal excretion 
was not significantly correlated with urinary excretion for daidzein (r=0.35; p=0.24), 
glycitein (r=0.16; p=0.6) and genistein (r=0.29; p=O.34). However, daidzein fecal excretion 
correlated significantly with that of glycitein (r=0.92; pO.OOl) and genistein (r=0.91; 
pO.OOl), and glycitein with genistein (r=0.86; pO.OOl). 
Correlation between in vitro fecal degradation and urinary excretion of isoflavone 
From study #1, based on their overall urinary excretion pattern for all three isoflavones, 4 
high (3 females and 1 male, Fig. 3) and 4 low urinary excreters (3 males and 1 female, Fig. 3) 
were assessed for their in vitro fecal isoflavone degradation capacity. Mean degradation rates 
were not significantly different between high and low urinary excreters for daidzein (0.0101 
± 0.0076 vs. 0.0151 ± 0.0037 h"1; p=0.28), glycitein (0.0302 ± 0.0178 vs. 0.0308 ± 0.0357 h 
l; p=0.95) and genistein (0.2655 ± 0.1357 vs. 0.2978 ± 0.1566 h"1; p=0.76). Correlations 
between in vitro fecal degradation rates and urinary excretion were not statistically 
significant for daidzein (r=0.49; p=0.21), glycitein (r=0.31; pO.44) and genistein (r=0.33; 
p=0.41). Correlations between in vitro fecal degradation rates and fecal isoflavones excretion 
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were not statistically significant for daidzein (r=0.5; p=0.19), glycitein (r=0.28; p=0.49) or 
genistein (r=0.16; p=0.69). 
Correlation between in vitro cecal degradation and urinary excretion of isoflavone 
From study #2, based on their overall urinary excretion pattern for all three isoflavones, 3 
high (2 females and 1 male, Fig. 4) and 3 low urinary excreters (3 males, Fig. 4) were 
assessed for their in vitro cecal isoflavone degradation capacity. Mean cecal degradation 
rates were significantly different between high and low urinary excreters for daidzein (0.031 
± 0.015 vs. 0.123 ± 0.029b"1; p-0.009), and genistein (0.192 ± 0.071 vs. 1.38 ± 0.1551V1; 
p=0.004) while mean glycitein degradation rates of high and low urinary excreters were not 
significantly different (0.186 ± 0.096 vs. 0.310 ± 0.099b"1; p=0.19). Correlations between in 
vitro cecal degradation rates and urinary excretion were statistically significant for daidzein 
(r=0.90; p=0.01) and genistein (f=0.93; p=0.004; Figure 5; data not showed for daidzein and 
glycitein), but failed to show a significant correlation for glycitein (r=0.50; p=0.3). 
DISCUSSION 
This study focused on establishing Golden Syrian hamsters as a potential animal 
model to study bioavailability with relevance to humans. 
Despite initial body weight and similar daily food intake, females gained significantly 
more weight on a daily basis compared to males. This fits typical growth patterns for 
hamsters. Urinary isoflavone excretion levels showed a similar pattern between studies in 
females (daidzein>glycitein=genistein). In males, glycitein urinary excretion in males shifted 
from being similar to daidzein and significantly higher than genistein in study 1 to being not 
different from either other isoflavone in study 2, suggesting that glycitein bioavailability in 
males may be more unstable than in females. However, aside from glycitein, daidzein 
apparent absorption was greater than that of genistein in both sexes and both studies. A 
similar pattern was also observed in humans across several bioavailability studies (Xu et al. 
1994 & 1995; Lu et al. 1998; Zheng et al. 1999; erratum 2001). Our data also differed from 
Lee (2004), a study in which female hamsters (10/group; 11-12 weeks old) were fed a single 
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purified isoflavone in the diet for 4 weeks. They found mean urinary excretion levels of 4.6 ± 
1.8, 32.2 ± 25.7 and 2.2 ± 1.7% for daidzein, glycitein and genistein, respectively. Thus, 
feeding one versus all three isoflavone together led to less daidzein and genistein excretion 
compared with that of glycitein. This might be partly due to the absence of competition 
among isoflavones for microbial degradation so that daidzein and genistein were much more 
degraded. Other differences possibly responsible for these data were age of animals (12 
weeks vs. 6 weeks in the present study) and greater equimolar concentration of dietary 
isoflavones in the diet (-50 pmol/kg body weight/day). In our study, animals were fed 25, 8 
and 35 nmol/kg body weight/day of daidzein, glycitein and genistein, respectively. Dose, 
age, sex and proportion of isoflavones when fed together would therefore be significant 
factors to consider for future studies. 
A strong sex difference was observed in both studies, with males being lower urinary 
excreters of all three isoflavones compared to females. With respect to humans, Lu et al 
(1998) also observed lesser isoflavone bioavailability in men than in women. During a one 
month intervention, women (n=6) excreted 24 and 66% of the ingested doses of genistein and 
daidzein, respectively, whereas men (n=6) excreted 15 and 47% as genistein and daidzein 
respectively. Lu et al. (1998) findings suggested that in humans, as in hamsters, males are 
lower urinary excreters than females. While urinary levels detected by Lu et al. (1998) in 
women were within the same range observed in the present study with respect to female 
hamsters for daidzein (-55 vs. 40% ingested dose) and genistein (-20 vs. -20% ingested 
dose for Lu and present study, respectively), levels between men and males hamsters were 
different for daidzein (-15 vs. —45% ingested dose) and genistein (-8 vs. -15% ingested 
dose). Thus, despite some discrepancies between studies in female hamsters, overall levels of 
urinary excretion showed greater similarities to humans than did male hamsters. On the other 
hand, the present data in males confirmed those obtained in other rodent models. King et al. 
(1998) compared the bioavailability of daidzein and genistein in male Wistar rats fed a soy 
extract providing 74 pmol genistein and 77 pmol daidzein/kg body weight. 48 h urinary 
excretion of daidzein and genistein were 17.4 ± 1.2% (-15% in the present study) and 11.9 ± 
1.1% (-8% here) of the ingested dose, respectively, while fecal excretion was 2.3 ± 0.5% and 
3.4 ± 0.4%, respectively. Thus, male rodents may not be the best model to study 
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bioavailability of isoflavones considering a much lower ability to excrete (apparent 
absorption) isoflavones whereas females may be overall more suitable overall for data 
extrapolation to humans. 
Fecal isoflavone excretion in study #1 did not show any sex difference and very low 
levels of excretion (0.1 to 0.5% ingested dose). King et al. (1998) found up to 3.5% ingested 
dose present in fecal samples from rats, while in humans, Xu et al. (1995) found that subjects 
who excreted large amounts of isoflavone in their urine also excreted larger amounts in their 
feces (up to 6% ingested dose) compared to lower urinary excreters. Thus, since female 
hamsters were significantly higher urinary excreters than males, we expected greater amounts 
of isoflavones in feces from females than males. No significant difference was found, neither 
was there a correlation between fecal and urinary excretion of individual isoflavones. Xu et 
al. (1995) and Zhang et al. (1999; erratum 2001) both found positive correlations between 
isoflavone excretion in urine and feces. We therefore hypothesized that fecal microbial 
activity in hamsters may be greater than in humans or other rodent models, thereby 
explaining such low levels of fecal excretion. In addition, sex differences in microbial 
degradation and possibly biliary excretion of isoflavones being greater in males than females 
could explain the low levels of urinary excretion obtained in male hamsters. 
To predict apparent absorption and pattern of urinary excretion in humans, in vitro fecal 
degradation of isoflavones has shown applicability in determining bioavailability of 
isoflavones in humans (Hendrich et al. 1998; Xu et al. 1995; Zhang et al. 1999; erratum 
2001). Indeed, subjects who were high fecal degraders in vitro were low urinary and fecal 
excreters while those who degraded smaller amounts of isoflavones in vitro excreted greater 
proportion of the ingested dose in both urine and feces. Thus we originally hypothesized that 
fecal in vitro degradation rates in hamsters would correlate with urinary excretion patterns. 
However, fresh feces collected from the large intestine from high and low urinary isoflavone 
excreters after euthanizing them failed not only to show any correlation to urinary or fecal 
excretion, but also the range of isoflavone degradation rates obtained were very low. 
Degradation rates of low urinary excreters (hypothesized high in vitro degraders) did not 
exceed 0.015, 0.030 and 0.300b"1 for daidzein, glycitein and genistein respectively, while in 
humans, high fecal isoflavone degradation rates reached 0.299 and 0.400b"1 for daidzein and 
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genistein, respectively (Hendrich et al. 1998). Only genistein degradation seemed to reach 
levels that showed some fecal bacterial activity, but the absence of correlation with urinary 
excretion and low to nearly absent fecal degradation of daidzein and glycitein led us to the 
conclusion that fecal in vitro degradation and the fecal microflora were not a useful tool to 
assess bioavailability of isoflavones in this animal model and that hamster fecal isoflavone 
degradation might not be relevant to human fecal isoflavone degradation. Investigation of 
cecal degradation rates in study #2 produced more appropriate data. Indeed, high daidzein 
and genistein degraders had a mean degradation of 0.123 and 1.38h"', which showed greater 
bacterial activity and degradation of isoflavone compared to fecal activity. Significant 
correlation between urinary excretion of isoflavone and their associated in vitro cecal 
degradation rates of daidzein and genistein was of greater biological similarity to human 
fecal isoflavone degradation rates. Therefore, the cecal microflora was more active than the 
fecal microflora with respect to isoflavone degradation in hamsters and shown to be of 
greater relevance to the fecal microflora in humans when depicting and comparing the 
overall bioavailability pattern in humans versus hamsters. Hence, hamster cecum is more 
metabolically equivalent to the human colon. Glycitein remained an issue in the present study 
considering that neither fecal nor cecal degradation correlated significantly with urinary 
excretion. The absence of conclusive human fecal degradation data on glycitein and its 
relationship to isoflavone bioavailability did not allow us to draw any definite conclusions on 
the data obtained in the present study. Further investigations in both models are needed to 
understand with greater accuracy bioavailability of glycitein. 
CONCLUSION 
The present study investigated in more details the bioavailability of isoflavones and how 
relevant the hamster model may be to humans. The main reason for this investigation was 
that if hamsters and humans share similar patterns of bioavailability of isoflavones, this 
animal model could then be used to study prevention of chronic diseases that could not be 
induced in humans (hypercholesterolemia, cancer...). From both studies, we concluded that 
female hamsters had a more similar pattern of urinary excretion compared to women, while 
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male hamsters had a lower isoflavone bioavailability than men. However, a strong and 
constant sex difference was observed across both studies and was relevant to humans. We 
also predicted that a sample size of at least 20 animals/ group would produce more robust 
bioavailability patterns of all three isoflavones. Moreover, hamster cecal but not fecal 
bacterial activity was strongly related to urinary excretion of daidzein and genistein as 
observed in humans between in vitro fecal degradation and urinary excretion. Therefore, the 
hamster cecal microflora is hypothesized to be metabolically analogous to the human fecal 
microflora. Further investigation of glycitein metabolism and bioavailability in both hamsters 
and humans is needed. 
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Figure 1 : Comparison of mean percentage urinary excretion of ingested dose between male 
and female Golden Syrian hamsters (Study 1). 
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Different letters indicate statistically significant differences across sexes and isoflavone. 
# p value < 0.05: indicates statistical difference between males and females 
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Figure 2: Comparison of mean percentage urinary excretion of ingested dose between male 
and female Golden Syrian hamsters (Study 2). 
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Different letters indicate statistically significant differences across sexes and isoflavone. 
# p value < 0.05: indicates statistical difference between males and females 
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Figure 3: Ranking and cluster analysis of individual genistein urinary excretion values in 
male and female Golden Syrian hamsters (Study #1) 
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Figure 4: Ranking and cluster analysis of individual genistein urinary excretion values in 
male and female Golden Syrian hamsters (Study #2) 
High excreters 
Low excreters 
Grey bars are male hamsters 
Black bars are female hamsters 
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Figure 5: Correlation between genistein in vitro cecal degradation rates and in vivo urinary 
excretion data between high (n=3) and low (n=3) urinary excreters (Study #2). 
y = -0.0176x+ 1.4747 
R = 0.8349 
p=0.004 
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IDENTIFICATION OF BACTEROIDES OVATUS, BACTEROIDESACIDIFACIENS, 
EUBACTERIUMRAMULUS, CLOSTRIDIUM ORBISCINDENS AND TANNERELLA 
FORSYTHENSIS AS MICROORGANISMS INCREASING ISOFLAVONE 
DISAPPEARANCE IN HUMAN FECES, USING POLYMERASE CHAIN 
REACTION AND DENATURING GRADIENT GEL ELECTROPHORESIS 
Manuscript in process. 
Mathieu Renouf, Andrean L. Simons and Suzanne Hendrich 
ABSTRACT 
Subjects who apparently absorb small amounts of isoflavones show high in vitro fecal 
degradation of these compounds. We hypothesized that high fecal isoflavone degradation rate 
coincided with distinct fecal bacterial species. To identify these bacteria, fresh feces from 33 
healthy adult subjects (20 men, 13 women, mean age 26 ± 4 years; 15 Caucasians, 8 Indians, 
6 Asians and 4 African Americans) were incubated anaerobically with isoflavones to assess 
degradation rates using HPLC. Fecal DNA was extracted, bacterial 16S rDNA sequences 
amplified by polymerase chain reaction (PCR) and separated by denaturing gradient gel 
electrophoresis (DGGE). Cluster analysis identified high and low degraders of daidzein, 
genistein and glycitein. DGGE analysis showed that high genistein degraders (n=4; fecal 
degradation rate 1.47 ± 0.14b"1) shared 5 bands of greater intensity than found in feces of low 
genistein degraders (n=4; fecal degradation rate 0.146 ± 0.034 h"1) high glycitein degraders 
(n-4; 0.574 ± 0.299b"1) also shared 5 bands of greater intensity than found in feces of low 
glycitein degraders (n=4; 0.146 ± 0.034 h"1). 
Sequencing of 16S rDNA from the bands of interest showed concordance with known 
species from the Bacteroides and Prevotella genus as well as the Clostridials order. In one 
individual who switched from high to low glycitein degradation rate when fecal samples 
were analyzed at two time points one month apart, 5 DNA bands associated with high 
glycitein degradation were matched to bacteria from the same bacterial families as those 
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identified in the other subjects who were high glycitein and/or genistein degraders. After 
developing two in vitro systems, one rich (rumen fluid based brain heart infusion media) and 
one poor in nutrients (feces incubated overnight in brain heart infusion media), we identified 
Bacteroides ovatus, Bacteroides acidifaciens, Eubacterium ramulus, Clostridium 
orbiscindens and Tannerella forsythensis as the major human gut microbial species that 
increased isoflavones degradation compare to control under both nutrient rich and poor 
conditions, thus the presence of these species may indicate the greatest relevance in 
degrading isoflavone in the human gut. Significant increases in isoflavone disappearance 
with other species only in nutrient-poor conditions suggested that some species may 
influence isoflavone degradation when nutrient availability is lower. These species showed 
different response in increasing isoflavone degradation from one individual to another and 
from isoflavone to another between and within individuals, demonstrating the complexicity 
of bacterial activity with respect to isoflavone degradation. Bacterial species that stimulated 
isoflavone degradation in nutrient rich media are likely to be the major species involved in 
isoflavone degradation in both high and low degraders. We propose that the greater amounts 
of these species found in high degraders may predict lesser overall bioavailability of 
isoflavones in such individuals. Microbial species influencing isoflavone degradation in 
nutrient poor conditions only seem to be the major species accounting for the high fecal 
genistein or glycitein degradation phenotype in humans. Intersubject variability in fecal 
isoflavone degradation rate was useful in identifying human gut microbial species associated 
with isoflavone degradation and will deserve further attention. 
Key words: PGR, DGGE, fecal microflora, isoflavone-degrading microorganisms, 
bioavailability. 
Isoflavones are found in the human diet almost exclusively in soybeans and soy 
products. Their chemical structure is estrogen-like (Setchell and Adlercreutz 1988). 
Moreover, there has been evidence that isoflavones consumption may prevent several chronic 
diseases, such as breast cancer where higher soy consumption (>18.66 nmol isoflavone/mg 
creatine in urine) was associated with lower breast cancer risks compare to lower soy 
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consumption (<5.58 nmol/mg creatine in urine) (Zheng et al. 1999), but the health effects of 
these compounds are highly variable among individuals, which may be attributed in part to 
variability in bioavailability. One to 25% of the ingested dose of isoflavones is excreted in 
the urine, while less than 1% is recovered in the feces. The great proportion not recovered or 
disappearing has been linked to microbial metabolism, where fresh but not autoclaved feces 
were capable of degrading isoflavones over time (Xu et al. 1995; Hur et al. 2000; Zheng et al. 
2003 & 2004). When isoflavones are incubated in vitro with feces, they disappear almost 
completely within 48 h. Fecal isoflavone degradation rates can be statistically sorted into 
clusters so that people are grouped as high (-0.4 h"1), moderate (-0.2 h"1) or low degraders 
(-0.05 h"1, based on daidzein disappearance phenotypes) (Zheng et al. 2003). Low degraders 
have greater apparent absorption (urinary excretion) of isoflavones whereas high degraders 
have lower urinary excretion. Zheng et al. (2004) found that high daidzein degraders (n=13; 
k=0.36 ± 0.01 h"1) had significantly lower bioavailability of daidzein (43.1 ± 5.0 vs. 60.6 ± 
5.1% ingested dose) and glycitein (41.4 ± 6.4 vs. 68.6 ± 6.6% ingested dose) as reflected in 
mean urinary excretion compare to low daidzein degraders (n=12; k= 0.14 ± 0.01 h"1). The 
gap in knowledge needs to be filled about what occurs between ingestion and absorption of 
isoflavones. In vitro fecal incubation with isoflavones showed disappearance of these 
compounds over time. Gut bacterial activity was identified as responsible for this 
degradation, as it did not occur with autoclaved fecal material (Hendrich et al. 1998). 
Identification of the specific microbial species or strains catabolizing isoflavones 
must be done to fully understand isoflavone bioavailability. Several techniques have 
facilitated the identification of the complex composition of microbial ecology. Based on 
molecular biology procedures, one of these techniques, polymerase chain reaction coupled 
with denaturing gradient gel electrophoresis (PCR-DGGE) was reported by Muyzer et al. 
(1993). The principle of PCR-DGGE is to multiply the 16S rRNA gene variable region that 
seems to be a unique "signature" DNA sequence for each bacterial species. To obtain an 
optimum separation of the different 16S rRNA gene segments based on their GC content, 
DGGE must be performed with an appropriate urea gradient. This technique can be applied 
to virtually any type of microbial environment and became a useful tool to assess microbial 
composition of fecal samples with relevance to gut microbial ecology. Indeed, PCR-DGGE 
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can be applied to bacterial communities from soil and rhizosphere (Smalla et al. 2001), water 
(Murray et al. 1996), feces from animals (Simpson et al. 1999) or humans (Walter et al. 
2001). 
Our hypothesis is that humans with different fecal isoflavone degradation phenotypes 
have different gut microbial ecologies and that individuals sharing similar in vitro fecal 
degradation rates also possess similar microorganisms that could be involved in degrading 
isoflavone, as reflected by PCR-DGGE analysis. To that end, we screened fecal samples 
from a small but diverse human population, compared in vitro fecal isoflavone degradation 
rates with microbial DNA band patterns obtained after PCR-DGGE, sequenced bands, 
identified the corresponding species using a DNA sequence database, and tested the ability of 
these identified species to degrade isoflavones in simulated human gut/fecal environments. 
MATERIAL AND METHODS 
Human studies 
This project was approved by the Institutional Review Board of Iowa State 
University. 
In a preliminary study, one subject gave a fresh fecal sample one month apart in 
November and December 2003. Each sample was assessed for in vitro fecal isoflavone 
degradation and gut microbial profile analysis. 
In a larger scale study, 33 subjects were recruited at Iowa State University and 
surrounding areas for this study. Eligibility criteria included age of 18 to 40 years, no use of 
antibiotics in the past three months and no bowel diseases (e.g., colitis). Users of oral 
contraceptives or smokers were not excluded. Subjects were asked to avoid consumption of 
soy-containing foods (a list of selected food items were given to subjects) three days before 
giving a fresh fecal sample and instructed to avoid exposure of the sample to air insofar as 
possible, by compressing a plastic bag around the sample and excluding air from the sample 
bag as soon as possible. 
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Fecal Incubation 
Feces in closed bags were mixed by hand to obtain more homogenous samples. One 
gram of feces was added to 30 mL of sterile anaerobic Brain Heart Infusion (BHI) media 
(Fisher, Chicago, IL) prepared with 4 g sodium bicarbonate/L media as a buffer and 20 mL 
cysteine sulfide (Sigma, St Louis) as an oxygen indicator. Chemically synthesized daidzein, 
genistein and glycitein were added to the fecal BHI mixture to obtain a final concentration of 
100 p.M for each isoflavone. Isoflavones were synthesized chemically according to Chang et 
al. (1994) and Lang'at-Thoruwa et al. (2003). Duplicate tubes were incubated for each 
sample as well as a negative control (feces + BHI). Each tube was then vortexed for 10 sec to 
homogenize feces and isoflavones and duplicate samples taken immediately afterwards and 
frozen at -60°C to measure isoflavone concentration at baseline. Tubes were placed at 37°C 
and isoflavone concentration over time was assessed by taking duplicate samples from each 
tube at 3, 6, 9, 12 and 24 h. All the samples taken were put at -60°C until isoflavone 
extraction and HPLC analysis. Incubation tubes were maintained anaerobically at all times 
during this process to preserve bacterial quality. 
Isoflavone extraction from fecal incubation samples and HPLC analysis 
Isoflavone extraction from fecal in vitro incubations was done using a protocol from 
Zheng et al. (2003). Samples were thawed and centrifuged at 13,000 g for 2 min. lmL of the 
supernatant was loaded on a pre-wetted Sep-Pak CI8 cartridge (Waters, Milford, MA) along 
with 50 pL of 2 mg/mL THB (2,4,4'-trihydroxydeoxybenzoin) in 80% methanol used as an 
internal standard.. The column was washed with 2 mL of deionized water to eliminate water-
soluble contaminants. Isoflavones were then eluted with 1 mL 80% methanol, filtered using 
17 mm PFTE filters (Alltech, Deerfield, IL) into an HPLC vial and stored at 4°C until 
analysis. HPLC analysis of the samples was done using a protocol established by Zhang et al. 
(1999) with 100% acetonitrile (ACN) and 0.1% glacial acetic acid (GAA) solution. Starting 
gradient was 15% ACN / 85% GAA, 50% / 50% at 22 min, 100% / 0% at 15 min, 15% / 85% 
at 28 min followed by an equilibration phase of 3 min at 15% / 85%. Degradation rates were 
established by calculating the natural logarithm of the percentage remaining isoflavones over 
time. All 4 values were considered (2 tubes/sample and 2 samples/time point) at each time 
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point for each subject to establish the isoflavone degradation rate. To quantify isoflavones, 
standard curves for each compound were established using chemically synthesized 
isoflavones and analyzed by reverse-phase HPLC using the same protocol as above. We 
focused solely on isoflavone disappearance over time in this project. Thus, isoflavone 
metabolites were not investigated here. 
Bacterial DNA extraction from fecal incubation 
At baseline of the fecal incubation, 2 samples from each tube for each individual were 
taken and immediately frozen at -60°C. To extract DNA from fecal bacteria, a DNA 
extraction kit from Promega (Madison, WI) was used and its associated protocol modified for 
fecal bacterial DNA extraction. 500 pL of fecal incubation mixtures were mixed with 500 pL 
of 50 mM EDTA. 60 pL oflyzozyme (Sigma, St Louis, MO), 35 pL lyzostaphin (Sigma) and 
60 pL cell lysis solution (Promega) were added to that mixture and incubated at 37°C for 1 h. 
Samples were then centrifiiged at 14,000 g for 2 min, the supernatant discarded and the pellet 
redissolved in 600 pL nuclei lysis solution (Promega). Heating for 5 min at 80°C was 
followed by a cool-down 15 min at room temperature and 30 min incubation with 3 pL 
RNAse at 37C°. 200 pL of protein precipitation solution (Promega) were then added to the 
RNAse treated mixture, vortexed for 20 sec and incubated on ice for 5 min. Samples were 
then centrifuged 3 min at 14,000 g and the supernatant transferred to a clean 1.5 mL tube 
containing 600 pL of isopropanol in order to condense DNA into a visible mass. Following 
another 2 min centrifugation, DNA was washed with 600 pL 70% ethanol, and resuspended 
in TE buffer (10 mM Tris, 1 mM EDTA). DNA concentration (ng/|_iL=A260* 50*di 1 ution 
factor) and purity (^A^A^o) were then measured using a Beckman DU® 640 
spectrophotometer (Beckman, Schaumburg, IL) at 260 and 280 nm wavelengths. 
Bacterial 16S rDNA amplification 
Bacterial DNA was amplified using a touchdown PCR method, which decreases the 
annealing temperature over time (1°C every other cycle) in order to target non-specifically all 
bacterial 16S rRNA gene variable region sequences. Primers were synthesized to target non-
specifically the constant region of the variable region of the rRNA gene. Three primers were 
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used for that PGR: 1 foward (3'GGTGGTCGGCGCGATTA5'), 1 reverse 
(3'GACGACGGAGGGCATCC5') and 1 reverse with a GC clamp 
(3'GACGACGGAGGGCATCCGGGGGGCACGGGGGCGGGGCGGGCGGCGCGCGCC 
GCCCGC5'). Each PGR mixture contained (final concentration): 1 pi each primer (1 pMol), 
1 pi dNTP mixture (50 pMol each dNTP), 5 pi of nuclease-free PGR buffer (500 mMol KC1, 
100 mMol Tris HC1 pH=9 @ 25°C, 1.0% Triton X-100 and 15 mMol MgCh), 28 pi water 
and target DNA (8 ng/pl PGR mixture). Primers were synthesized by Sigma Genosis (The 
Woodlands, TX) and PGR components obtained as a kit from Promega (Madison, WI). After 
the first step of the PGR program (4 min 94°C), 1 pi nuclease-free PGR buffer, 0.5 pi water 
and 0.5 pi Taq polymerase at 5 units/pl were added. The PGR program was established as 
followed: 4 min 94°C, 20 cycles with touchdown: 1 min 94°G, 1 min 65°C (decrease 1°C 
every other cycle), 3 min 72°C; 10 regular cycles: 1 min 94°C, 1 min 55°C, 3 min 72°C; 7 
min 72°C; cool down at 4°C. PGR products should be around 200 base pair (bp) and were 
checked using a 0.1% agarose gel with ethidium bromide and a PGR ladder used as a 
standard (Sigma). A UV lamp was used to visualize DNA and compare it to a standard DNA 
PGR ladder (mixture of 50, 150, 300, 500, 750 and 1,000 bp DNA fragments) commercially 
available (Sigma, St. Louis, MO). DNA concentration was measured using a Beckman DU® 
640 spectrophotometer (Beckman, Schaumburg, IL) at 260 and 280 nm wavelength. 
Denaturing gradient gel electrophoresis 
Two acrylamide stock solutions were used to prepare the gel: 100% urea denaturing 
solution (42 g urea, 16.9 mL acrylamide, 2 mL 50xTris Acetate EDTA (TAE), 40 mL 100% 
formamide and made to 100 mL with distilled deionized (dd) water) and 0% urea denaturing 
solution (16.9 mL acrylamide, 2 mL 50*TAE and made to 100 mL with dd water). To obtain 
an optimum separation of the bacterial 16S rRNA gene sequence mixtures, 2 acrylamide 
gradients were used: 32.5-45% urea and 35-50% urea. The different acrylamide 
concentrations were done as follow: for example, 50% urea in acrylamide solution was 
prepared by mixing 50 mL 100% and 50 mL 0% urea denaturing solutions. DGGE was done 
using a D-Code universal mutation detection system from Bio-Rad (Hercules, CA). 
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Acrylamide gels were prepared as follows: smooth edged glass plates (front plate: 
16x20 cm; back plate: 18.5x20 cm; previously cleaned with 100% ethanol). A PAG film 
(Cambrex Bio Science Rockland Inc. Rockland, Maine) was cut with a razor blade to fit the 
back plate. The hydrophilic side of the PAG film was in contact with the gel, the 
hydrophobic with the back plate. To assure that the film was secured to the back plate, water 
was put between the film and the plate and visible air bubbles completely removed from 
under the film. Spacers were covered with cello-seal (Fisher, Chicago, IL) and put on each 
side of the back plate covered with the PAG film. The front plate was placed on top of 
spacers and the entire apparatus was clamped according to instructions provided with the En­
code system. The bottom of the sandwich was covered with a thin film of Cello-Seal and the 
apparatus clamped over a water-proof seal in order to avoid leakage when pouring the gel. 
The gel was poured with a Hoefer SG 50 gradient former (Amersham Biosciences, 
Piscataway, NJ) with a stir bar in each chamber on medium speed. The gel was poured within 
3 min or less and a 16 well comb inserted at the top of the gel. Polymerization of the gel 
occurred within 30 min. Samples were normalized by loading in each well 2000 ng DNA 
PCR product samples previously mixed with 6 pL DGGE loading dye. The gel was then run 
at 160 V for 3.5 h, and cooled down by turning off and opening the top part of the D-code 
system for 20 min before removing the sandwich apparatus. The gel was silver stained by 
washing 3x1 min with dd water, adding 200 mL solution I (200 mg AgNQ3 in 200 ml H2O) 
for 15 min, washing 2x1 min with dd water, adding 200 ml of solution II (20 mg NaBFLt, 
0.8 ml 37% formaldehyde, 3 g NaOH in 200 ml) for 20 minutes and washing 4x1 min with 
dd water (Liu and Ritalahti. 1996). The gel was then scanned using a GS-800 calibrated 
imaging densitometer (Bio-Rad, Hercules, CA) and an image obtained for analysis of DNA 
bands using Quantity One software (band migration and intensity and lane profiles). After 
analysis, the bands of interest were excised and DNA eluted following a protocol from 
Rieman and Winding (2001).Using a sterile razor blade, pieces of acrylamide containing the 
DNA of interest were put in 40 pL of 1*SSC buffer in a 0.6 mL sterile tube. Samples were 
incubated overnight at room temperature and 2 h at 37°C the next morning, then centrifuged 
to precipitate acrylamide pieces, the supernatant containing the DNA transferred into new 
sterile tubes containing 3 volumes of 96% ethanol and 0.1 volume of 8 mol/L lithium 
140 
chloride. DNA was then precipitated by centrifuging the tubes 3 min at 14,000 g, discarding 
the supernatant, and dissolving the DNA in 15 pL TE (10 mM Tris, 1 mM EDTA) Buffer. 
DNA amplification from acrylamide gels, sequencing and identification of the micro­
organisms from 16s rDNA sequence 
DNA eluted from acrylamide was re-amplified using the same protocol as described 
earlier, with a slightly different PGR mixture (15 pL TE buffer containing the target DNA 
eluted as above, 1 pL each primer (5 pMol), 1 pi dNTPs mixture (20 pMol each dNTP), 5 pi 
buffer with 15 mMol MgCl and 24 pL dd water. After 4 min 94°C, the TAQ mixture was 
added as described before. After PGR, the samples were checked for length of the products 
(200 bp, using a standard DNA ladder as above) using a 0.1% agarose gel, purified using a 
PGR purification kit from Promega (Madison, WI) and quantified as described before. For 
sequencing, PGR samples concentrations were 50 pg/pL and the primer with the lowest Tm 
or % GC was at 10 pmol/L. Sequencing was performed by the Iowa State University DNA 
sequencing facility and results checked to confirm sequence identity. The final sequence was 
matched to a library of 16S rRNA gene sequences using Basic Local Alignment Search Tool 
(available at http://www.ncbi.nlm.nih.gov/BLAST/). 100 possible matches were provided for 
each sequence and the possible matches that corresponded to known microorganisms were 
considered as possible species that degraded isoflavones (Overall PCR/DGGE protocol 
summarized, Fig 1). 
Culture of selected micro-organisms 
Putative isoflavone degrading microorganisms selected from the BLAST analysis 
were purchased as pure single strains from the American Type Culture Collection (Manassas, 
VA): Bacteroides eggerthii (ATCC 27754), Bacteroides uniformis (ATCC 8492), 
Bacteroides vulgatus (ATCC 31376), Bacteroides fragilis (ATCC 43858), Bacteroides 
ovatus (ATCC 700292), Bacteroides thetaiotaomicron (ATCC 29148), Prevotella ruminicola 
(ATCC 19189), Prevotella oralis (ATCC 33322), Prevotella pallens (ATCC 700821), 
Prevotella veroralis (ATCC 33779), Tannerella forsythensis (ATCC 43037), Ruminococcus 
obeum (ATCC 29174), Clostridium orbiscindens (ATCC 49531), Eubacterium ramulus 
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(ATCC 29099), Fusobacterium prausnitzii (ATCC 27766) and Porphyromonas gingivalis 
(ATCC 33277). Bacteroides acidifaciens (DSM 15896) was purchased from the German 
Collection of Microorganisms and Cell Culture (Braunschweig, Germany). To revive the 
freeze-dried culture, a specific medium was prepared following protocols provided by 
ATCC. The medium contained (L"1): 50 g Brain heart infusion powder, 30 g peptone, 25 mL 
1 N sodium hydroxide, 5 g yeast extract, 5 g glucose, 1 g starch, 1 g cellobiose, 1 g maltose, 
10 mL hemin solution (0.5 g hemin/L dd water), 200 jj,L vitamin K1 solution (0.5 mL 
vitamin K1 solution/L 95% ethanol), 20 mL cysteine sulfide (prepared with 10 g cystein HC1 
and 10 g sodium sulfide per L dd water, pH=10.0), 1 mL 0.1% resazurin and 100 mL/L of 
sterile rumen fluid (obtained from Dr. Mark Rasmussen, National Animal Disease Center, 
Ames, LA). The medium was anaerobic and flushed with 80% Na — 20% CO2, then tightly 
closed and sterilized in 20 mL aliquots. Freeze-dried microbial cultures were anaerobically 
and aseptically transferred into the sterile medium and placed in an incubator-shaker for 24-
48 h at 37°C and 140 rpm. Once grown, the bacteria were transferred into sterile 1.5 mL 
centrifuge tubes, centrifuged at 14,000 g for 2 min to pellet the cells, the supernatant 
removed and the bacteria frozen at -4° then -60°C until further growth and use required. 
Fecal incubation with selected micro-organisms in nutrient-rich or nutrient-poor media 
To perform fecal incubation with or without selected microorganisms, we selected 2 
different media: nutrient rich and nutrient poor. The nutrient rich media was the same as 
described for revival of microorganisms. To create a nutrient poor environment, BHI media 
(similar to the one used for screening fecal isoflavone degradation) was deprived of nutrients 
by incubating 1 g fresh human fecal sample from one subject overnight. After this overnight 
incubation, 2.5 mL of overnight grown culture of selected microorganisms were added, either 
alone or in combination, and the bacteria allowed settling for 6h before adding isoflavones. 
In vitro degradation was then assessed as above. In nutrient-rich media, 1 g of fresh fecal 
sample with the selected microorganism(s) (2.5 mL of overnight grown culture) were added 
to 30 mL media and allowed to settle for 6h, before adding isoflavones. 
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Two separate sets of incubations using nutrient rich and poor media were performed. 
Between both sets, all species identified by DGGE were screened for isoflavone degradation. 
Fecal samples from three individuals were considered for each set. 
The first set of microbial culture isoflavone degradation studies included fecal 
samples from a Caucasian male (26 years of age), an Asian female (24 years) and an Indian 
male (18 years), all previously screened as moderate or moderate/low daidzein degraders 
during screening of the original 33 subjects. Treatments included (duplicate tubes for each 
treatment and each fecal sample): P. oralis, Ppallens, P. ruminicola, B. eggerthii, B. fragilis, 
a mixture of Prevotella {ruminicola, oralis, pallens and veroralis), a mixture of Bacteroides 
(eggerthii, thetaitaomicron, fragilis and vulgatus) and a mixture of Bacteroidales (all 4 
Prevotella and Bacteroides together + Porphyromonas gingivalis). Despite not finding 
significant microorganisms of interest related to daidzein degradation, we still included that 
compound in all incubations along with genistein and glycitein. 
The second set of microbial culture isoflavone degradation studies included fecal 
samples from a Caucasian male (same subject as in the first set of incubations), an African-
American female (26 years of age) and an Asian female (30 years), all previously screened as 
moderate or moderate/low daidzein degraders during screening of the original 33 subjects. 
Treatment tubes included re-evaluation of B. fragilis and P. ruminicola in nutrient rich and 
poor-media. Strains identified by DGGE but not included in the first set of incubations were 
investigated in this second set. Species investigated in nutrient-poor vs. nutrient rich media 
were Bacteroides ovatus, Bacteroides acidifaciens, Porphyromonas gingivalis, 
Ruminococcus obeum, Eubacterium ramulus, Clostridium orbiscindens, Fusobacterium 
prausnitzii and Tannerella forsythensis. Due to limitation in time and supplies, we 
investigated in nutrient-poor only Prevotella veroralis, Bacteroides thetaitaomicron, 
Bacteroides uniformis and Bacteroides vulgatus. Species selected for these incubations were 
selected from DGGE and literature data only. Microorganisms not expected to degrade 
isoflavone were not included in this project. 
All isoflavone degradation rate results were expressed as a percentage of control 
(feces and isoflavones only) response for a final concentration of 109 cells added/mL media. 
Cell concentration after overnight growth varied from 0.6* 109 cells/mL media for T. 
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forsythensis to 1.2*109 cells/mL media for Bacteroides vulgatus. Normalization expressing 
results as a percentage was done because control degradation rate differed between 
individuals and isoflavones; normalization of cell concentration allowed comparison among 
treatments. 
Statistical analysis 
All statistical analyses were performed using SAS (SAS Institute, version 6.12; 1998, 
Cary, NC). One-way ANOVA and multiple comparisons were used to compare band 
intensity, degradation rates between clustered isoflavone degrader phenotypes and among 
incubation with bacterial species in nutrient rich and poor incubations. 
RESULTS 
Interindividual short-term difference in isoflavone degradation rate and gut microbial profile 
Comparison of degradation rates established in November and December 2003 for the 
same subject (Caucasian male, age 24) showed that daidzein (0.0458 vs. 0.0421 h"1) and 
genistein (0.127 vs. 0.107 h"1) degradation rates were similar at both times. However, a -2.5 
fold decrease in glycitein degradation rate was observed between November (0.1988 h"1) and 
December (0.5385 h"1). DGGE analysis of gut microbial profile at both time points (results 
shown in duplicate for each time point) showed 5 bands (Band A through E) of greater 
intensity (Table 1) in the fecal sample taken in November compared to that taken in 
December (Figure 2), while bands F and G were in greater intensity in December compared 
to November. 
In vitro screening of fecal isoflavone degradation rates 
Thirty-three subjects were selected for this screening (20 men, 13 women; mean age 
was 25.6 ± 4.4 years; 45.5% Caucasian, 24.2% Indian, 18.2% Asian and 12.1% African 
American). All subjects were screened for their fecal isoflavone degradation over 12 h. 
Segmented analysis over time revealed that most individuals differed in fecal isoflavone 
degradation between the first 6 h and the second 6 h of incubation (increase, decrease or 
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stable). There was no correlation between 0-6 h and 6-12 h rates for daidzein (r=0.11; 
p=0.55), glycitein (r=0.26; p=0.31), and genistein (r=0.17; p=0.61). Figure 3 described the 
segmented degradation rates between 0-6 h and 6-12h for genistein when still quantifiable by 
time 12 h (data not shown for daidzein and glycitein). With respect to these changes over 
time, a DGGE of bacterial 16S rDNA of time 0 and 12 h incubation of one individual was 
run to assess stability of the fecal flora in vitro over time (Figure 4). Analysis of the gel 
showed several changes in band patterns (increased or decreased band intensity), suggesting 
significant changes over time when assessing the human fecal flora in vitro. Considering the 
differences in segmented degradation rates and gut flora observed in figures 3 and 4, 
selection and ranking of individuals were done based on their 0-6h degradation rates, 
assuming a more accurate reflection of the gut microbial metabolism and physiology. 0-6 h 
isoflavone degradation rates were significantly albeit weakly correlated with one another 
(daidzein vs. glycitein: r=0.1343, p=0.035; daidzein vs. genistein: r=0.2059, p=0.008; 
glycitein vs. genistein: r=0.2656, p=0.002). However, the highest and lowest degradation 
rates of all three isoflavones did not correspond completely to the same individuals. 
Therefore, we investigated the fecal microbial DNA profiles of high and low degraders for 
each isoflavone separately. 
DGGE of fecal microbial DNA in high vs. low isoflavone degraders 
The four highest and lowest degraders for each isoflavone were selected for DGGE 
analysis. Subjects 11, 21, 29, 28 and 18, 20, 4, 1 were low and high daidzein degraders, 
respectively (daidzein degradation rates of 0.051 ± 0.032 vs. 0.304 ± 0.096 h"1; p=0.002). 
Subjects 21, 33, 9, 2 and 18, 26, 13, 4 were low and high glycitein degraders, respectively 
(0.084 ± 0.025 vs. 0.574 ± 0.299 h"1; p=0.017). Subjects 11, 28, 33, 2 and 4, 5, 18, 19 were 
low and high genistein degraders, respectively (0.146 ± 0.034 vs. 1.47 ± 0.14b"1; pO.OOOl). 
DGGE analysis of fecal microbial profiles associated with glycitein degradation 
showed 5 bands of greater intensity in high compared to low degraders (Gly 1 to Gly 5) 
(Figure 5). Comparison of gut microbial profiles associated with genistein degradation also 
showed 5 bands of greater intensity present in high genistein degraders (Gen 1 to Gen 5) 
145 
(Figure 6). However, daidzein high degraders did not show any significant bands of greater 
intensity compared to low daidzein degraders. 
Sequencing and identification of micro-organisms from the bands of interest 
Sequencing and matching of the sequences using BLAST gave for each band 100 
possible matches to known and unknown bacteria (Figures 2, 5 and 6). The overall results 
from all bands associated with isoflavone degradation gave strong similarities in 
microorganism identification. Indeed, all known microorganisms possibly related to bands 
present in high degraders were from the CFB group (Cytophagia-Flavobacteria-Bacteroides) 
and Clostridium genus. Most of the possible matches corresponded to Bacteroides, 
Prevotella, Clostridium, Ruminococcus and Fusobacterium. Based on BLAST analysis, we 
selected the following strains: Bacteroides fragilis (band A), Bacteroides uniformis (Band 
Gen 3), Bacteroides ovatus (Band G), Bacteroides vulgatus (Band C), Bacteroides 
thetaitaomicron (Band Gen 3), Bacteroides eggerthii (Band gly 2), Porphyromonas 
gingivalis (Band B), Prevotella pallens (Band E), Prevotella ruminicola (Band D), 
Prevotella oralis (Band F), Prevotella veroralis (Band F), Ruminococcus obeum (Band Gly 
4), Fusobacterium prausnitzii (Band Gen 5), Bacteroides acidifaciens (Band Gly 3), 
Tannerella Forsythensis (Band Gly 1). We also selected the following strains from published 
literature describing isoflavone degradation: Eubacterium ramulus (Schoefer et al. 2002) and 
Clostridium orbiscindens (Schoefer et al. 2003). All DGGE bands had significant differences 
in mean band intensity between duplicate bands at each time point one month apart when 
establishing intra-individual variability of degradation (Table 1). Significance was also 
observed when comparing mean band intensity of low (n=4) and high (n=4) glycitein and 
genistein degraders (Table 1). These strains were first investigated in several different 
preliminary experiments with small power then re-investigated using a higher power. 
Preliminary findings 
Single strain incubation with basic BHI media did not show any significant isoflavone 
degradation over 24 h incubation for E. ramulus, B. ovatus, B. fragilis, B. vulgatus and P. 
veroralis (data not shown). Other strains were not tested for this preliminary screening. 
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Incubation with autoclaved fecal suspension in BHI media and subsequent added micro­
organisms also failed to show any significant isoflavone degradation (data not showed). 
Fecal incubation with fresh fecal suspension in basic BHI media and added micro­
organisms showed similar 0-9 h degradation rates compared to control. Strains tested here 
were B. fragilis, B. ovatus, B. thetaitaomicron, B. vulgatus, B. uniformis, P. veroralis, E. 
ramulus and C. orbiscindens. Only one subject was screened for this preliminary experiment. 
A substantial decrease (~2-fold; p<0.05, based on duplicate samples for each incubation 
treatment) in 6-9 h degradation rate was observed in the control (feces and isoflavone only) 
while bacterial strains added to the fecal suspension maintained in vitro isoflavone 
degradation rate constant and higher than control during that 3h period (Figure 7). B. 
thetaitaomicron and B. uniformis showed a significantly higher rate of degradation between 
6-9 h compared to the overall 0-9 h rate (p<0.05). Considering that the presence of selected 
microorganisms in a fecal suspension had a greater influence on isoflavone disappearance 
compare to control when nutrients were less available, we screened and compared bacterial 
metabolism of different strains in two separate media, one poor and one rich in nutrients. 
First set of incubation in nutrient-rich and -poor media 
Analysis of baseline isoflavone degradation rates in control incubations (feces + 
isoflavone) showed that mean daidzein and genistein rates were similar between nutrient-rich 
and nutrient-poor media (0.051 ± 0.04 vs. 0.040 ± 0.012 h"1 and 0.074 ± 0.027 vs. 0.052 ± 
0.028 h"1 in nutrient rich vs. nutrient poor for daidzein and genistein, respectively; p>0.05). 
However, glycitein showed a ~4-fold mean increase of degradation rate in nutrient-poor 
compared to nutrient-rich media (0.153 ± 0.064 vs. 0.026 ± 0.012 h"1, respectively; p<0.05) 
(Figure 8). 
In nutrient poor media, we observed an increase in mean degradation rate for all three 
isoflavones for each bacterial species tested. These increases did not correlate with initial 
control degradation rates of each individual (data not shown). However, due to large standard 
deviations, only a few results showed significant differences. Combinations of bacteria failed 
to show a significant increase compared to control in nutrient poor media. Daidzein 
disappearance rate was significantly increased (p<0.05) by the presence of P. pallens (119 ± 
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30% increase over control response) and P. oralis (287 ± 105% increase over control 
response). Glycitein disappearance rate was significantly increased by the presence of P. 
oralis (193 ± 54% increase over control response) and B. eggerthii (146 ± 29% increase over 
control response) and genistein by the presence of P. pallens (165 ± 74% increase over 
control response), P. oralis (263 ± 74% increase over control response), B. eggerthii (196 ± 
92% increase over control response) and B. fragilis (156 ± 56% increase over control 
response) (Figure 9). 
In nutrient rich media, much smaller increases in degradation rates compared to 
control were observed. These increases did not correlate with initial control degradation rates 
of each individual (data not shown). Statistical significance was obtained for daidzein 
disappearance by the presence of Prevotella (mixture of P. ruminicola, oralis, pallens and 
veroralis) (23 ± 9% increase over control response) and genistein disappearance by the 
presence of P. pallens (33 ± 10% increase over control response). Glycitein rates showed 
decreases in percentage of control response with significance when B. eggerthii (-56 ± 8% 
decrease over control response) was added to the fecal suspension (Figure 10). 
Second set of incubation in nutrient-rich and —poor media 
With two new subjects and one recalled from the first set of incubations, analysis of 
baseline isoflavone degradation rates in control (feces + isoflavone) showed a marginally 
significant increase of daidzein degradation rate in nutrient rich compared to nutrient poor 
media (0.031 ± 0.006 vs. 0.098 ± 0.061 h"1). Glycitein degradation rates were similar in both 
media (0.219 ± 0.141 vs. 0.171 ± 0.092 h"1 in nutrient poor and rich, respectively) while 
mean genistein degradation rate significantly increased in nutrient-rich media (0.223 ± 0.112 
vs. 0.049 ± 0.016 h"1 in nutrient rich and poor, respectively) (Figure 8). The same subject 
investigated in both sets of incubations had degradation rates that followed the overall results 
obtained with all 3 subjects for each set of incubations. 
Data obtained from nutrient poor incubations produced a greater range of mean 
percentage increase in isoflavone degradation rates compared to the first set of incubations 
(Figure 9). These increases did not correlate with initial control degradation rates of each 
individual (data not shown). Despite observing increases in percentage degradation rates 
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from the control, some strains produced very little effect while other gave a mean percentage 
increase up to more than 800% when added to the fecal suspension. For example, the 
presence of B. thetaitaomicron gave only 46 ± 32% increase over control response in 
genistein degradation rate while daidzein and glycitein increased by 10 ± 25 and 7 ± 27% 
increase over control response. On the other hand, adding B. acidifaciens to a nutrient-poor 
media produced 789 ± 249, 584 ± 222 and 753 ± 63% increases over control response of 
daidzein, glycitein and genistein degradation respectively, all with p<0.05. Trends similar to 
B. acidifaciens were observed with B. uniformis and T. forsythensis. The latter did not show a 
significant increase in glycitein degradation over control due to a large standard deviation 
(469 ± 320% increase over control response). Several other strains did not produced 
increases as large as B. acidifaciens, but due to a similar increase of isoflavone degradation 
rates among fecal samples of all three subjects (small standard deviation), the percentage 
increase compared to the control response was significant (p<0.05). Daidzein degradation 
was significantly increased by the presence of P. ruminicola (206 ± 108% increase over 
control response), B. vulgatus (104 ± 40% increase over control response), E. ramulus (210 ± 
55% increase over control response), C. orbiscindens (469 ± 95% increase over control 
response) and F. prausnitzii (94 ± 40% increase over control response). Glycitein 
degradation was significantly affected by the presence of P. veroralis (117 ± 59% increase 
over control response), B. ovatus (106 ± 17% increase over control response) and C. 
orbiscindens (181 ±71% increase over control response) whereas strains increasing genistein 
degradation were B. ovatus (106 ± 17% increase over control response) and E. ramulus (117 
± 52% increase over control response). 
In nutrient rich media, several strains gave similar results to those obtained during the 
first set of incubations (Figure 10). These variations in percentage of control response did not 
correlate with initial control degradation rates of each individual (data not shown). Some 
decreases in percentage of the control response were observed, but not statistically 
significantly different from the control. The presence of P. pallens with respect to genistein 
disappearance caused a significant increase in degradation rate compared to control in a 
nutrient rich media during the first set of incubation (33 ± 10% increase over control 
response; p<0.05). In the second set of incubations (Figure 15), five strains caused significant 
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increases in degradation rate compare to control. Daidzein degradation was significantly 
affected by adding to nutrient rich media B. acidifaciens (429 ± 95% increase over control 
response) and C. orbiscindens (147 ± 28% increase over control response), while glycitein 
degradation was significantly higher in the presence of B. ovatus (78 ± 42% increase over 
control response), B. acidifaciens (632 ± 35% increase over control response), E. ramulus 
(49 ± 19% increase over control response) and T. forsythensis (251 ± 103% increase over 
control response). As for genistein, a statistically significant increase in degradation 
compared to control was observed with the presence of B. ovatus (57 ± 29% increase over 
control response), B. acidifaciens (615 ± 82% increase over control response), E. ramulus 
(33 ± 6% increase over control response), C. orbiscindens (68 ± 25% increase over control 
response) and T. forsythensis (236 ± 76% increase over control response). 
Comparison of percentage variations over control response for B. fragilis and P. 
ruminicola that were investigated in both sets of incubations did not give any significant 
differences. Comparison of daidzein, genistein and glycitein mean percentage variation 
between set 1 and 2 in either nutrient rich or poor gave p values of 0.08 or above (Figures 9 
and 10). Compare to control response, only P. ruminicola showed a significant increase of 
daidzein degradation in the second set of experiment (206 ± 108% increase over control 
response; p<0.05). 
DISCUSSION 
This study was the first to investigate fecal microbial disappearance of soy 
isoflavones. This project not only would provide new screening tools for human isoflavone 
bioavailability based on gut microbial profile, but it also lays a foundation for dietary 
interventions to decrease isoflavone-degrading human gut microorganisms in order to 
improve absorption and health-promoting effects of isoflavones. We hypothesized that feces 
of high isoflavone degraders share isoflavone degrading bacterial strains not seen in feces of 
low isoflavone degraders. Developed by Muyzer et al. (1993), PCR-DGGE is a molecular 
tool to characterize microbial populations. This technique was based on targeting and 
multiplying by PCR the DNA sequences coding for the V3 region of 16S rRNA with primers 
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designed to match the conserved region of the 16S rRNA gene. This sequence is different 
from one species to another and highly conserved within the same species. The 16S rDNA 
V3 region sequence is a unique "signature" of a microbial species. Theoretically, PGR of the 
16S rRNA sequences of a bacterial community should represent the original population, both 
in a quantitative and a qualitative manner. The rationale for using PCR-DGGE techniques is 
because of their advantages in studying complex microbial ecology: easiness, reproducibility, 
reliability and speed (Muyzer and Smalla. 1998; Muyzer et al. 1993). All gels in this study 
were done twice from separate DNA extraction samples and separate PCRs and produced the 
same results. By comparing standard microbiological techniques with PCR-DGGE, it has 
been shown that touchdown PGR gives an accurate estimate of the original bacterial 
population present in the sample as reflected in bacterial 16S rDNA. The intensity of the 
bands obtained after staining should represent the frequency of the species in the original 
sample studied (Murray et al. 1996). The use of touchdown PGR with a decreasing annealing 
temperature from 65 to 55°C enables the PGR primers to target all 16S DNA sequences that 
vary from one another in their GC content, thus in their melting and annealing temperatures. 
Silver staining was used to reveal the DNA band profiles on the gel but one of the 
disadvantages of using this technique is that only species represented at > 1% of the total 
bacterial population will be visualized (Muyzer et al. 1993). Thus, minor species cannot be 
studied using this technique and gut microbial populations are still only partially understood 
(Muyzer et al. 1993; Fuller and Perdigôn. 2003). 
With respect to isoflavone fecal in vitro degradation rates in the present study, 
selection of the 4 highest degraders gave respective degradation rates for daidzein, glycitein 
and genistein of 0.304 ± 0.096 h"1, 0.574 ± 0.299 h"1 and 1.47 ± 0.14 h"1 while those of low 
degraders were 0.051 ± 0.032 h"1, 0.084 ± 0.025 h"1 and 0.146 ± 0.034 h"1. Focusing only on 
daidzein and genistein, Hendrich et al. (1998) found degradation of high daidzein and 
genistein degraders (n=5) to be 0.299 and 0.299 h"1, respectively. Low degraders (n=5) had 
rates of 0.012 and 0.023 h"1 for daidzein and genistein, respectively. Zheng et al. (2003) 
found that mean high (n=13) vs. low (n=12) daidzein degradation rates were 0.44 ± 0.02 h"1 
and 0.06 ± 0.02 h"1, respectively in Asian women. Similar mean rates were found for 
Caucasian women who were high (n=4; k=0.47 ± 0.03 h"1) and low (n=13; k=0.08 ± 0.02 h"1) 
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daidzein degraders. Mean high (n=25; k=0.47 ± 0.02 h"1) and low (n=10; k=0.19 ± 0.04 h"1) 
genistein degradation rates in Asian women were similar to those of Caucasian women who 
were high (n-18; k=0.45 ± 0.03 h"1) and low (n=15; k=0.18 ± 0.02 h"1) genistein degraders. 
Zheng et al. (2004) found that mean high (n=13) vs. low (n=12) daidzein degradation rates 
were 0.36 ± 0.01 h"1 and 0.14 ± 0.01 h"1, respectively. 
Daidzein rates were in agreement between Hendrich et al. (1998), Zheng et al. (2003) 
and Zheng et al. (2004) studies and the present one, but the genistein rates were much higher 
here. A possible explanation for that phenomenon is that we established our degradation rates 
on 0-6 h data, while Hendrich et al. (1998) established theirs on 0-24 h data. We decided to 
restrict the number of time points when establishing degradation rates because of the changes 
occurring in rates past 6 h (Figure 3) along with changes occurring in microbial profile when 
incubated over 24 h (Figure 4). To produce data as physiologically relevant as possible, we 
decided that 0-6 h rates and time 0 h gut microbial profiles would be more physiologically 
and metabolically relevant to human nutritional circumstances. These findings also question 
the extrapolation of in vitro fecal degradation rate data obtained over 24 h to in vivo 
situations. When dealing with a matrix as complex as a fecal suspension, it is essential that 
the data obtained are relevant to the original composition of the sample along with avoiding 
as much as possible any artifacts that would influence the results (Simpson et al. 1999; 
Moore and Moore. 1995; Fuller and Perdigôn. 2003). 
Comparison of microbial profile after analysis of DGGE showed how complex and 
different they were among individuals. Despite finding bands that were shared by several or 
sometimes all individuals, the overall band patterns differed from one individual to another 
(Figures 5 and 6) and confirms previous findings of great interindividual variability in gut 
microbial composition (Fuller and Perdigôn. 2003). On the other hand, the presence of 
several bands of greater intensity found in feces of high genistein and glycitein degraders, 
bands that were much weaker or absent in feces of low degraders, supported our initial 
hypothesis that high degraders shared bands of greater intensity (Figures 5 and 6; table 1). 
The fact that no significant bands were found to differ between high and low daidzein 
degraders may be partly explained by the fact that daidzein rates were lower than those of 
glycitein and genistein and that only a 5-6-fold difference was observed between mean 
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daidzein low vs. high degradation rates while those of glycitein and genistein were 7- and 10-
fold difference, respectively. Preliminary experiment done with one subject also supported 
our hypothesis that high isoflavone degradation was associated with DGGE bands of greater 
intensity (Figure 2), at least with respect to glycitein degradation, even though an n of 1 was 
insufficient to draw definite conclusions for daidzein or genistein as well as for extrapolation 
to the general population. On the other hand, dealing with the same individual gave much 
closer gut microbial profiles at both time points (November and December 2003) so that 
differences in band patterns possibly related to glycitein degradation were much easier to 
observe (Figure 2). Bacterial identification of the bands of interest from one individual over 
time (Figure 2) or comparison of 4 low versus 4 high degraders (Figure 5 and 6) gave results 
corresponding to the same bacterial families (Bacteroides, Prevotella and Clostridials) led 
us to believe that there may be different ways to approach our initial objective of identifying 
isoflavone-degrading microorganisms and still obtained similar conclusions. 
From microbial DNA database analysis, we selected for each DGGE band the match 
that gave the greatest number of hits to the DNA sequence extracted and amplified after 
DGGE. As a first approximation of human gut microorganisms that degraded isoflavones, 
this chosen sequence match corresponded to known and culturable microorganisms known to 
be present in the human gut (Tables 1). Despite these restrictions in the process of 
sequencing and identifying microorganisms, most of the DGGE bands associated with high 
fecal isoflavone degradation corresponded to specific microbial strain. Some bands gave 2 
matches; the 2 strains selected were from the same family and very close phylogenetically. 
The overall results from three gels showed that higher isoflavone degradation may be related 
to higher levels of Bacteroides, Prevotella and certain strains of Clostridials (Tables 1). 
Bands F and G obtained from one individual (figure 2 and table 1) were higher in intensity in 
microbial DNA from a fecal sample that showed less glycitein degradation compared with a 
fecal sample taken one month earlier from that subject. These bands may indicate microbial 
species that inhibited glycitein degradation. But the species encoded by these DNA 
sequences were Bacteroides and Prevotella (species also associated with higher isoflavone 
degradation rates), so more subtle analysis will be needed to clarify the microbial 
interrelationships associated with lower isoflavone degradation rates. We focused on the 
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hypothesis that microbial species present more predominantly in feces of high degraders 
would be likely responsible for isoflavone degradation. Bands A though E were thought to be 
responsible for glycitein degradation at a time of high degradation rate (November sample) 
whereas bands F and G might have corresponded to species responsible for glycitein 
degradation in December, where glycitein degradation was still occurring, but at a lower rate. 
The microbial strains tentatively identified as isoflavone degrading are some of the major 
human gut microbial species as Prevotella and Bacteroides can account for up to 95% of the 
total gut bacterial population in humans (Fuller and Perdigôn. 2003). 
In addition to the strains selected from DGGE, we also screened isoflavone 
degradation for 2 strains previously shown to degrade isoflavone or flavonoids. Schoefer et 
al. (2002) found that a pure strain of Eubacterium ramulus degraded 0.5 mM genistein 
completely in 4 h into 6'-hydroxy-ODMA and 2-(4-hydroxyphenyl)-propionic acid. Daidzein 
was degraded over 12 h by E. ramulus to yield ODMA at an amount equal to 70% of the 
daidzein initially present. In the present study, we solely focused on isoflavone disappearance 
over time when fecal incubations are spiked with this microorganism. Identification and 
quantification of metabolites will deserve further investigations. Clostridium orbiscindens 
was also selected for its capability of degrading the fiavonoid quercitin (Schoeffer et al. 
2003). Hur et al. (2002) also found that a Clostridium sp. isolated from human fecal samples 
(200 different unknown bacterial colonies cultured from fecal sample and each incubated 
with daidzein) that was capable of transforming daidzein (400 uM) into ODMA (112 uM) 
over a 3 d incubation, but we could not include this species because we could not obtain it. 
Preliminary experiments done with the selected strains gave disappointing results 
considering that single strain incubations did not give any significant isoflavone degradation 
(data not shown). The same result was obtained with an autoclaved fecal matrix. Therefore, 
we hypothesized that if these strains were involved in degrading isoflavone, a viable fecal 
background would be necessary to exert a significant effect. Fresh fecal suspension with 
added overnight grown bacterial cultures of Bacteroides, Prevotella or Clostridiales (Figure 
7), but with no adaptation time for the species to accommodate to the fecal environment 
showed that treatment degradation rates seemed to be maintained more stably and higher 
than in fresh fecal suspensions not containing the putative isoflavone-degrading microbial 
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species. This was more obvious in the last segment of the incubation period (6-9h) (Figure 
7). With longer adaptation time, the presence of selected strains were better able to maintain 
isoflavones degradation to a higher level, even though an n of 1 done for this preliminary 
experiment did not allow us to draw any definite conclusions. After 6-9h incubation in brain 
heart infusion media, nutrient availability to the microbial species may start to decrease. This 
hypothesis of nutrient availability and bacterial activity of putative strains with respect to 
isoflavone disappearance was investigated using an in vitro system. Isoflavone degradation 
rates by bacteria added to a fecal sample were compared between two environments: one in 
which nutrient availability was low (nutrient-poor media) and one in which nutrient 
availability was high (nutrient-rich media). A rationale for this comparison came from the 
study of Zheng et al. (2003) who compared in vitro disappearance of genistein and in vivo 
genistein urinary excretion and gut transit time in 35 Asian and 33 Caucasian females. Asians 
with low in vitro fecal genistein degradation had a significantly shorter mean gut transit time 
and greater genistein urinary excretion compared to Asians with rapid in vitro fecal genistein 
degradation (GTT was 40 ± 8h vs. 63 ± 5h and genistein urinary excretion was 11.0 ± 2.7% 
vs. 4.0 ± 1.7% of ingested dose from soymilk for low and high genistein degraders, 
respectively). This was not observed in Caucasian subjects, probably because Caucasian low 
genistein degraders had a mean gut transit time significantly higher than Asian subjects with 
the same phenotype (86 ± lOh vs. 40 ± 8h, respectively). Zheng et al. (2003) concluded that 
rapid gut transit time coupled with low in vitro genistein disappearance resulted in greater 
bioavailability as reflected in urinary excretion. Based on these findings, we attempted to 
reproduce in vitro a similar situation to short and long gut transit time. We hypothesized that 
a long gut transit time would be associated with greater nutrient fermentation in the large 
intestine. This would ultimately correspond to an in vitro nutrient-poor media in which, 
according to Zheng et al. (2003), greater isoflavone degradation rates would be expected. In 
the present study, we would expect greater isoflavone degradation rates when strains of 
interest are added to a fecal matrix in nutrient-poor media. The use of a nutrient-rich media 
would mimic an in vivo rapid gut transit time, where less fermentation is occurring in the 
colon because gut contents have less time in residence there. Thus, a nutrient-rich media 
would produce lower isoflavone degradation rates and much smaller effects when strains of 
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interests are added to the fecal suspension. An adaptation time of 6h was necessary for the 
bacterial species added to the fecal matrix to adapt to this environment (figure 7). Even 
though a standard fecal in vitro isoflavone rate was better assessed between 0 and 6h for 
correlation to DGGE (figure 3), the main goal of this part of the project was to alter 
significantly the original fecal flora by adding bacterial species grown separately. Modifying 
the in vitro fecal environment was not related anymore to the in vivo colonic environment of 
the subjects providing the samples. Therefore, in this particular case, adding an adaptation 
time should not be of concern since we focused on measuring how isoflavone disappearance 
is affected over time by a greater presence of the bacterial species selected. 
To test this hypothesis, we designed a first set of incubation with both media and fecal 
samples from three individuals. We selected fecal samples from individual of both sexes and 
from different ethnicities. For this first set of incubations, we investigated 4 strains (P. oralis, 
P. ruminicola, B. eggerthii and B. fragilis) as well as a mixture of Prevotella, Bacteroides 
and Bacteroidales (Figures 9 and 10). All three isoflavones were investigated despite the fact 
that no specific microorganism was identified as a possible daidzein degrader. However, 
considering a similar pattern of bacteria identified for glycitein and genistein, we 
hypothesized that species from Prevotella, Bacteroides and Clostridials might also have a 
significant effect on daidzein. To normalize and allow comparisons among treatments, we 
expressed the results as a percentage of the control response (feces and isoflavone without 
any added bacterial strains). The reason for this normalization is that control degradation 
rates were different from one subject to another and from one isoflavone to another (Figure 
8). Differences in control degradation rates obtained in the first and second set of 
experiments (higher mean glycitein degradation rate in nutrient poor for the first set of 
incubation and higher mean genistein degradation rate in nutrient rich for the second set of 
incubation) may be due to the fact that different fecal background were chosen for each set of 
incubation. Thus, making comparison among baseline degradation rates was impossible and 
the different patterns observed harder to interpret with certitude. 
Results observed from the first set of incubations in nutrient poor media gave 
marginal or significant increases in degradation rates of all three isoflavones for almost every 
treatment (Figure 9). This fits with our hypothesis that a nutrient-poor media mimicking long 
156 
GTT resulted in increased isoflavone degradation compare to control when putative 
isoflavone-degrading microorganisms were added to the fecal suspension. However, we 
obtained for most of the data very large standard deviations. This was due to a difference in 
percentage of the control response from one individual to another for the same strain studied. 
Therefore, it seemed that, bacterial metabolic activities may be influenced by the fecal 
background matrix. Large interindividual differences in fecal isoflavone degradation rates 
expressed as % control response may fit with the known great variability among individuals 
in isoflavone bioavailability. Indeed, this process is not homogenous and showed great 
variation in urinary (up to 100-fold difference), plasma and fecal kinetics from one individual 
to another (Hendrich et al. 1998; Xu et al. 1994), hence these variations could then be due not 
only to certain bacterial species present in the gastro-intestinal tract, but also to the level of 
metabolic and enzymatic activities of these microbial species influenced by the gastro­
intestinal environment between individuals. The fact that bacteria in combination produced 
the same range of increase in isoflavone degradation rate compared to single strains showed 
that there may not be an additive effect when different were added in the same treatment 
tube. It seemed that the putative isoflavone degrading strains may compete for isoflavones, 
resulted in no increase in degradation rate by multiple strains compared to a single strain 
added to the fecal mixture. 
The first set of incubations in nutrient-rich media gave a much smaller percentage 
increase in isoflavone degradation rate expressed as a percentage of the control response 
compared to that in nutrient poor media (Figure 10). These results fitted with our hypothesis 
that a nutrient rich media representing a rapid gut transit time resulted in lower response of 
isoflavone degradation by putative isoflavone-degrading microorganisms when compared to 
nutrient poor conditions. The highest mean increase was 67% of control response in genistein 
degradation for P. ruminicola in rich media. We observed inhibitory effects of a nutrient rich 
media on glycitein degradation rates (the presence of B. eggerthii showed a significant 
decrease compared with control response). Trends towards statistical significance 
(0.1<p<0.05) were also observed with some daidzein degradation rates (Bacteroides, 
Bacteroidales, P. pallens and B. eggerthii) and one genistein degradation rate (Bacteroides). 
These trends observed will deserve further investigation with greater sample size (Figure 10). 
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Due to a more homogenous effect that led to a smaller standard deviation in nutrient 
rich media, significant increased daidzein degradation rates were observed with the presence 
of Prevotella (mean increase 23%) as well as genistein with P. pallens (mean increase 33%) 
when compared to the control response in nutrient rich media. P. pallens produced a 
significant increase in genistein degradation when in a nutrient-rich media led us to 
hypothesize that some strains are capable of influencing isoflavone degradation even though 
nutrient availability is rich, partly explaining why individuals with rapid gut transit time 
(higher colonic nutrient availability) do degrade isoflavone to some extent. 
Control degradation rates in the second set of incubations gave different results from 
the first set of incubations (Figure 8). Genistein degradation was significantly higher in 
nutrient rich media while glycitein degradation was higher in nutrient poor during the first set 
of experiment. Considering that different fecal matrix were considered for each set, statistical 
comparison of baseline degradation rates between both sets were impossible to make. 
However, the fact that the same subject investigated in both sets two months apart 
(Caucasian male) had degradation rates that followed the overall results obtained with an n of 
3 for each set of incubations supported our preliminary observation that degradation rates 
studied even one month apart may show great variation, probably because of differences in 
microbial profiles and isoflavone-degrading microorganisms already present in the control 
fecal samples. Therefore, the fecal matrix and bacterial ecology may be of importance in 
determining bacterial adaptation and degradation of isoflavones. Even though gut bacterial 
ecology is thought to be stable over time (Fuller and Perdigôn. 2003) our result on DGGE in 
the same individual one month apart (Figure 2) showed some differences in band profiles so 
that colonic factors may influence not only bacterial metabolism, but also bacterial profile, 
even over short periods of time, which ultimately would influence isoflavone disappearance. 
This phenomenon was also observed by Zheng et al. (2003) who investigated stability of 
isoflavone degradation phenotypes in Asian (n=35) and Caucasian (n=31) at two time points 
five months apart. 22/35 Asian and 17/31 Caucasian switched their daidzein disappearance 
phenotypes, while 11/35 Asian and 16/31 Caucasian switched their genistein disappearance 
phenotypes. Low degraders were more stable between both time points whereas moderate 
and high degraders were less stable. Indeed, while 4 Caucasians were identified as high 
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degraders at time 0, none were identified in this cluster 5 months later. In the present study, 
we selected moderate or moderate borderline low daidzein degraders so that these individuals 
may have been more susceptible to modify their degradation phenotype, which may provide 
some understanding in the differences observed in control rates in the first and second set of 
incubations (figure 8). In addition, the subject selected for the intra-individual variation study 
was previously assessed as overall moderate degrader for all three isoflavones. Variation in 
glycitein disappearance may be due to a baseline phenotype apparently less stable over time 
(Zheng et al. 2003). Finally, this would also agree with the data obtained from the same 
individual (male Caucasian) selected for both sets of incubations in nutrient poor and rich 
media. His baseline rates followed those obtained with an n of 3, where variations in 
glycitein and genistein degradation were noticed. 
Results obtained from nutrient-poor incubations in the second set of incubations 
showed similar results to those obtained in the first set of treatments (Figure 9). This 
confirmed our hypothesis that a nutrient-poor media mimicking long GTT resulted in 
increased isoflavone degradation compare to control when putative isoflavone-degrading 
microorganisms were added to the fecal suspension. In addition, the range of increased 
percentage control response varied tremendously, with 3 strains influencing to greater extent 
isoflavone degradation rates: B. acidifaciens, B. uniformis and T. forsythensis. Isoflavone 
degradation rates obtained with the presence of P. veroralis and C. orbiscidens showed 
intermediate increase between those produced with the three strains influencing degradation 
the greatest and other strains that produced a lower mean percentage increase compared to 
control. The fact that we observed a greater range of increase degradation as percentage 
control response with these bacteria and compared to the strains investigated during the first 
set of incubations led us to hypothesize that some strains may actually be more efficient in 
influencing isoflavone degradation than others. 
In nutrient rich conditions, B. ovatus, B. acidifaciens, E. ramulus, C. orbiscindens and 
T. forsythensis showed significantly increased isoflavone degradation rates (up to 600% of 
control response for B. acidifaciens) which were different from the first set of incubation in 
which only P. pallens was a significant genistein degrader (Figure 10). Overall, we were not 
able to identify a specific relationship between presence of a putative strain and degradation 
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of a specific isoflavone. It seemed that these species were capable of degrading at least two 
isoflavones. Only P. pallens seemed to be more specific to genistein degradation (p<0.05 
when compare to control response in the first set of incubation) despite a trend in increasing 
glycitein and daidzein degradation rates as well (0.05<p<0.08). B. uniformis was not 
investigated in nutrient rich media, but considering the high increase in isoflavone 
degradation rate in nutrient-poor media similar to B. acidifaciens and T. forsythensis, we 
expect that the presence of this species would cause significant isoflavone degradation in 
nutrient rich media. This deserves further investigation. Identifying E. ramulus as one of the 
key species in influencing isoflavone degradation is in agreement with Schoeffer et al. 
(2002). But in our hands, E. ramulus did not degrade isoflavones as a single strain. When 
using different media and in a fecal matrix, E. ramulus increased significantly isoflavones. C. 
orbiscindens, shown by Schoeffer et al. (2003) to degrade flavonoids was also one of the 
main species that we identified as having a significant effect in degrading isoflavone. These 
results did not confirm our hypothesis that a nutrient rich media representing a rapid gut 
transit time resulted in lower response of isoflavone degradation by putative isoflavone-
degrading microorganisms when compared to nutrient poor conditions. However, it 
confirmed what was found with P. pallens in the first set of incubations. Some species may 
influence isoflavone degradation, regardless of the nutrient availability. This would suggest 
that if these species do actually degrade isoflavones, lower population of these strains in low 
degraders and higher population in high degraders would agree with the results found with 
PCR-DGGE (figures 2, 5 and 6). Species increasing significantly isoflavones degradation in 
nutrient poor only may suggest that a wider range of bacterial species would degrade 
isoflavones under these circumstances, explaining partly why individuals with long gut 
transit time degrade isoflavone to a greater extent (more species involved). A narrower range 
of species were found to increase isoflavone degradation in nutrient rich, which in turn may 
explain the fact that individuals with rapid gut transit time have lower isoflavone degradation 
rates (less species involved) 
An interesting finding constant throughout this project was that variations in 
percentage degradation rate over control response with feces and isoflavones only did not 
correlate with baseline control rates, whether it was in nutrient rich or poor. Therefore, the 
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data obtained with fecal incubation and species selected were independent of baseline 
isoflavone degradation rates. 
From observations that some bacterial species were capable of increasing 
significantly isoflavone degradation whether the media was rich or poor in nutrients, we 
suggested that these strains may be responsible for isoflavone degradation in high and low 
degraders with the assumption that high degraders have greater amounts of these species 
compared to low degraders, as reflected in DGGE analysis. High degradation pattern 
associated with lower nutrient availability may also be explained by a greater number of 
species degrading isoflavones that might be used as an alternate source of nutrient for these 
species to survive and compete. However, the actual relationship of these species using 
isoflavone as a nutrient source deserves more investigation. Our data suggest that the 
presence of these species increased isoflavone degradation, but did not prove with certitude 
that these same species were actually capable of using isoflavone as a nutrient source. 
Last, but not least, one of the most difficult factors to include in such a design would 
be bacterial competition over time. Some fecal bacterial species may be more prone to 
compete with the added bacteria, resulting in a lower (or possibly higher) isoflavone 
degradation rate but this remains to be further investigated. Thus, bioavailability of 
isoflavone must include a complex system of parameters that must be identified and 
controlled and in which each individual may have to be considered separately in order to 
fully understand how microbial metabolism and composition influence isoflavone 
degradation. 
SUMMARY AND RECOMMENDATIONS 
As a summary, our in vitro incubations provided us with strong basis to study 
isoflavone disappearance by putative isoflavone-degrading microorganisms. The presence of 
a fecal background was of greater relevance to an in vivo situation compare to single strain 
incubations, where no bacterial competition occurs. Selecting moderate degraders in the 
present study for nutrient rich and poor experiments needs to be reconsidered for future 
experiments. Too much variability in baseline degradation rates indicated that selecting low 
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degraders may be more appropriate, because these individuals may have a more stable flora 
over time (Zheng et al. 2003). Reproducibility of incubation treatments with added bacteria 
may also be greater with fecal backgrounds from low degraders. On the other hand, moderate 
degraders may be of greater interest to study short-term changes in gut microflora and how 
these changes would affect isoflavone degradation. Significant data obtained here with one 
individual would deserve further attention with greater number of moderate degraders. It 
would be also of interest to study high degraders and how the species identified in the present 
study would affect isoflavone degradation. If high degraders have significantly greater 
amounts of strains identified in the present study, we may expect a lower response from 
adding the same microorganisms. This would also lead to study dose-response type of 
experiment to assess the minimal bacterial concentration needed to significantly modify the 
response in degradation compare to control. Screening bacterial species from other families 
could be of importance as well. If no significant variations in degradation occur with other 
strains, it would limit our focus to the Bacteroidales (Bacteroides & Prevotella) and 
Clostridials groups. Finally* finding a bacterial strain that would not alter significantly the 
original fecal microflora, nor control degradation rates would lead to the establishment of a 
negative control to better assess data from treatments. 
CONCLUSION 
The present study confirmed the significant effect of several bacterial species 
identified through PCR-DGGE on isoflavone degradation in human high and low fecal 
degraders. Many questions about gut microbial isoflavone metabolism remain unsolved. The 
complexity of the fecal microflora, coupled with many aspect of gut microbial ecology that 
have not been elucidated make our conclusions preliminary. 
Aside from B. uniformis that will deserve further attention, we concluded that in this 
study, the main species that influenced isoflavone degradation were B. ovatus, B. 
acidifaciens, E. ramulus, C. orbiscindens, T. forsythensis and possibly P. pallens. This 
conclusion is based on the fact that isoflavones were significantly more degraded in the 
presence of these species regardless of the nutrient environment, which would explain not 
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only why all individuals degrade isoflavones but also the higher presence of these species in 
high degraders compared to low degraders as reflected on DGGE analysis. Other species 
involved in a high degradation in vitro simulation only may also indicate that a greater 
number of species may explain high isoflavone degradation. Considering that subjects 
selected for this study were from different backgrounds, it would be helpful to re-investigate 
isoflavone degradation in nutrient-rich and poor media with fecal background of individuals 
from carefully defined population subgroups. Thus, factors that must be considered in future 
studies to fully understand microbial metabolism of isoflavone include: sex, ethnicity, age, 
gut transit time, stability of fecal isoflavone degradation phenotype and dietary habits. 
Further studies should also include dose-response analysis of the different strains identified 
here with respect to isoflavone degradation. 
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Figure 1: overview of PCR-DGGE protocol and methods 
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Figure 2: DGGE (32.5-45% urea gradient) of fecal DNA from the same individual over two 
months and associated glycitein degradation rates. Microbial profiles are shown in duplicates 
for each time point. Bands of interest are noted as A through G. 
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Figure 3: Segmented (0-6h and 0-12h) genistein degradation rates from in vitro fecal 
degradation screening of subjects showing 3 patterns of degradation (stable, decrease and 
increase). 
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Figure 4: DGGE profile (35-50% urea gradient) of fecal microbial 16S rRNA variable region 
DNA sequences from the same individual at 0 and 12h of in vitro incubation in treatment 
(feces + isoflavone) and control (feces only). 
Treatment Control 
Oh 12h Oh 12h 
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Figure 5: DGGE profile (32.5-45% urea gradient) of fecal microbial 16S rRNA variable 
region DNA sequences from low (first 4 lanes) and high (last 4 lanes) glycitein degraders and 
bands of interest (Gly 1 through Gly 5). 
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Figure 6: DGGE profile (32.5-45% urea gradient) of fecal microbial 16S rRNA variable 
region DNA sequences from low (first 4 lanes) and high (last 4 lanes) genistein degraders 
and bands of interest (Gen 1 through Gen 5). 
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Table 1: Analysis of bands found in figure 2, 5 and 6: band intensity, overall taxonomy 
reports and bacterial identification 
Band 
Identifier 
Mean 
Low 
Mean 
High 
Taxonomy report Bacterial 
Ab 104.5 ±2.1 158.5 ±4.8 63% unclassified 
37% Bacteroidales 
Bacteroides fragilis 
Bb 104.5 ±2.1 131.5 ± 2.1 46% unclassified 
54% Bacteroidales 
Porphyromonas 
gingivalis 
Cb 95.0 ±3.2 128.0 ± 1.4 73% unclassified 
27% Bacteroidales 
Bacteroides vulgatus 
Db 94.0 ±3.8 127.5 ± 1.3 65% unclassified 
35% Bacteroidales 
Prevotella ruminicola 
Eb 123.0 ±2.8 170.0 ± 1.4 64% unclassified 
36% Bacteroidales 
Prevotella pallens 
Fb 118.0 ±2.8 107.0 ±2.8 50% unclassified 
50% Bacteroidales 
Prevotella oralis 
Prevotella veroralis 
Gb 142.5 ± 2.9 121.0 ± 2.8 50% unclassified 
50% Bacteroidales 
Bacteroides ovatus 
Gen Ie 107.5 ± 14.4 154.8 ± 13.8 42% unclassified 
58% proteobacteria 
Gen 2° 113.8 ± 14.9 159.5 ± 11.4 100% unknown 
Gen 3° 171.3 ±21.0 210.0 ± 10.8 56% unclassified 
44% Bacteroidales 
Bacteroides uniformis 
B. thetaitaomicron 
Gen 4' 128.3 ± 14.0 168.3 ±4.5 89% unclassified 
6% Clostridiales 
5% Fusobacterium 
Gen 5C 120.0 ± 12.2 164.3 ± 14.9 75% unclassified 
25% Clostridiales 
Fusobacterium 
prausnitzii 
Gly Ie 120.5 ± 18.1 187.5 ±22.5 57% unclassified 
43% Bacteroidales 
Tannerella 
Gly 2C 132.3 ±36.7 177.5 ±20.6 61% uncultured 
39% bacteroidales 
Bacteroides eggerthii 
Gly 3C 146.3 ± 16.0 180.3 ±5.0 62% unclassified 
38% Bacteroidales 
Bacteroides 
acidifaciens 
Gly 4° 142.5 ± 17.6 183.8 ± 16.5 87% unclassified 
13% Clostridiales 
Ruminococcus obeum 
Gly 5C 141.5 ±16.0 180.3 ±5.0 100% unclassified 
a: All means within the same row are significantly different from each other at p<0.05. 
b: mean band intensity (by densitometry) ± standard deviation calculated from duplicate 
values for each time point. 
c: mean band intensity (by densitometry) ± standard deviation calculated from the four 
individuals selected within each phenotype. 
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Figure 7: Genistein in vitro fecal degradation rates obtained between 0-9h and 6-9h 
incubation in control showing a significant decrease and treatments with selected species 
showing either stability or significant increase (n=l). 
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Figure 8: Mean control in vitro fecal degradation rates showing a significant decrease for 
glycitein (first set of incubations, n=3) and increase for genistein (second set of 
incubations, n=3) under nutrient rich conditions. 
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Figure 9: Mean isoflavone in vitro fecal degradation rates expressed as percentage of 
control response (feces and isoflavone only) per 109 bacteria/mL media in nutrient poor 
media (Top: first set of incubations, n=3) (Bottom: second set of incubations; n=3). 
(*p<0.05 when compare to control: feces and isoflavone only normalized at 100%). 
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Figure 10: Mean isoflavone in vitro fecal degradation rates expressed as percentage of 
control response (feces and isoflavone only) per 109 bacteria/mL media in nutrient rich 
media (Top: first set of incubations, n=3) (Bottom: second set of incubations; n=3). 
(*p<0.05 when compare to control: feces and isoflavone only normalized at 100%). 
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GENERAL CONCLUSIONS 
To better assess health-promoting effects of isoflavones and their prevention of 
chronic diseases, a more accurate understanding of isoflavone bioavailability must be also 
considered, in humans and animals. The studies performed here clearly showed how intricate 
and complicated the process of bioavailability is. In addition to the difficulties in drawing 
definite conclusions in humans, the establishment of a valid animal model close to humans is 
even more difficult, considering all the knowledge gaps that must be filled to fully appreciate 
the potential of these compounds. 
When establishing bioavailability of isoflavones in Golden Syrian hamsters, we found 
several aspects similar to humans. Male hamsters are lower urinary isoflavone excreters than 
females. The range of urinary excretion in female hamsters is close to that of women whereas 
male hamsters have lower bioavailability than men. Daidzein was shown to be more 
bioavailable than genistein (similar to that in humans), while glycitein was somewhat 
intermediate (whereas glycitein is similar to daidzein in bioavailability in humans). Human in 
vitro fecal degradation of isoflavones is a good predictor of bioavailability. We found that in 
hamsters, a closer relationship was observed to apparent absorption with cecal rather than 
fecal in vitro isoflavone degradation rate. Finally, fecal isoflavone excretion is extremely low 
and does not correlate with urinary excretion. Therefore, considering similar ranges of 
urinary excretion sex and isoflavone difference and the relationship between in vivo and in 
vitro cecal data, hamsters may be a good model of isoflavone bioavailability that might be 
useful in simulating long term effects of human variability in gut microbial degradation of 
isoflavones on isoflavone health effects. 
Another major aspect investigated in the present project was to identify isoflavone-
degrading microorganisms, a major aspect of the overall pattern of isoflavone bioavailability. 
Using molecular and microbiological techniques as well as new in vitro simulations that were 
hypothesized to mimic in vivo gut microbial conditions associated with rapid and long gut 
transit time, we found that B. ovatus, B. acidifaciens, E. ramulus, C. orbiscindens, T. 
forsythensis and possibly P. pattens and B. uniformis used isoflavones as a primary source of 
nutrients, thus playing a major role in degrading these compounds as a ubiquitous action, 
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possibly explaining why isoflavone degradation occurs in every individual. However, 
different proportions of these strains among individuals may explain the wide range of 
isoflavone degradation, leading people to be phenotyped as high, moderate and low 
degraders. In addition, a wide range of other strains degraded isoflavones especially in 
nutrient poor media, suggesting that a poor colonic nutrient availability may permit gut 
microbes to degrade isoflavones, species that may differ from one individual to another, 
considering that some microbial species were able to greatly increase isoflavone degradation 
in one subject whereas different microbial species may be involved in additional degradation 
in another individual. 
As a conclusion, isoflavone bioavailability is a complex process and it will take many 
more years to fill all the knowledge gaps of this particular research area. It will be extremely 
challenging to find an animal model showing bioavailability patterns that would exactly 
mimic what is known in humans. Hamsters, because of close cholesterol metabolism and also 
great similarities in bioavailability compared to humans may be one of the most appropriate 
animal models to study isoflavone health-related effects. Difficulties in finding a valid 
animal model are also related to the fact that isoflavone bioavailability is not folly understood 
in humans. Identifying isoflavone-degrading human gut microorganisms would fill one of the 
main knowledge gaps in this area. In this project, we identified with great confidence 5 
strains and possibly 2 more that are involved in degrading isoflavones in the human gut. 
Greater proportion of these strains in high degraders coupled with other secondary strains 
that may be involved in degradation when nutrient availability is low is relevant to the large 
range of degradation rates observed among humans. 
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